Document:

Stock Purchase Agreement

 Exhibit 10.2 
 Execution Version 
 STOCK PURCHASE AGREEMENT 

by and between 
 MEDICIS PHARMACEUTICAL CORPORATION (“Seller”) 
 and

 SOLTA MEDICAL, INC. (“Buyer”) 

dated as of 
 September 12, 2011 

 Table of Contents 

 

							
	 	  	Page	 
	ARTICLE 1 DEFINITIONS AND REFERENCES	  	 	2	  
		
	ARTICLE 2 PURCHASE AND SALE OF THE SHARES; PURCHASE PRICE	  	 	2	  
			
	 Section 2.1
	  	Purchase and Sale of the Shares.	  	 	2	  
	 Section 2.2
	  	Purchase Price.	  	 	2	  
	 Section 2.3
	  	Payment of the Purchase Price.	  	 	2	  
	 Section 2.4
	  	Working Capital Adjustment.	  	 	2	  
	 Section 2.5
	  	Assumption of Obligations under the LipoSonix Agreement.	  	 	4	  
	 Section 2.6
	  	Seller Contingent Payments.	  	 	4	  
	 Section 2.7
	  	Payment of Seller Contingent Payments.	  	 	12	  
	 Section 2.8
	  	Consent Requirement.	  	 	20	  
		
	ARTICLE 3 CLOSING	  	 	21	  
			
	 Section 3.1
	  	Closing.	  	 	21	  
	 Section 3.2
	  	Closing Deliveries.	  	 	21	  
		
	ARTICLE 4 REPRESENTATIONS AND WARRANTIES OF SELLER	  	 	22	  
			
	 Section 4.1
	  	Organization and Qualification.	  	 	22	  
	 Section 4.2
	  	Charter and Bylaws.	  	 	23	  
	 Section 4.3
	  	Shares; Indebtedness.	  	 	23	  
	 Section 4.4
	  	Authority; Enforceability.	  	 	23	  
	 Section 4.5
	  	No Conflict; Required Filings and Consents.	  	 	24	  
	 Section 4.6
	  	Material Contracts.	  	 	24	  
	 Section 4.7
	  	Compliance.	  	 	27	  
	 Section 4.8
	  	Absence of Certain Changes or Events.	  	 	28	  
	 Section 4.9
	  	Liabilities.	  	 	29	  
	 Section 4.10
	  	Absence of Litigation.	  	 	30	  
	 Section 4.11
	  	Employee Benefit Plans.	  	 	30	  
	 Section 4.12
	  	Employment and Labor Matters.	  	 	32	  
	 Section 4.13
	  	Title to Assets; Leases; Sufficiency of Assets.	  	 	33	  
	 Section 4.14
	  	Taxes.	  	 	34	  
	 Section 4.15
	  	Environmental Matters.	  	 	36	  
	 Section 4.16
	  	Intellectual Property.	  	 	37	  
	 Section 4.17
	  	Insurance.	  	 	41	  
	 Section 4.18
	  	Brokers.	  	 	42	  
	 Section 4.19
	  	Certain Business Practices.	  	 	42	  
	 Section 4.20
	  	Interested Party Transactions.	  	 	42	  
	 Section 4.21
	  	Health Regulatory.	  	 	43	  
	 Section 4.22
	  	FDA and International Regulatory and Related Matters.	  	 	44	  
	 Section 4.23
	  	Product Liability; Product Warranties.	  	 	49	  
	 Section 4.24
	  	Inventories.	  	 	49	  

  
 i 

							
	 Section 4.25
	  	Trade Compliance Matters.	  	 	49	  
	 Section 4.26
	  	Manufacturing and Marketing Rights.	  	 	51	  
	 Section 4.27
	  	Corporate Records.	  	 	51	  
	 Section 4.28
	  	Financial Statements.	  	 	51	  
	 Section 4.29
	  	LipoSonix Agreement.	  	 	51	  
	 Section 4.30
	  	[Reserved].	  	 	52	  
	 Section 4.31
	  	Exclusivity of Representations and Warranties.	  	 	52	  
		
	ARTICLE 5 REPRESENTATIONS AND WARRANTIES OF BUYER	  	 	52	  
			
	 Section 5.1
	  	Organization and Good Standing.	  	 	52	  
	 Section 5.2
	  	Authority; Enforceability.	  	 	52	  
	 Section 5.3
	  	No Conflict; Required Filings and Consents.	  	 	53	  
	 Section 5.4
	  	Absence of Litigation.	  	 	53	  
	 Section 5.5
	  	Available Funds.	  	 	53	  
	 Section 5.6
	  	No Brokers.	  	 	54	  
	 Section 5.7
	  	Investment Representation.	  	 	54	  
	 Section 5.8
	  	Buyer Review.	  	 	54	  
	 Section 5.9
	  	No Outside Reliance.	  	 	54	  
		
	ARTICLE 6 COVENANTS	  	 	54	  
			
	 Section 6.1
	  	Conduct of Business by the Company Pending the Closing.	  	 	54	  
	 Section 6.2
	  	No Solicitation of Other Proposals.	  	 	58	  
	 Section 6.3
	  	Access to Information; Confidentiality.	  	 	59	  
	 Section 6.4
	  	Commercially Reasonable Efforts; Further Assurances.	  	 	60	  
	 Section 6.5
	  	Employee Benefits.	  	 	62	  
	 Section 6.6
	  	Notification of Certain Matters.	  	 	63	  
	 Section 6.7
	  	Public Announcements.	  	 	64	  
	 Section 6.8
	  	Claims.	  	 	64	  
	 Section 6.9
	  	Delivery of Corporate Records.	  	 	64	  
	 Section 6.10
	  	Certain Litigation Matters.	  	 	65	  
	 Section 6.11
	  	Post-Closing Books and Records of the Company.	  	 	65	  
	 Section 6.12
	  	FDA Approval Matters.	  	 	65	  
	 Section 6.13
	  	Additional Covenants Regarding LipoSonix Agreement.	  	 	65	  
	 Section 6.14
	  	Control of Business.	  	 	69	  
	 Section 6.15
	  	Seller Marks.	  	 	69	  
	 Section 6.16
	  	Audit and Preparation of Company Financial Statements.	  	 	69	  
	 Section 6.17
	  	Buyer Financing.	  	 	69	  
	 Section 6.18
	  	Transition Services Agreement.	  	 	70	  
	 Section 6.19
	  	No Use of Corporate Name.	  	 	70	  
		
	ARTICLE 7 CONDITIONS	  	 	70	  
			
	 Section 7.1
	  	Conditions to Each Party’s Obligations.	  	 	70	  
	 Section 7.2
	  	Additional Conditions to Obligations of Buyer.	  	 	71	  
	 Section 7.3
	  	Additional Conditions to Obligations of Seller.	  	 	71	  
		  		  			

  
 ii 

							
	ARTICLE 8 TERMINATION, AMENDMENT AND WAIVER	  	 	72	  
			
	 Section 8.1
	  	Termination.	  	 	72	  
	 Section 8.2
	  	Effect of Termination.	  	 	73	  
	 Section 8.3
	  	Amendment.	  	 	73	  
	 Section 8.4
	  	Waiver.	  	 	73	  
		
	ARTICLE 9 INDEMNIFICATION	  	 	73	  
			
	 Section 9.1
	  	Survival; Time Limitation.	  	 	73	  
	 Section 9.2
	  	Indemnification; Remedies.	  	 	74	  
	 Section 9.3
	  	Calculation of Losses; Indemnification Limitations.	  	 	76	  
	 Section 9.4
	  	Notice of Claims	  	 	77	  
	 Section 9.5
	  	Third Party Claims.	  	 	78	  
	 Section 9.6
	  	Other Matters.	  	 	79	  
	 Section 9.7
	  	Exclusive Remedies.	  	 	79	  
	 Section 9.8
	  	No Special, Punitive or Consequential Damages.	  	 	80	  
		
	ARTICLE 10 TAX	  	 	80	  
			
	 Section 10.1
	  	Tax Allocation.	  	 	80	  
	 Section 10.2
	  	Returns and Payments.	  	 	80	  
	 Section 10.3
	  	Contests.	  	 	81	  
	 Section 10.4
	  	Cooperation and Exchange of Information.	  	 	82	  
	 Section 10.5
	  	Characterization of Payments.	  	 	82	  
	 Section 10.6
	  	Transfer Taxes.	  	 	82	  
		
	ARTICLE 11 MISCELLANEOUS	  	 	82	  
			
	 Section 11.1
	  	Fees and Expenses.	  	 	82	  
	 Section 11.2
	  	Notices.	  	 	83	  
	 Section 11.3
	  	Severability.	  	 	84	  
	 Section 11.4
	  	Entire Agreement.	  	 	84	  
	 Section 11.5
	  	Assignment.	  	 	84	  
	 Section 11.6
	  	Parties in Interest.	  	 	84	  
	 Section 11.7
	  	Failure or Indulgence Not Waiver; Remedies Cumulative.	  	 	84	  
	 Section 11.8
	  	Governing Law; Jurisdiction.	  	 	84	  
	 Section 11.9
	  	Waiver of July Trial.	  	 	85	  
	 Section 11.10
	  	Enforcement of Agreement; Specific Performance.	  	 	85	  
	 Section 11.11
	  	Counterparts.	  	 	86	  
	 Section 11.12
	  	Due Diligence Materials; Seller Disclosure Schedule.	  	 	86	  
		
	ANNEX I DEFINITIONS	  	 	I - 1	  

  
 iii

 EXHIBITS 
  

			
	 Exhibit A
	  	Statement of Working Capital
	 Exhibit B
	  	Form of Confidentiality Agreement

  
 iv 

 STOCK PURCHASE AGREEMENT 

THIS STOCK PURCHASE AGREEMENT, dated as of September 12, 2011 (this “Agreement”), is entered into by and
between Medicis Pharmaceutical Corporation, a Delaware corporation (“Seller”), and Solta Medical, Inc., a Delaware corporation (“Buyer”). Buyer and Seller are sometimes referred to herein as the
“Parties.” 
 WHEREAS, pursuant to that certain Agreement and Plan of Merger dated as of June 16,
2008 (the “LipoSonix Agreement”) by and among Seller, Donatello, Inc., a direct wholly owned subsidiary of Seller, LipoSonix, Inc., a Delaware corporation, Rebecca Robertson, as Equityholders’ Representative, and Wilfred
Jaeger, as Alternate Equityholders’ Representative, Donatello, Inc. merged into LipoSonix, Inc., whereby LipoSonix, Inc. became a wholly-owned subsidiary of Seller and is now Medicis Technologies Corporation, a Delaware corporation (the
“Company”); 
 WHEREAS, Seller owns one hundred percent (100%) of the issued and outstanding shares
of capital stock (the “Shares”) of the Company; 
 WHEREAS, Seller desires to sell to Buyer and Buyer
desires to purchase from Seller, the Shares, for the consideration and on the terms and conditions set forth in this Agreement; and 
 WHEREAS, simultaneously with the execution and delivery of this Agreement, Medicis Aesthetics Canada Ltd. (“MAC”), a Subsidiary of Seller, and Buyer, have entered into an Asset
Purchase Agreement of even date herewith (the “Asset Purchase Agreement”), pursuant to which Medicis Aesthetics Canada Ltd. will (i) sell to Buyer certain assets related to the business of the Company and (ii) assign to
Buyer all of its right, title and interest in, to and under certain contracts, equipment, leases and rental contracts related to the business of the Company. 
 NOW, THEREFORE, in consideration of the foregoing and the mutual representations, warranties, covenants and agreements set forth herein, intending to be legally bound hereby, the Parties hereto
agree as follows: 

 ARTICLE 1 
 DEFINITIONS AND REFERENCES 
 Capitalized terms used herein without
definition shall have the respective meanings assigned thereto in Annex I attached hereto and incorporated herein for all purposes of this Agreement (such definitions to be equally applicable to both the singular and plural forms of the
terms defined). Unless otherwise specified, all references herein to “Articles,” “Sections,” “Exhibits,” “Annexes” or “Schedules” are to Articles, Sections, Exhibits, Annexes or Schedules of this
Agreement. The words “include,” “includes” and “including” shall be deemed to be followed by the phrase “without limitation.” The words “hereof,” “herein” and “herewith” and words
of similar import shall, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision of this Agreement. The table of contents and headings contained in this Agreement are for reference purposes
only and shall not affect in any way the meaning or interpretation of this Agreement. 
 ARTICLE 2 

PURCHASE AND SALE OF THE SHARES; PURCHASE PRICE 
 Section 2.1 Purchase and Sale of the Shares. Upon the terms and subject to the conditions set forth in this Agreement, at the Closing, Seller shall sell, assign, transfer, convey and deliver to
Buyer the Shares owned by Seller, free and clear of all Liens, and Buyer shall deliver to Seller the portion of the Purchase Price to be paid to Seller for the Shares at the Closing as provided in this Article 2. 

Section 2.2 Purchase Price. Upon the terms and subject to the conditions set forth in this Agreement, the aggregate purchase price
to be paid for the Shares shall be (a) fourteen million five hundred fifty-eight thousand three hundred seventy-eight dollars and sixteen cents ($14,558,378.16) (the “Base Purchase Price”), plus (i) the amount, if
any, by which the Final Working Capital exceeds the Target Working Capital, or minus (ii) the amount, if any, by which the Final Working Capital is less than the Target Working Capital (the Base Purchase Price, as adjusted in accordance
with Section 2.4, the “Purchase Price”), and (b) the contingent payments to be paid by Buyer to Seller pursuant to the terms and conditions set forth in Sections 2.6 and 2.7 of this Agreement
(collectively, the “Seller Contingent Payments”). 
 Section 2.3 Payment of the Purchase Price. At the
Closing, upon the terms and subject to the conditions set forth in this Agreement, Buyer shall pay fourteen million five hundred fifty-eight thousand three hundred seventy-eight dollars and sixteen cents ($14,558,378.16) of the Purchase Price
in cash to Seller or Seller’s designee in consideration for the Shares, by wire transfer of immediately available funds pursuant to the wire transfer instructions provided by Seller at least one (1) day prior to the Closing Date.

 Section 2.4 Working Capital Adjustment. 
 (a) Not later than three (3) Business Days prior to the scheduled Closing Date, Seller shall deliver to Buyer a schedule (the “Estimated Working Capital Schedule”)

  
 2 

 
summarizing Seller’s good faith estimate of the Working Capital of the Company as of the Closing Date (such estimated Working Capital being the “Estimated Working Capital”).
Seller shall prepare the Estimated Working Capital Schedule using the same accounting policies, methodologies, practices and assumptions as used in the preparation of the Statement of Working Capital as of August 31, 2011 attached hereto as
Exhibit A (the “Statement of Working Capital”), which Seller (after reasonable consultation with Buyer or its designee) is delivering to Buyer concurrently with the execution and delivery of this Agreement. Seller shall
provide Buyer with such information as Buyer may reasonably request to verify the Estimated Working Capital Schedule. The Base Purchase Price shall be adjusted either (i) upward by the amount the Estimated Working Capital is greater than the
Target Working Capital or (ii) downward by the amount the Estimated Working Capital is less than the Target Working Capital. 
 (b) As promptly as practicable, and in any event within sixty (60) days, following the Closing Date, Buyer shall deliver to Seller a schedule (the “Final Working Capital Schedule”)
with reasonable supporting detail summarizing Buyer’s calculation of the Working Capital of the Company as of the Closing Date (such Working Capital, subject to potential adjustments in accordance with this Section 2.4, being the
“Final Working Capital”). Buyer shall prepare the Final Working Capital Schedule using the same accounting policies, methodologies, practices and assumptions as used in the preparation of the Statement of Working Capital. Buyer
shall provide Seller with such information as Seller may reasonably request to verify the Final Working Capital Schedule. In the event that Buyer does not deliver the Final Working Capital Schedule within sixty (60) days following the Closing
Date, Buyer shall be deemed to have accepted the Estimated Working Capital as the Final Working Capital and the Estimated Working Capital shall be the Final Working Capital. 
 (c) Seller may dispute any amounts reflected on the Final Working Capital Schedule; provided, however, that Seller shall have notified Buyer in writing of each disputed item, specifying the
amount thereof in dispute and setting forth, in reasonable detail, the basis for such dispute, within thirty (30) days after Buyer’s delivery of the Final Working Capital Schedule to Seller. In the event of such a dispute, Seller and Buyer
shall attempt to reconcile their differences, and any resolution by them as to any disputed amounts shall be final, binding and conclusive on Seller and Buyer. If Seller and Buyer are unable to reach a resolution with such effect within fifteen
(15) Business Days after receipt by Buyer of Seller’s written notice of dispute, either Seller or Buyer shall have the right, upon delivery of written notice to the other Party, to submit the items remaining in dispute for resolution by an
independent accounting firm of nationally recognized standing which is reasonably acceptable to both Seller and Buyer (a “Qualified Accountant”), which shall, within thirty (30) days after such submission, deliver a report to
Seller and Buyer setting forth the resolution of such disputed items and the adjustment, if any, to be made to the Final Working Capital, and such report shall be final, binding and conclusive on Seller and Buyer, absent fraud. The fees and expenses
of the Qualified Accountant shall be borne by Seller, on the one hand, and Buyer, on the other hand, in inverse proportion as they may prevail on the matters resolved by the Qualified Accountant, which proportionate allocation will also be
determined by the Qualified Accountant and be included in the Qualified Accountant’s report. In acting under this Agreement, the Qualified Accountant shall be entitled to the privileges and immunities of arbitrators. 

  
 3 

 (d) After the Closing, Buyer shall, and shall cause its respective employees and agents to,
provide Seller, its accountants and the Qualified Accountants access at reasonable times to the personnel, properties and books and records of the Company for the purpose of reviewing the Final Working Capital Schedule or in connection with any
dispute under this Section 2.4. 
 (e) Within three (3) Business Days after the final determination of the
Final Working Capital pursuant to this Section 2.4, (i) if the Final Working Capital exceeds the Estimated Working Capital, Buyer shall pay to Seller the aggregate amount of such excess, by wire transfer of immediately available
funds to an account designated by Seller; and (ii) if the Final Working Capital is less than the Estimated Working Capital, Seller shall pay to Buyer the aggregate amount of such deficiency, by wire transfer of immediately available funds to an
account designated by Buyer. 
 Section 2.5 Assumption of Obligations under the LipoSonix Agreement. In accordance with
Section 3.12 of the LipoSonix Agreement, effective as of the Closing, Buyer hereby assumes the obligations set forth in the LipoSonix Agreement to make the Contingent Payments as set forth in the LipoSonix Agreement and hereby agrees to be
bound by and to comply with the terms and conditions set forth in the LipoSonix Agreement and the applicable terms of Sections 3.9 through 3.11 of the LipoSonix Agreement. From and after the Closing, Seller shall have no further obligation to make
any Contingent Payments pursuant to the LipoSonix Agreement. For the avoidance of doubt, the foregoing provision does not, and shall not be deemed to, constitute an assignment of the entire LipoSonix Agreement pursuant to Section 11.5 of the
LipoSonix Agreement, rather it constitutes only an assignment of all rights and obligations with respect to Contingent Payments in accordance with Section 3.12(d) of the LipoSonix Agreement. 

Section 2.6 Seller Contingent Payments. 
 (a) Certain Definitions. For purposes of this Agreement, the following definitions shall apply: 
 (i) “Additional LipoSonix Contingent Payment” means, for the period commencing on the first fiscal quarter immediately following the occurrence of the earliest of
(A) December 31, 2019, (B) the date that is the last day of the “Seventh Contingent Payment Year” under the LipoSonix Agreement and (C) the date on which Buyer has made (or has been deemed to have made pursuant to
Section 3.10 of the LipoSonix Agreement) the aggregate “Sales/Profit Contingent Payments” under the LipoSonix Agreement equal to ***, and ending on the Contingent Payment Termination Date, the amount that would otherwise be payable by
Buyer pursuant to Section 2.5 of this Agreement (or its permitted assignee) under the LipoSonix Agreement in respect of the “Sales/Profit Contingent Payment Amount” (as defined in the LipoSonix Agreement) for the then
applicable “Contingent Payment Year” (as defined in the LipoSonix Agreement) had none of the events described in clauses (A), (B) or (C) above occurred. 
 (ii) “Company Incremental Amount” means, with respect to any Contingent Payment Year, the amount equal to (x) the sum of (1) the amount of Worldwide Net

  
 4 

 
Sales for the Sales Payment Product for such Contingent Payment Year, (2) the amount of Worldwide Gross Profit for the Gross Profit Payment Product for such Contingent Payment Year and
(3) the amount of Worldwide Ancillary Gross Profit for the Contingent Payment Products for such Contingent Payment Year, minus (y) the sum of (1) the amount of Worldwide Net Sales for the Sales Payment Product for the immediately
completed previous Contingent Payment Year (or, with respect to the first Contingent Payment Year, the immediately completed previous twelve (12) consecutive calendar month period), (2) the amount of Worldwide Gross Profit for the Gross
Profit Payment Product for the immediately completed previous Contingent Payment Year (or, with respect to the first Contingent Payment Year, the immediately completed previous twelve (12) consecutive calendar month period) and (3) the
amount of Worldwide Ancillary Gross Profit for the Contingent Payment Products for the immediately completed previous Contingent Payment Year (or, with respect to the first Contingent Payment Year, the immediately completed previous twelve
(12) consecutive calendar month period); provided, that if the amount otherwise determined in accordance with this definition for any Contingent Payment Year is not greater than zero, then the Company Incremental Amount for such Contingent
Payment Year shall be deemed to be zero. 
 (iii) “Contingent Payment Commencement Date” means the first day
of the fiscal quarter following the fiscal quarter in which, after the “FDA Milestone” (as defined in the LipoSonix Agreement) has been achieved, the LipoSonix Product is first sold commercially to unaffiliated parties in the United
States. 
 (iv) “Contingent Payment Product” means either the Gross Profit Payment Product or the Sales
Payment Product, as applicable. 
 (v) “Contingent Payment Termination Date” means the last day of the
Contingent Payment Year that is the seventh full Contingent Payment Year after (A) the FDA Milestone has been achieved and (B) the Second Generation LipoSonix Product is first sold commercially to unaffiliated parties in the United States.

 (vi) “Contingent Payment Year” means each of the successive twelve (12) consecutive calendar month
periods beginning with the twelve (12) calendar month period commencing on the Contingent Payment Commencement Date and ending on the Contingent Payment Termination Date. 

(vii) “FDA Milestone” shall be deemed to be achieved upon receipt by any member of the Buyer Group of written approval
or clearance from the FDA, or a successor entity, allowing for the initiation of the marketing or sales of any version or derivative of the second generation of LipoSonix Product, part number P005700-01 and successor thereto (the “Second
Generation LipoSonix Product”), in the United States; provided, that the FDA Milestone shall not be deemed to have been achieved until all conditions and limitations contained in the written approval or clearance from the FDA that preclude
immediate marketing and commercialization of the LipoSonix Product have been satisfied or waived. 
 (viii) “FDA
Milestone Payment Amount” means the amount of: (a) $20,000,000, if the FDA Milestone is achieved on or before April 2, 2012; (b) the difference between (i) $20,000,000, minus the product of (x) the number of full
thirty (30) day periods 

  
 5 

 
between April 2, 2012 and October 1, 2012 that has passed prior to achieving the FDA Milestone, times (y) $1,000,000, if the FDA Milestone is achieved after April 2, 2012, but
on or before October 1, 2012; and (c) $0, if the FDA Milestone is achieved after October 1, 2012. 
 (ix)
“Gross Profit Payment Product” means the LipoSonix Product, excluding the Sales Payment Product. 
 (x)
“LipoSonix Product” means (A) the Company’s LipoSonix System, including the Sales Payment Product, which applies high intensity focused ultrasound for the purpose of using thermal lipolysis to treat adipose tissue, as it
has been developed and commercialized by the Company prior to the Closing, and (B) following the Closing, any Product of the Company (including the Sales Payment Product), any modifications or enhancements of any Product of the Company and any
product of the Buyer Group that applies high intensity focused ultrasound and that incorporates, uses, or is covered by the LipoSonix Technology. 
 (xi) “LipoSonix Technology” means any technology, including any methods, materials or products, that (i) was first disclosed in or is covered by (i.e., would infringe a claim
of) any patents and patent applications owned by or exclusively licensed by the Company and is disclosed in Section 4.16(a) of the Seller Disclosure Schedule (including, without limitation, any continuation, divisional or reissue of
any patent application or patent disclosed in Section 4.16(a) of the Seller Disclosure Schedule), or (ii) incorporates or uses any trade secret of the Company disclosed in Section 2.6(a)(x) of the Seller Disclosure
Schedule.  
 (xii) “Sales Milestone” shall be deemed to be achieved upon the first occurrence in
which, with respect to any Contingent Payment Year, the sum of Worldwide Net Sales for the Sales Payment Product, and Worldwide Gross Profit for the Gross Profit Payment Product and Worldwide Ancillary Gross Profit for the Contingent Payment
Products recorded for such Contingent Payment Year exceeds $300,000,000. 
 (xiii) “Sales Milestone Payment
Amount” means the amount of $30,000,000, less any amounts paid or payable (including any amounts that may become payable) as a “Sales Milestone Payment Amount” under the LipoSonix Agreement. 

(xiv) “Sales Payment Product” means transducers for use as part of, or for use with, the LipoSonix Product, and any
other disposable or limited life items sold for use with such transducers, including, but not limited to, treatment caps or cartridges. 
 (xv) “Sales/Profit Contingent Payment Amount” means, with respect to any Contingent Payment Year, an amount equal to the sum of (A) (x) the Sales/Profit Contingent Payment
Percentage multiplied by (y) the Company Incremental Amount for such Contingent Payment Year and (B) the Additional LipoSonix Contingent Payment. 
 (xvi) “Sales/Profit Contingent Payment Percentage” means 25%. 

(xvii) “Worldwide Ancillary Gross Profit” means (A) total gross revenues actually recognized from Contingent
Payment Products, including, without limitation, (1) the leasing and servicing of Contingent Payment Products, (2) the use of Contingent Payment 

  
 6 

 
Products by third parties (such as on a “fee for service basis”) and (3) licenses and similar arrangements pursuant to which a Person is granted the right to manufacture and/or
market, lease, sell, service or otherwise obtain revenues from a Contingent Payment Product (but in each case excluding gross revenues that are included in Worldwide Gross Profit or Worldwide Net Sales) minus (B) the cost of such revenues, each
as adjusted by any Worldwide Ancillary Gross Profit Adjustments (including amortization and depreciation) and all as recorded by Buyer (or any other applicable member of the Buyer Group if any such licensing, leasing or servicing contemplated hereby
is recorded by such member of the Buyer Group but not by Buyer), all in accordance with standard allocation procedures, allowance methodologies and accounting methods consistently applied, which procedures, methodologies and methods shall be in
accordance with GAAP. Notwithstanding anything to the contrary in this Agreement or in any financial statements prepared by Buyer with respect to any Contingent Payment Year or portion thereof, or to the extent it may otherwise be required pursuant
to GAAP, the term “Worldwide Ancillary Gross Profit” shall not include: (A) any revenues or other value received for the lease or service of a specified Contingent Payment Product used for research, manufacturing or quality testing,
clinical trials, compassionate or humanitarian purposes including expanded access programs (which provide access to therapies for no monetary consideration) or charitable donations; (B) any revenues or other value received (and related costs)
by Buyer or any other member of the Buyer Group from the license of any Intellectual Property related to the Contingent Payment Products (other than for the right to manufacture and/or market, lease, sell, service or otherwise obtain revenues from
any Contingent Payment Products); or (C) any amounts otherwise included in Worldwide Gross Profit or Worldwide Net Sales. For purposes of calculating “Worldwide Ancillary Gross Profit”, cost of revenues of any member of the Buyer
Group shall exclude any payments, or amounts payable, to any other member of the Buyer Group, to the extent that such payments or amounts payable are in excess of actual costs incurred by such other member of the Buyer Group in connection with the
applicable transaction. 
 (xviii) “Worldwide Ancillary Gross Profit Adjustments” means all adjustments,
including the following items as applicable to each such Contingent Payment Product, to the extent such adjustments are customary under industry practices and are reflected as a reduction to gross revenue or an increase to cost of goods sold in the
consolidated financial statements of Buyer in accordance with GAAP: 
 (A) credits or allowances granted upon returns,
rejections or recalls (due to spoilage, damage, expiration of useful life), price reductions, or billing corrections; 
 (B)
invoiced freight, postage, shipping and insurance, handling and other transportation costs; 
 (C) credits or allowances
granted including quantity, cash, bad debt and other trade discounts; 
 (D) Taxes (excluding withholding Taxes and Taxes paid
by Buyer on the net income derived from licensing for manufacture and leasing of and servicing the Contingent Payment Products), tariffs, customs duties, surcharges and other governmental charges incurred in connection with the production, lease,
service, transportation, delivery, use, 

  
 7 

 
exportation or importation of Contingent Payment Products that are incurred at the time of license for manufacture, lease or service or are directly related to the license for manufacture, lease
or service and not otherwise previously deducted; 
 (E) discounts, refunds, rebates, returns, charge backs, fees, credits or
allowances (including billing corrections, amounts incurred in connection with government-mandated rebate and discount programs, third party rebates and charge backs, hospital buying group/group purchasing or leasing organization administration fees
and managed care organization rebates), distribution fees and sales and other similar commissions to third parties, actually paid or incurred and which effectively reduce gross revenue; 

(F) warranties, guaranties and maintenance arrangements; and 
 (G) any other customary adjustments related to products licensed for manufacture, leased or serviced and reasonably allocated to such Contingent Payment Products as a portion of the gross revenue or
related cost of goods sold, in accordance with GAAP. 
 (xix) “Worldwide Gross Profit” means the difference
between (A) the Worldwide Net Sales of a specified Contingent Payment Product minus (B) the cost of goods sold (as adjusted by any Worldwide Net Sales Adjustments), for such specified Contingent Payment Product, each as recorded by Buyer
(or any other applicable member of the Buyer Group if any sales contemplated hereby are recorded by such member of the Buyer Group but not by Buyer), all in accordance with standard allocation procedures, allowance methodologies and accounting
methods consistently applied, which procedures, methodologies and methods shall be in accordance with GAAP, but excluding from cost of goods sold of any member of the Buyer Group any gross profit recorded by any member of the Buyer Group on any
sales to any other member of the Buyer Group. 
 (xx) “Worldwide Net Sales” means the gross amounts invoiced
for sales by Buyer (or any other applicable member of the Buyer Group if any sales contemplated hereby are recorded by such member of the Buyer Group but not by Buyer) from the sales of a specified Contingent Payment Product by a member of the Buyer
Group or its authorized or licensed distributor after the Closing to unaffiliated third parties less the Worldwide Net Sales Adjustments, all in accordance with standard allocation procedures, allowance methodologies and accounting methods
consistently applied, which procedures and methodologies shall be in accordance with GAAP. For purposes of clarification, when measuring the Worldwide Net Sales recorded in respect of sales of a specified Contingent Payment Product by any Person
other than a member of the Buyer Group, only the revenue recorded by Buyer or another member of the Buyer Group shall be included (for example, the transfer price or other amount received by Buyer or such other member of the Buyer Group, in the
event of any sales by an authorized or licensed distributor of the specified Contingent Payment Product manufactured by Buyer), and the amount of revenue that may be recorded or achieved by such other Person who is not a member of the Buyer Group
shall be disregarded. Notwithstanding anything to the contrary in this Agreement or in any financial statements prepared by Buyer with respect to any Contingent Payment Year or portion thereof, or to the extent it may otherwise be required pursuant
to GAAP, the term “Worldwide Net Sales” shall not include (A) gross amounts invoiced for sales 

  
 8 

 
by Buyer or any member of the Buyer Group from transactions with another member of the Buyer Group unless such other member of the Buyer Group is an end user of the specified Contingent Payment
Product; provided, however, that “Worldwide Net Sales” shall in such event include the gross amounts invoiced for sales, if any, recorded upon the further resale of such specified Contingent Payment Product by such other member of the
Buyer Group less the Worldwide Net Sales Adjustments or (B) distribution to a third party of a specified Contingent Payment Product for research, manufacturing or quality testing, clinical trials, compassionate or humanitarian purposes
including expanded access programs (which provide access to therapies for no monetary consideration) or charitable donations. 
 In the event
that Sales Payment Products are sold on a bundled basis with Gross Profit Payment Products, the gross amount invoiced for such bundled sale will be allocated for purposes of Sections 2.6(a)(xviii) and (xix) between the
Sales Payment Product and the Gross Profit Payment Product in proportion to the list price that would generally apply to sales to the applicable purchaser. 
 (xxi) “Worldwide Net Sales Adjustments” means all adjustments, including the following items as applicable to each such Contingent Payment Product, to the extent such adjustments are
customary under industry practices and are reflected as a reduction to net sales or, for purposes of determining Worldwide Gross Profit, an increase to cost of goods sold in the consolidated financial statements of Buyer in accordance with GAAP:

 (A) credits or allowances granted upon returns, rejections or recalls (due to spoilage, damage, expiration of useful life),
retroactive price reductions, or billing corrections; 
 (B) invoiced freight, postage, shipping and insurance, handling and
other transportation costs; 
 (C) credits or allowances granted including quantity, cash, bad debt and other trade discounts;

 (D) Taxes (including sales, value-added and excise Taxes, but excluding withholding Taxes and Taxes paid by Buyer on the net
income derived from sales of the Contingent Payment Products), tariffs, customs duties, surcharges and other governmental charges incurred in connection with the production, sale, transportation, delivery, use, exportation or importation of
Contingent Payment Products that are incurred at the time of sale or are directly related to the sale and not otherwise previously deducted; 
 (E) discounts, refunds, rebates, returns, charge backs, fees, credits or allowances (including billing corrections, amounts incurred in connection with government-mandated rebate and discount programs,
third party rebates and charge backs, hospital buying group/group purchasing organization administration fees and managed care organization rebates), distribution fees and sales commissions to third parties, actually paid or incurred and which
effectively reduce the selling price; 
 (F) warranties, guaranties and maintenance arrangements; and 

  
 9 

 (G) any other customary adjustments related to products sold and reasonably allocated to
such Contingent Payment Products as a portion of the total products sold or, for purposes of determining Worldwide Gross Profit, related cost of goods sold, in accordance with GAAP. 

(b) Seller Contingent Payments. In the event that the Closing occurs, and subject to the set-off rights of Buyer pursuant to
Section 2.7(h) and Article 9 hereof, after the Closing, but before the Contingent Payment Termination Date, Seller shall be entitled to receive the Seller Contingent Payments when and if required to be made in accordance with the
provisions of this Section 2.6 and Section 2.7, and subject to the limitation on the Seller Contingent Payments set forth in this Section 2.6 and Section 2.7. The Seller Contingent Payments shall
include the FDA Milestone Payment, the Sales Milestone Payment and the Sales/Profit Contingent Payments, as applicable, none of which Seller Contingent Payments shall bear interest. 

(c) FDA Milestone Payment. Subject to the set-off rights of Buyer pursuant to Section 2.7(h) and Article 9
hereof, Buyer shall make a one-time Seller Contingent Payment equal to the FDA Milestone Payment Amount if and only if the FDA Milestone is achieved on or before October 1, 2012 (the “FDA Milestone Payment”). 

(d) Sales Milestone Payment. Subject to the Contingent Payment Termination Date and the set-off rights of Buyer pursuant to
Section 2.7(h) and Article 9 hereof, Buyer shall make a one-time Seller Contingent Payment (the “Sales Milestone Payment”) equal to the Sales Milestone Payment Amount following achievement of the Sales Milestone.

 (e) Sales/Profit Contingent Payments. Subject to the Contingent Payment Termination Date and the set-off rights of
Buyer pursuant to Section 2.7(h) and Article 9 hereof, Buyer shall make a Seller Contingent Payment, with respect to the Worldwide Net Sales for the Sales Payment Product, the Worldwide Gross Profit for the Gross Profit Payment
Product, the Worldwide Ancillary Gross Profit for the Contingent Payment Products, the “Worldwide Net Sales” (as defined in the LipoSonix Agreement) for the “Sales Payment Product” (as defined in the LipoSonix Agreement), the
“Worldwide Gross Profit” (as defined in the LipoSonix Agreement) for the “Gross Profit Payment Product” (as defined in the LipoSonix Agreement) and the “Worldwide Ancillary Gross Profit” (as defined in the LipoSonix
Agreement) for the “Contingent Payment Products” (as defined in the LipoSonix Agreement), equal to the Sales/Profit Contingent Payment Amount for each Contingent Payment Year (each, a “Sales/Profit Contingent Payment” and
collectively, the “Sales/Profit Contingent Payments”), in accordance with Section 2.7. 
 (f)
Contingent Payments Not Certain. Each of Buyer and Seller hereby acknowledge that the achievement of the FDA Milestone is uncertain and that Buyer and its Affiliates may not achieve the FDA Milestone prior to October 1, 2012 or at all,
and it is therefore not assured that Buyer will be required to pay the FDA Milestone Payment at all. Each of Buyer and Seller hereby further acknowledge that the achievement of the Sales Milestone is uncertain and that Buyer and its Affiliates may
not achieve the Sales Milestone prior to the Contingent Payment Termination Date or at all, and it is therefore not assured that Buyer will be required to pay the Sales Milestone Payment at all. Each of Buyer and Seller hereby further

  
 10 

 
acknowledge that the amount of Worldwide Net Sales for the Sales Payment Product and Worldwide Gross Profit for the Gross Profit Payment Product and the Worldwide Ancillary Gross Profit for the
Contingent Payment Products, if any, that Buyer and its Affiliates may generate during any one or more Contingent Payment Years is uncertain and that (i) Buyer and its Affiliates may not generate any Worldwide Net Sales, Worldwide Gross Profit
or Worldwide Ancillary Gross Profit with respect to any Contingent Payment Product in any Contingent Payment Year, and (ii) it is therefore not assured that Buyer will be required to make any Sales/Profit Contingent Payments for any particular
Contingent Payment Year, or at all. 
 (g) Commercially Reasonable Efforts. 

(i) Commencing on the Closing Date and until the Contingent Payment Termination Date, Buyer shall use Commercially Reasonable Efforts to
develop, market and sell the LipoSonix Product, and shall use all Commercially Reasonable Efforts to do so in a manner designed to achieve the overall growth and success (both in terms of Worldwide Net Sales, Worldwide Gross Profit and Worldwide
Ancillary Gross Profit of the Contingent Payment Products) of such operations. In addition to the foregoing and not in limitation in anyway thereof, Buyer hereby agrees that, commencing on the Closing Date and until the Contingent Payment
Termination Date, Buyer shall not, and shall cause its Subsidiaries and Affiliates (including the Company after the Closing) not to, take any actions or fail to take any actions concerning the operations of the Company (or any successor to the
Company) with the intention of avoiding or reducing Buyer’s obligations under this Agreement with respect to the development, marketing and selling of the LipoSonix Product, including its obligations to make payment of any Seller Contingent
Payments hereunder or the Contingent Payments under the LipoSonix Agreement. 
 (ii) For purposes of this
Section 2.6(g) only, “Commercially Reasonable Efforts” means efforts reasonably used by Buyer for Buyer’s own products (including internally developed, acquired and in-licensed products) with similar commercial
potential (assuming continuing development of such product), taking into consideration the competitiveness of the marketplace, the proprietary position of the product, the regulatory structure involved, issues of safety and efficacy, the
profitability (not taking into account any payments payable under this Agreement), the extent of market exclusivity, the likely timing of the regulatory approval necessary to permit the product’s entry into the market, the then current level of
market penetration, patent protection, cost to develop the product, promotable claims, health economic claims and other relevant factors, in each case, taking into account the facts and circumstances at the time such efforts are due. 

(iii) In the event Seller asserts a Claim alleging that Buyer has failed to satisfy the Commercially Reasonable Efforts requirements set
forth in Section 2.6(g)(i), any liability of Buyer under such Claim shall not exceed, and Seller shall not be entitled to recover any Losses in excess of, an amount equal to ***, which amount shall be reduced to *** after the FDA
Milestone has been achieved and the FDA Milestone Payment has been paid to Buyer; provided, however, that no such limitation shall apply to the extent that Buyer (A) has failed to satisfy the Commercially Reasonable Efforts
requirements in connection with the second sentence of Section 2.6(g)(i) or (B) has failed to satisfy the Commercially Reasonable Efforts requirements in connection in the first sentence of Section 2.6(g)(i) as a result
of an Intentional 

  
 11 

 
Breach of the first sentence of Section 2.6(g)(i) by Buyer. Notwithstanding anything to the contrary herein, to the extent that any Additional LipoSonix Contingent Payments become
payable to Seller, Buyer shall have no obligation to, and Seller shall have no right to make any Claim for Losses arising out of any obligation of Buyer to, use Commercially Reasonable Efforts or any other level of efforts to achieve overall growth
and success with respect to the Additional LipoSonix Contingent Payment, but will have only the obligations set forth in the LipoSonix Agreement with respect thereto. The limitation in this Section 2.6(g)(iii) is a limitation on
liability and not a statement of liquidated damages. 
 (h) Cooperation on FDA Milestone 

(i) After the Closing and until the FDA Milestone is achieved, Buyer shall notify Seller of any material communications with any
applicable Governmental Authority (including the FDA), whether written or oral, as soon as reasonably practicable, but in no event later than three (3) Business Days after the receipt of such communications, and within such same time period,
Buyer shall provide Seller with copies of any such written communications and written summaries of any such oral communications. Buyer shall also provide to Seller monthly updates regarding the progress of the Company’s regulatory filings and
strategy for achieving the FDA Milestone. 
 (ii) After the Closing and until the FDA Milestone is achieved, the Joint Steering
Committee (the “JSC”) shall make recommendations with respect to the progress of the Company’s regulatory filings and strategy for achieving the FDA Milestone, including regulatory filings to the applicable Governmental
Authority (including the FDA), and responding to any communications or requests for information from any applicable Governmental Authority (including the FDA). The JSC shall be composed of four members, two of which shall be appointed by Buyer and
two by Seller. To the extent that the JSC is unable to reach agreement with respect to an issue or resolve a dispute for a period of fifteen (15) days, such matter shall be submitted to direct negotiation and shall be resolved between the Chief
Executive Officers of Buyer and Seller. Notwithstanding the foregoing, all final determinations with respect to any filings and interactions of Buyer with any Governmental Authority shall be ultimately made by Buyer. 

(iii) Notwithstanding the foregoing, Seller shall have no obligations whatsoever with respect to the achievement of the FDA Milestone
and shall not be liable whatsoever to any Person for Buyer’s inability to achieve the FDA Milestone. 
 Section 2.7
Payment of Seller Contingent Payments. 
 (a) FDA Milestone Payment. On or prior to the thirtieth (30th) day
following the achievement of the FDA Milestone, Buyer shall deliver to Seller the FDA Milestone Payment Amount; provided, however, that Buyer shall not be required to make, and Seller shall not be entitled to receive, the FDA Milestone Payment if
the FDA Milestone is achieved after October 1, 2012. 
 (b) Sales/Profit Contingent Payment Amount Certificates.

  
 12 

 (i) On or prior to the twentieth (20th) day following the last day of each fiscal
quarter during each Contingent Payment Year, Buyer shall deliver to Seller a certificate (each, a “Quarterly Contingent Payment Certificate”), setting forth for such fiscal quarter (A) (i) the amount of Worldwide Net Sales
for the Sales Payment Product, Worldwide Gross Profit for the Gross Profit Payment Product and Worldwide Ancillary Gross Profit for the Contingent Payment Products, (ii) for the Gross Profit Payment Product, the number of units produced, the
number of units sold, the average manufacturing cost per unit, and the average sales price per unit, (iii) for the Sales Payment Product, a detailed list of units produced, a detailed list of units sold, and the sales price per unit sold,
(iv) the unconsolidated revenue and gross profit of each entity within the Buyer Group that is derived from the LipoSonix Product and (v) an allocation of Worldwide Net Sales for the Sales Payment Product and Worldwide Gross Profit for the
Gross Profit Payment Product from sales and an allocation of Worldwide Ancillary Gross Profit for the Contingent Payment Products from licensing, leasing and provision of services (each identified separately) by each member of the Buyer Group,
(B) if applicable, (i) the amount of “Worldwide Net Sales” (as defined in the LipoSonix Agreement) for the “Sales Payment Product” (as defined in the LipoSonix Agreement), “Worldwide Gross Profit” (as defined
in the LipoSonix Agreement) for the “Gross Profit Payment Product” (as defined in the LipoSonix Agreement) and “Worldwide Ancillary Gross Profit” (as defined in the LipoSonix Agreement) for the “Contingent Payment
Products” (as defined in the LipoSonix Agreement), (ii) for the “Gross Profit Payment Product” (as defined in the LipoSonix Agreement), the number of units produced, the number of units sold, the average fully-loaded
manufacturing cost per unit, and the average sales price per unit, (iii) for the “Sales Payment Product” (as defined in the LipoSonix Agreement), a detailed list of units produced, a detailed list of units sold, and the sales price
per unit sold, (iv) the unconsolidated revenue and gross profit of each entity within the Buyer Group that is derived from the “LipoSonix Product” (as defined in the LipoSonix Agreement) and (v) an allocation of “Worldwide
Net Sales” (as defined in the LipoSonix Agreement) for the “Sales Payment Product” (as defined in the LipoSonix Agreement) and “Worldwide Gross Profit” (as defined in the LipoSonix Agreement) for the “Gross Profit
Payment Product” (as defined in the LipoSonix Agreement) from sales and an allocation of “Worldwide Ancillary Gross Profit” (as defined in the LipoSonix Agreement) for the “Contingent Payment Products” (as defined in the
LipoSonix Agreement) from licensing, leasing and provision of services (each identified separately) by each member of the Buyer Group, and (C) the amount, if any, to be set off by Buyer against the Seller Contingent Payments.

(ii) On or prior to the twentieth (20th) day following the last day of each Contingent Payment Year, Buyer shall deliver to Seller
a certificate (each, a “Contingent Payment Certificate”), setting forth for such Contingent Payment Year (i) the amount of Worldwide Net Sales for the Sales Payment Product, Worldwide Gross Profit for the Gross Profit Payment
Product and Worldwide Ancillary Gross Profit for the Contingent Payment Products, (ii) for the Gross Profit Payment Product, the number of units produced, the number of units sold, the average fully-loaded manufacturing cost per unit, and the
average sales price per unit, (iii) for the Sales Payment Product, the number of units produced, the number of units sold, and the average sales price per unit, (iv) the unconsolidated revenue and gross profit of each entity within the
Buyer Group that is derived from the LipoSonix Product and (v) an allocation of Worldwide Net Sales for the Sales Payment Product and Worldwide Gross Profit for the Gross Profit Payment Product from sales and an allocation of Worldwide
Ancillary Gross Profit 

  
 13 

 
for the Contingent Payment Products from licensing, leasing and provision of services (each identified separately) by each member of the Buyer Group, (B) if applicable, (i) the amount
of “Worldwide Net Sales” (as defined in the LipoSonix Agreement) for the “Sales Payment Product” (as defined in the LipoSonix Agreement), “Worldwide Gross Profit” (as defined in the LipoSonix Agreement) for the
“Gross Profit Payment Product” (as defined in the LipoSonix Agreement) and “Worldwide Ancillary Gross Profit” (as defined in the LipoSonix Agreement) for the “Contingent Payment Products” (as defined in the LipoSonix
Agreement), (ii) for the “Gross Profit Payment Product” (as defined in the LipoSonix Agreement), the number of units produced, the number of units sold, the average fully-loaded manufacturing cost per unit, and the average sales price
per unit, (iii) for the “Sales Payment Product” (as defined in the LipoSonix Agreement), a detailed list of units produced, a detailed list of units sold, and the sales price per unit sold, (iv) the unconsolidated revenue and
gross profit of each entity within the Buyer Group that is derived from the “LipoSonix Product” (as defined in the LipoSonix Agreement) and (v) an allocation of “Worldwide Net Sales” (as defined in the LipoSonix Agreement)
for the “Sales Payment Product” (as defined in the LipoSonix Agreement) and “Worldwide Gross Profit” (as defined in the LipoSonix Agreement) for the “Gross Profit Payment Product” (as defined in the LipoSonix Agreement)
from sales and an allocation of “Worldwide Ancillary Gross Profit” (as defined in the LipoSonix Agreement) for the “Contingent Payment Products” (as defined in the LipoSonix Agreement) from licensing, leasing and provision of
services (each identified separately) by each member of the Buyer Group, and (C) (i) Buyer’s determination of the Sales/Profit Contingent Payment Amount, if any, for such Contingent Payment Year (including the calculation thereof, in
reasonable detail) and (ii) the amount, if any, set off by Buyer against the Seller Contingent Payments. 
 (c) Seller
Audit Rights. Buyer hereby grants, and shall cause the other members of the Buyer Group to grant, Seller and its representatives and advisers, at Seller’s sole expense, the right, exercisable no more than once during each thirty
(30) day period following the receipt by Seller of a Contingent Payment Certificate, subject to the execution of, and compliance with, a confidentiality agreement with Buyer in substantially the form attached hereto as Exhibit B (which
shall permit disclosure of information to Seller), to examine and have full access to the Buyer Group’s personnel, books of account and records of Worldwide Net Sales for the Sales Payment Product, Worldwide Gross Profit for the Gross Profit
Payment Product, Worldwide Ancillary Gross Profit for the Contingent Payment Products, “Worldwide Net Sales” (as defined in the LipoSonix Agreement) for the “Sales Payment Product” (as defined in the LipoSonix Agreement),
“Worldwide Gross Profit” (as defined in the LipoSonix Agreement) for the “Gross Profit Payment Product” (as defined in the LipoSonix Agreement) or “Worldwide Ancillary Gross Profit” (as defined in the LipoSonix
Agreement) for the “Contingent Payment Products” (as defined in the LipoSonix Agreement) for the applicable Contingent Payment Year with respect to which the most recent Contingent Payment Certificate has been delivered, as well as the
immediately prior Contingent Payment Year (or, with respect to the first Contingent Payment Year after the Contingent Payment Commencement Date, the immediately completed previous twelve (12) consecutive calendar month period), at the location
of such records on prior written notice of at least ten (10) days, for the purpose of verifying and assessing the amount of Worldwide Net Sales for the Sales Payment Product, Worldwide Gross Profit for the Gross Profit Payment Product,
Worldwide Ancillary Gross Profit for the Contingent Payment Products, “Worldwide Net Sales” (as defined in the LipoSonix Agreement) for the “Sales Payment Product” (as defined in the LipoSonix Agreement), “Worldwide Gross

  
 14 

 
Profit” (as defined in the LipoSonix Agreement) for the “Gross Profit Payment Product” (as defined in the LipoSonix Agreement) or “Worldwide Ancillary Gross Profit” (as
defined in the LipoSonix Agreement) for the “Contingent Payment Products” (as defined in the LipoSonix Agreement) for such Contingent Payment Years (each such review shall be referred to herein as a “Contingent Payment
Audit”). Notwithstanding the foregoing, absent fraud, willful misconduct, or the discovery (following the completion of any Contingent Payment Audit) of a material fact in existence at the time of such Contingent Payment Audit and not
disclosed by Buyer to Seller or its representatives in the course of conducting such Contingent Payment Audit, which material fact, if taken into account in the calculation of the applicable Sales/Profit Contingent Payment Amount, would have
resulted in an increase in such Sales/Profit Contingent Payment Amount, Seller or its representatives shall not be permitted to review any records of Worldwide Net Sales, Worldwide Gross Profit or Worldwide Ancillary Gross Profit with respect to any
Contingent Payment Product or of “Worldwide Net Sales” (as defined in the LipoSonix Agreement), “Worldwide Gross Profit” (as defined in the LipoSonix Agreement) or “Worldwide Ancillary Gross Profit” (as defined in the
LipoSonix Agreement) with respect to any “Contingent Payment Product” (as defined in the LipoSonix Agreement) for any Contingent Payment Year for which a Contingent Payment Audit has previously been performed. For the purpose of conducting
a Contingent Payment Audit, Seller may hire, at its expense, one or more auditors or attorneys of Seller’s choosing to assist in such examination; provided, that such auditors or attorneys have entered into confidentiality agreements with Buyer
in substantially the form attached hereto as Exhibit B (which shall permit disclosure of information to Seller). Seller and such representatives shall have access to all of the books, records and personnel required in the good faith judgment
of the Seller to perform any Contingent Payment Audit for a thirty (30) day period, beginning on the date on which access to substantially all of such books and records is first given to Seller. Nothing in this Section 2.7(c) shall
be deemed to require any member of the Buyer Group to keep any books of account or records other than those which they maintain in the ordinary course of business in its usual and customary practice, to retain any such books of account or records
for any period in excess of the period for which they retain such records in the ordinary course of business in their usual and customary practice, or to provide access to any books and records other than that specified above, and no presumption
shall be made against any member of the Buyer Group as a result of the absence of any such books and records as a result of the disposition of any such books and records in the ordinary course of business after such period as provided above;
provided, however, that in no case shall any member of the Buyer Group dispose of such books of account or records with respect to a Contingent Payment Year earlier than the date one hundred eighty (180) days following the last
day of the subsequent Contingent Payment Year or, if such Contingent Payment Year is the last Contingent Payment Year, one hundred eighty (180) days following the last day of such Contingent Payment Year; and, provided further, that once Seller
gives notice of its intention to commence a Contingent Payment Audit with respect to a Contingent Payment Year or Contingent Payment Years, the Buyer Group shall keep and retain all books of account relating to Worldwide Net Sales for the Sales
Payment Product, Worldwide Gross Profit for the Gross Profit Payment Product, Worldwide Ancillary Gross Profit for the Contingent Payment Products, “Worldwide Net Sales” (as defined in the LipoSonix Agreement) for the “Sales Payment
Product” (as defined in the LipoSonix Agreement), “Worldwide Gross Profit” (as defined in the LipoSonix Agreement) for the “Gross Profit Payment Product” (as defined in the LipoSonix Agreement) and “Worldwide Ancillary
Gross Profit” (as defined in the LipoSonix Agreement) for the “Contingent Payment 

  
 15 

 
Products” (as defined in the LipoSonix Agreement) for the Contingent Payment Year or Contingent Payment Years for which such Contingent Payment Audit is being conducted that are identified
in a request or requests from Seller with respect to the Sales/Profit Contingent Payment Amount for such Contingent Payment Year or Contingent Payment Years. 
 (d) Dispute Notice. In the event that Seller does not agree with the Sales/Profit Contingent Payment Amount set forth on any Contingent Payment Certificate, Seller shall be entitled, during the
period following delivery of such Contingent Payment Certificate and ending on the later of (i) ninety (90) days after delivery of such Contingent Payment Certificate and (ii) thirty (30) days following the completion of a
Contingent Payment Audit commenced in connection with the delivery of such Contingent Payment Certificate (the “Dispute Period”), to give Buyer written notice (a “Dispute Notice”) of such disagreement. In the event
that Seller does not deliver a Dispute Notice during the Dispute Period, the Sales/Profit Contingent Payment Amount set forth on such Contingent Payment Certificate shall irrevocably be deemed to be the final Sales/Profit Contingent Payment Amount
for such Contingent Payment Year and all purposes of this Agreement, absent fraud and willful misconduct. 
 (e) Agreed
Contingent Payment. In the event that Seller delivers a Dispute Notice within the Dispute Period, Seller and Buyer shall for a period of not less than thirty (30) days after delivery of the Dispute Notice attempt in good faith to resolve
the Sales/Profit Contingent Payment Amount that is in dispute (the “Disputed Contingent Payment Amount”), and mutually determine any adjustments to such Sales/Profit Contingent Payment Amount (the “Agreed Contingent Payment
Amount”). Buyer and Seller shall, subject to the execution of a confidentiality agreement in substantially the form attached hereto as Exhibit B, provide each other with such information, records and material kept in the ordinary
course of business in such Party’s possession and which such Party may disclose without violating confidentiality obligations to third parties, as is reasonably necessary and appropriate in attempting to resolve such Disputed Contingent Payment
Amount, including the delivery of a copy to Seller of any such information, records and material, to the extent then available, that was used to calculate the amount of Worldwide Net Sales for the Sales Payment Product, Worldwide Gross Profit for
the Gross Profit Payment Product, Worldwide Ancillary Gross Profit for the Contingent Payment Products, “Worldwide Net Sales” (as defined in the LipoSonix Agreement) for the “Sales Payment Product” (as defined in the LipoSonix
Agreement), “Worldwide Gross Profit” (as defined in the LipoSonix Agreement) for the “Gross Profit Payment Product” (as defined in the LipoSonix Agreement), “Worldwide Ancillary Gross Profit” (as defined in the
LipoSonix Agreement) for the “Contingent Payment Products” (as defined in the LipoSonix Agreement) and the Sales/Profit Contingent Payment Amount set forth on each relevant Contingent Payment Certificate. If the final Agreed Contingent
Payment Amount determined pursuant to this Section 2.7(e) is greater than the Sales/Profit Contingent Payment Amount set forth on the relevant Contingent Payment Certificate by an amount equal to more than $1,000,000, Buyer shall pay all
of the reasonable out-of-pocket costs and expenses actually incurred by Seller in connection with such Contingent Payment Audit. 
 (f) Arbitration of Disputes. In the event that no agreement can be reached by Seller and Buyer as to the calculation of the Disputed Contingent Payment Amount within ninety (90) days after
delivery of a Dispute Notice and such disagreement relates only to the amount of Worldwide Net Sales for the Sales Payment Product, Worldwide Gross Profit for the Gross 

  
 16 

 
Profit Payment Product, Worldwide Ancillary Gross Profit for the Contingent Payment Products, “Worldwide Net Sales” (as defined in the LipoSonix Agreement) for the “Sales Payment
Product” (as defined in the LipoSonix Agreement), “Worldwide Gross Profit” (as defined in the LipoSonix Agreement) for the “Gross Profit Payment Product” (as defined in the LipoSonix Agreement) or “Worldwide Ancillary
Gross Profit” (as defined in the LipoSonix Agreement) for the “Contingent Payment Products” (as defined in the LipoSonix Agreement), then, pursuant to this Section 2.7(f), either Party shall have the right to submit the
Disputed Contingent Payment Amount to arbitration by the Los Angeles, California office of one (1) of the following entities or their respective successors, or such other accountants as Seller and Buyer may mutually agree, so long as such
entity or its successors is not the principal regularly-engaged outside accountant to Buyer or the Company or any auditor that may have assisted Seller in any Contingent Payment Audit: Deloitte & Touche LLP, KPMG, Ernst & Young
LLP, PricewaterhouseCoopers, BDO Seidman, LLP, Grant Thornton LLP, or any successor entity to the foregoing (individually, an “Accountant,” and collectively, the “Accountants”). Seller and Buyer shall jointly select
which of the Accountants will perform the calculation within thirty (30) days after Seller and Buyer determine that they are unable to settle the amount independently; provided, that in the event that Seller and Buyer are unable to agree upon
the Accountant to perform such calculation within such thirty (30) day period, then each of Seller and Buyer shall select one of the Accountants and such Accountants shall jointly select a third Accountant to perform such calculation; provided,
further, that any Accountant consulted or selected in accordance with this sentence shall enter into a confidentiality agreement with Buyer in substantially the form attached hereto as Exhibit B. The Accountant selected in accordance with the
foregoing sentence shall be responsible for the determination of the Disputed Contingent Payment Amount (the “Appraiser”). The engagement and charge of the Appraiser shall be limited to determining the Worldwide Net Sales, Worldwide
Gross Profit, Worldwide Ancillary Gross Profit, “Worldwide Net Sales” (as defined in the LipoSonix Agreement), “Worldwide Gross Profit” (as defined in the LipoSonix Agreement) and “Worldwide Ancillary Gross Profit” (as
defined in the LipoSonix Agreement) of any identified Contingent Payment Product for the applicable Contingent Payment Year used to calculate the Disputed Contingent Payment Amount, and the Appraiser shall not be entitled to determine whether any
products sold by Buyer or its Affiliates are Gross Profit Payment Products, Sales Payment Products, “Gross Profit Payment Products” (as defined in the LipoSonix Agreement) or “Sales Payment Products” (as defined in the LipoSonix
Agreement) for purposes of this Agreement or any other matter (and any dispute with respect thereto shall be resolved in accordance with Section 11.8). The Appraiser shall determine the Disputed Contingent Payment Amount within the
limitations set forth above within ninety (90) days after the date of such Appraiser’s engagement and the Appraiser shall be provided with such information and records, which may include on-site access and access to personnel, relating to
such dispute as it may reasonably request. Any Disputed Contingent Payment Amount determined by an Appraiser in accordance with this Section 2.7(f) shall be deemed to be the final Sales/Profit Contingent Payment Amount for the applicable
Contingent Payment Year for all purposes of this Agreement. The fees and expenses of the Appraiser shall be paid by Seller, provided, that if the final Sales/Profit Contingent Payment Amount determined by the Appraiser in any examination conducted
pursuant to this Section 2.7(f) is greater than the Sales/Profit Contingent Payment Amount set forth on the relevant Contingent Payment Certificate by an amount equal to more than $1,000,000, then Buyer shall pay all of the fees and
expenses of the Appraiser and all 

  
 17 

 
reasonable out-of-pocket costs and expenses actually incurred by Seller in connection with any Contingent Payment Audit. 
 (g) Final Calculation and Payment of Sales/Profit Contingent Payment and Sales Milestone Payment. With respect to any Sales/Profit Contingent Payment Amount for any Contingent Payment Year:

 (i) In the event Seller does not deliver a Dispute Notice with respect to the Sales/Profit Contingent Payment Amount set
forth on the Contingent Payment Certificate delivered for such Contingent Payment Year within the Dispute Period, or Seller delivers to Buyer a written notice informing Buyer of its agreement with the Sales/Profit Contingent Payment Amount set forth
on such Contingent Payment Certificate, the Sales/Profit Contingent Payment Amount set forth in the relevant Contingent Payment Certificate shall irrevocably be deemed to be the final such Sales/Profit Contingent Payment Amount for such Contingent
Payment Year for all purposes of this Agreement, absent fraud and willful misconduct, and Buyer shall, within ten (10) days after such determination, pay to Seller the amounts required to be paid based on such Sales/Profit Contingent Payment
Amount and, if the Sales Milestone has also been achieved during such Contingent Payment Year, the Sales Milestone Payment Amount, subject to Section 2.7(h) hereof. 

(ii) In the event that Seller delivers a Dispute Notice pursuant to Section 2.7(d) with respect to a Sales/Profit Contingent
Payment Amount, and Buyer and Seller shall mutually determine the Agreed Contingent Payment Amount, then the Agreed Contingent Payment Amount shall irrevocably be deemed to be the final such Sales/Profit Contingent Payment Amount for such Contingent
Payment Year for all purposes of this Agreement, absent fraud and willful misconduct, and Buyer shall, within ten (10) days after such Agreed Contingent Payment Amount is determined, pay to Seller the amounts required to be paid based on such
Sales/Profit Contingent Payment Amount and, if the Sales Milestone has also been achieved during such Contingent Payment Year, the Sales Milestone Payment Amount, subject to Section 2.7(h) hereof. 

(iii) In the event that the final Sales/Profit Contingent Payment Amount for such Contingent Payment Year is determined by an Appraiser
pursuant to Section 2.7(f) above, then Buyer shall, within ten (10) days after such determination, pay to Seller the amounts required to be paid based on such Sales/Profit Contingent Payment Amount and, if the Sales Milestone has
also been achieved during such Contingent Payment Year, the Sales Milestone Payment Amount, subject to Section 2.7(h) hereof. 
 (iv) The determination of any Sales/Profit Contingent Payment Amount and Sales Milestone Payment pursuant to Sections 2.7(g)(i)-(iii) shall, in the absence of fraud and willful misconduct, be
conclusive, and in the absence of fraud and willful misconduct, Buyer and its Affiliates and Subsidiaries, Seller and Appraiser shall each be free from any and all liability resultant from such determination except as expressly set forth herein.
Furthermore, Buyer shall not be required to make, and Seller shall not be entitled to receive, the Sales Milestone Payment if the Sales Milestone is achieved after the Contingent Payment Termination Date. 

  
 18 

 (h) Unilateral Right of Set-Off. Subject to the express limitations and procedures
set forth in Article 9 and Section 6.13 hereof, the obligation of Buyer to make any Seller Contingent Payment shall be qualified by the right of Buyer to reduce the amount of any one or more of (i) the FDA Milestone Payment
Amount, (ii) the Sales Milestone Payment Amount or (iii) the Sales/Profit Contingent Payment Amount for any Contingent Payment Year, by the amount of any Losses actually incurred or suffered, or more likely than not to be incurred or
suffered, by Buyer for which Buyer is entitled to indemnification pursuant to Article 9, but, except for Claims based on fraud, in no event shall such Seller Contingent Payments be reduced by, (A) with respect to indemnification pursuant
to Section 9.2(a)(i) (except in respect of the representations and warranties made under Sections 4.3, 4.4, 4.14, 4.18 and 4.29), Section 9.2(a)(ii) (except in respect of an Intentional
Breach by Seller of the covenants or agreements described in such Section), Section 9.2(a)(iii) (except in respect of an Intentional Breach by Seller of the covenants or agreements described in such Section),
Section 9.2(a)(vii) and Section 9.2(a)(viii), more than an amount equal to the sum of (x) *** of the sum of the Purchase Price and the FDA Milestone Payment (to the extent actually paid by Buyer to Seller) and
(y) *** of the Seller Contingent Payments, other than the FDA Milestone Payment, actually paid by Buyer to Seller hereunder, and (B) with respect to indemnification pursuant to (1) Section 9.2(a)(i) with respect to the
representations and warranties made under Sections 4.3(a), 4.4, 4.18 and 4.29 and (2) Section 9.2(a)(v), more than an amount equal to *** of the sum of (x) the Purchase Price and (y) the Seller
Contingent Payments actually paid by Buyer to Seller hereunder; provided, that (x) the right of Buyer to reduce any Seller Contingent Payment pursuant to this Section 2.7(h) is subject to the limitations, notice
requirements and procedures set forth in Article 9, including Sections 9.3 through 9.5; (y) with respect to Losses more likely than not to be incurred or suffered with respect to any Third Party Claim, the amount by which
the Seller Contingent Payments are reduced shall not exceed the amount stated in any notice provided by Buyer of such Claim in accordance with Article 9 (if such amount is reasonably available); and (z) in the event that Buyer is
entitled to indemnification pursuant to Article 9 and entitled to offset hereunder, but its recovery is limited by clause (A) or (B) of this sentence, Buyer shall be entitled to recover any unrecovered amount as to which Buyer is
entitled to indemnification pursuant to Article 9 and entitled to offset hereunder from future Contingent Payments, subject to limitations set forth in clauses (A) and (B) of this sentence. In the event that (A) Buyer sets off
the amount of any Seller Contingent Payment by the amount of any Losses that have not been, at the time such Seller Contingent Payment is made, incurred by Buyer or (B) Seller objects to a Claim as set forth in Section 9.4, and it
is later finally determined that the full amount of such Losses will not be incurred by Buyer, or the applicable Buyer Indemnified Person is not entitled to indemnification pursuant to Article 9 with respect to any portion of such Losses, as
the case may be, then, following such determination, Buyer shall pay to Seller, promptly after such determination, the amount of the prior reduction attributable to such Losses that will not be incurred by Buyer (or for which the applicable Buyer
Indemnified Person is not entitled to indemnification). Any amounts paid to the Seller pursuant to the immediately preceding sentence shall be (i) increased by simple interest on such amount calculated at the Interest Rate to and including
the date of payment based on a 365-day year, without compounding, (ii) made by wire transfer of immediately available funds to an account designated by Seller, and (iii) treated as an adjustment to the Purchase Price for tax reporting
purposes. Subject to Section 9.7, Buyer shall have no right to set-off or reduce the amount of 

  
 19 

 
any Seller Contingent Payment otherwise required to be paid pursuant to this Section 2.7 except as is expressly set forth in this Section 2.7(h). 

(i) No Security. The Parties understand and agree that (a) the contingent rights to receive any Seller Contingent Payment
will not be represented by any form of certificate, are not transferable, except by operation of Laws relating to descent and distribution, divorce and community property, and do not constitute an equity or ownership interest in Buyer,
(b) Seller shall not have any rights as a security holder of the Company or Buyer as a result of such Seller’s contingent right to receive any Seller Contingent Payment hereunder and (c) no interest is payable with respect to any
Seller Contingent Payment. 
 (j) Seller Contingent Payments Not Royalties. The Seller Contingent Payments provided for
pursuant to this Article 2 are provided as a result of bona fide difficulties in determining the present value of the Company. The Seller Contingent Payments represent (and shall be reported by Buyer as) additional consideration for the
Shares and are not intended to be royalty payments. Buyer agrees that the Seller Contingent Payments will be reported by Buyer as deferred payments subject to installment sale treatment under Section 453 of the Code (and will be reported by
Buyer in part as payments of interest pursuant to Section 483 or Section 1274 of the Code). 
 Section 2.8 Consent
Requirement. If, after the Closing and prior to the Contingent Payment Termination Date: 
 (a) Buyer (or a Subsidiary or
Affiliate thereof) shall cease to own a majority of the outstanding voting securities of the Company (or of any other Subsidiary of Buyer that is engaged in developing, manufacturing, marketing or selling the LipoSonix Product (a “Successor
Subsidiary”)); or 
 (b) Buyer or any of its Subsidiaries, including the Company, shall, in one or a series of
transactions, sell, license or transfer to any Person all or substantially all of the Intellectual Property used in developing, manufacturing, marketing or selling the LipoSonix Product to any Person; 

then, (i) Buyer, prior to entering into such transaction or transactions, shall obtain Seller’s written consent, which shall
not be unreasonably withheld, and (ii) any Person acquiring a majority of the outstanding voting securities of the Company or a Successor Subsidiary after the Closing in a transaction described in Section 2.8(a) or acquiring all or
substantially all of the Intellectual Property used in developing, marketing or selling the LipoSonix Product in a transaction described in Section 2.8(b), as the case may be (the “Acquiring Person”), shall explicitly
assume in writing the obligations of Buyer to make the Seller Contingent Payments as set forth in this Agreement and shall agree in writing to be bound by and to comply with the terms and conditions set forth in this Agreement and the terms and
conditions of Sections 2.6 and 2.7 of this Agreement (including but not limited to the requirements set forth in Section 2.6(g)). For purposes of this Section 2.8, Seller shall be deemed to have unreasonably
withheld its consent if with respect to the transaction or transactions described in this Section 2.8, the Acquiring Person expressly assumes the obligations as set forth in clause (ii) of this Section 2.8 and if such
Acquiring Person is a Qualified Acquiring Person. A “Qualified Acquiring Person” 

  
 20 

 
means a Person (i) who (A) is directly engaged in any business that develops, manufactures, sells, markets or distributes pharmaceutical, medical device or any other healthcare products
or devices, and (B) has earnings before interest, taxes, depreciation and amortization (or EBITDA) of no less than $10,000,000 in each of the two fiscal years immediately preceding the transaction or transactions described in this
Section 2.8 or (ii) that is an Affiliate of a financial sponsor, private equity firm or similar organization, which Affiliate (together with the Company or Successor Subsidiary), (A) immediately after the closing of such
acquisition, has a consolidated ratio of total debt to EBITDA (as such term is defined in the Credit Agreement) for the 12-month period ended the date of such transaction that is no greater than 4.0 to 1(4.0x), and (B) has, on a pro forma
basis, earnings before interest, taxes, depreciation and amortization (or EBITDA) of no less than $10,000,000 in each of the two fiscal years immediately preceding the transaction or transactions described in this Section 2.8. Upon and
following Seller’s written consent and the express assumption and agreement by the Person referred to in this Section 2.8, Buyer shall have no further obligation to make any further Seller Contingent Payments pursuant to this
Agreement. For the avoidance of doubt, this Section 2.8 shall not apply to an acquisition of a majority of the outstanding voting securities of Buyer or a change of control of Buyer that does not involve a separate transfer of the assets
or equity securities of the Company; it being understood that, following any such transaction, this Section 2.8 shall continue to apply to any future transactions described under clauses (a) or (b) above. 

ARTICLE 3 

CLOSING 

Section 3.1 Closing. Upon the terms and subject to the conditions set forth in this Agreement, the closing of the Contemplated
Transactions (the “Closing”) shall take place at the Washington, DC offices of Hogan Lovells US LLP at 10:00 a.m. (local time), as soon as practicable, provided, that if all of the conditions set forth in Article 7 are not
satisfied or waived on or before such date (other than those conditions which by their nature are intended to be fulfilled at the Closing), the Closing shall be held on the date which is five (5) Business Days after the date on which all such
conditions shall have been satisfied or waived, or at such other time, date and place as the parties may agree (the date on which the Closing shall occur pursuant to this Section 3.1 is referred to herein as the “Closing
Date”). The transfer of the Shares pursuant to Section 2.1 shall be deemed to become effective as of 12:01 a.m. on the Closing Date. 
 Section 3.2 Closing Deliveries. At the Closing: 
 (a) Buyer shall deliver
to Seller evidence of the wire transfers referred to in Section 2.3; 
 (b) Seller shall deliver to Buyer one or
more stock certificates evidencing the Shares being sold by Seller, which certificates shall be duly endorsed to Buyer or accompanied by dully executed stock powers; and 

  
 21 

 (c) each Party shall deliver the certificates and other documents and instruments required
to be delivered by or on behalf of such Party pursuant to Article 7 and the other provisions of this Agreement, as applicable. 
 ARTICLE 4 
 REPRESENTATIONS AND 

WARRANTIES OF SELLER 
 Seller hereby represents and warrants to Buyer as follows (it being understood that each representation and warranty contained in this Article 4 is subject to: (a) the exceptions and
disclosures set forth in the section or subsection of the disclosure schedule delivered by Seller (the “Seller Disclosure Schedule”) corresponding to the particular section or subsection in this Article 4 in which such
representation and warranty appears; (b) any exceptions or disclosures explicitly cross-referenced in such section or subsection of the Seller Disclosure Schedule by reference to another section or subsection of the Seller Disclosure Schedule);
and (c) any exceptions or disclosures set forth in any other section of subsection of the Seller Disclosure Schedule to the extent it would be clear to a reasonable person that the disclosure contained in such section or subsection should
qualify such non-referenced representation or warranty without the necessity of repetitive disclosure or cross-reference): 

Section 4.1 Organization and Qualification. 
 (a) Seller is a corporation duly organized, validly existing and in good standing under the Laws of the State of Delaware. The Company is a corporation duly organized, validly existing and in good
standing under the Laws of the State of Delaware and has all the requisite corporate power and authority necessary to own, lease and operate its assets and properties and to carry on its business as it is now being conducted. The Company is in
possession of all franchises, grants, authorizations, licenses, permits, easements, consents, waivers, qualifications, certificates, Orders and approvals (collectively, “Approvals”) necessary to own, lease and operate its assets and
properties and to carry on its business as it is now being conducted, except where the failure to possess any such Approval would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on the Company. The
Company is duly qualified or licensed as a foreign corporation to do business, and is in good standing, in each jurisdiction (including any applicable non-U.S. jurisdiction) where the character of the assets or properties owned, leased or operated
by it or the nature of its activities makes such qualification or licensing necessary, except where the failure to be so qualified or licensed does not have and would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect on the Company. 
 (b) The Company has no Subsidiaries and does not control, directly or indirectly, or have any
direct or indirect equity participation or similar interest (or right convertible into any such interest) in any corporation, partnership, limited liability company or other entity or business association. The Company is not a participant in any
joint venture or similar arrangement. 

  
 22 

 Section 4.2 Charter and Bylaws. Seller has heretofore provided to Buyer true and
complete copies of the Charter and Bylaws, as modified, supplemented, amended or restated. Such Charter and Bylaws are in full force and effect, and no other organizational documents are applicable to or binding upon the Company. 

Section 4.3 Shares; Indebtedness. 
 (a) The authorized capital stock of the Company consists of 100 shares of Common Stock, 100 shares of which are issued and outstanding as of the date of this Agreement and constitute the Shares. Seller is
the sole beneficial and record owner of the Shares free and clear of all Liens. Except for the Shares, there are no other outstanding equity securities in the Company. Seller has, and shall have at the Closing, good and valid title, free and clear
of all Liens, to the Shares, with full right and lawful authority to sell and transfer such Shares to Buyer pursuant to this Agreement. Except as set forth in this Agreement, there are no outstanding Contracts or other rights to subscribe for or
purchase, or Contracts or other obligations to issue, sell or grant any rights to acquire, any Shares or other shares of capital stock of any class of the Company. All of the Shares are duly authorized, validly issued and outstanding and are fully
paid, and were issued in all material respects in conformity with all applicable state and federal securities laws. There are no preemptive or similar rights (under Contract or otherwise) in respect of any of the Shares. 

(b) As of the Closing, the Company will have no outstanding Indebtedness. As of the Closing, except for liabilities or obligations set
forth in (i) the Unaudited Financial Statements or (ii) the Statement of Working Capital, the Company will have no liabilities or obligations of any nature (whether known or unknown, absolute or contingent, liquidated or unliquidated, due
or to become due, accrued, fixed or otherwise) that are related to any business or operation of Seller (or a Subsidiary or Affiliate thereof, other than the business or operations of the Company). 

Section 4.4 Authority; Enforceability. Seller has all necessary corporate power and authority to execute and deliver this
Agreement and each other instrument and document required to be executed and delivered by it at or prior to the Closing, and to perform its obligations hereunder and thereunder and to consummate the Contemplated Transactions. The execution and
delivery by Seller of this Agreement, the performance by Seller of its obligations hereunder and thereunder, and the consummation by Seller of the Contemplated Transactions have been approved by Seller’s Board of Directors, duly and validly
authorized by all necessary action and no other proceedings on the part of Seller are necessary to authorize this Agreement or to perform Seller’s obligations hereunder or thereunder or to consummate the Contemplated Transactions. This
Agreement has been duly and validly executed and delivered by Seller, or will be duly and validly executed and delivered by Seller at or prior to Closing, and assuming the due authorization, execution and delivery thereof by Buyer, constitutes a
legal, valid and binding obligation of Seller enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar Laws relating to or affecting
creditors’ rights generally, general equitable principles (whether considered in a proceeding in equity or at law) and an implied covenant of good faith and fair dealing. 

  
 23 

 Section 4.5 No Conflict; Required Filings and Consents. 

(a) The execution and delivery by Seller of this Agreement and each other instrument and document required by this Agreement to be
executed and delivered by Seller do not, and the performance of this Agreement and each other instrument and document required by this Agreement to be executed and delivered by Seller, shall not, (i) conflict with or violate the certificate of
incorporation or the bylaws of Seller or the Charter or the By-Laws, (ii) subject to the filings and other matters referred to in Section 4.5(b), conflict with or violate in any respect any Law or Order, in each case applicable to
Seller or the Company, or by which any of their respective properties, rights or assets is bound or affected, or (iii) except as set forth in Section 4.5(a) of the Seller Disclosure Schedule result in any material breach or material
violation of or constitute a material default (or an event that with notice or lapse of time or both would become a material default) under, or materially impair the Company’s rights or alter the rights or obligations of any party under, or
give to others any rights of termination, amendment, acceleration or cancellation of, or result in the termination of any Material Contract or in the creation of a Lien on any of the properties, rights or assets of the Company pursuant to any bond,
indenture, Contract, permit, franchise or other instrument or obligation to which the Company is a party or by which the Company or its properties, rights or assets is bound or affected. 

(b) The execution and delivery by Seller of this Agreement and each other instrument and document required by this Agreement to be
executed and delivered by Seller at or prior to the Closing do not, and the performance of this Agreement and any instrument required by this Agreement to be executed and delivered by Seller at or prior to the Closing, shall not, require Seller or
the Company to obtain any Approval of any Person, observe any waiting period imposed by, or make any filing with or notification to, any Governmental Authority, except (i) for compliance with any applicable requirements of the pre-merger
notification requirements of the HSR Act, and any applicable Foreign Competition Laws or (ii) as set forth in Section 4.5(b) of the Seller Disclosure Schedule. 

Section 4.6 Material Contracts. 
 (a) Section 4.6(a) of the Seller Disclosure Schedule sets forth, as of the date of this Agreement, a true and complete list, and if oral, an accurate and complete summary, of all Contracts to
which the Company is a party or by which its properties, rights or assets are bound which are material to the Company or the operation of its business as conducted or as planned by the Company to be conducted as of the date hereof (collectively,
“Material Contracts;” provided, however, that the LipoSonix Agreement shall not be deemed a Material Contract), including, without limitation, the following Contracts: 

(i) employment Contracts, consulting Contracts or sales and distributor Contracts with any employee, consultant, sales representative,
distributor or other agent of the Company (other than offer letters with employees providing for “at will” employment with the Company with no obligation to pay severance), and all severance, change in control or similar Contracts with any
current or former stockholder, director, officer, employee, consultant, sales representative, distributor or other agent, or any member of their immediate family or any Affiliate of the Company that would result in any obligation (absolute or
contingent) of the Company to make any payment to any current or former stockholder, 

  
 24 

 
director, officer, employee, consultant, sales representative, distributor or other agent, or any member of their immediate family or any Affiliate of the Company following either the
Contemplated Transactions, termination of employment (or the relevant relationship), or both; 
 (ii) labor or collective
bargaining Contracts (if any); 
 (iii) Contracts for pre-clinical or other testing, clinical or marketing trials relating to
the Company’s Products and Contracts with physicians, hospitals, clinics or other healthcare providers, or other scientific or medical advisors; 
 (iv) any Contract reasonably likely to involve revenues, receipts, expenditures or liabilities in excess of $30,000 per annum or $50,000 in the aggregate, which is not cancelable by the Company (without
penalty, cost or other liability) upon thirty (30) days’ notice; 
 (v) promissory notes, credit agreements, loans,
indentures, evidences of Indebtedness or other instruments and Contracts relating to the borrowing or lending of money, whether as borrower, lender or guarantor, in each case, relating to Indebtedness or obligations in excess of $50,000; 

(vi) any interest rate swaps, caps, floors or option Contracts or any other interest rate risk management arrangement or foreign
exchange Contracts; 
 (vii) Contracts containing any provision limiting in any respect the freedom of the Company (or which
after the Closing purport to limit or would limit the freedom of Buyer or any of its Subsidiaries or Affiliates) to engage in any line of business, to develop, market or distribute products or services, to compete with any Person, to operate at any
location in the world or to change sales quotas or targets under any Contracts with distributors, sales representatives, or other agents; 
 (viii) joint venture or partnership agreements or joint development, distribution or similar Contracts pursuant to which any third party is entitled or obligated to develop or distribute any products or
provide any services on behalf of the Company or pursuant to which the Company is entitled or obligated to develop, manufacture, supply, process, produce or distribute any Products or provide any services on behalf of any third party; 

(ix) any Contract that is primarily a guarantee, indemnification, assumption or endorsement of, or any similar commitment with respect
to, the obligations, liabilities (whether accrued, absolute, contingent or otherwise) or Indebtedness of any other Person (except for Contracts in the ordinary course of business or standard agreements with end users and business partners);

 (x) any currently effective Contract, or any Contract that has expired or been terminated which has surviving provisions,
providing for indemnification of any Person with respect to liabilities relating to any current or former business of the Company or any predecessor Person; 

  
 25 

 (xi) any Contract with any Governmental Authority or with any labor union; 

(xii) Contracts for the acquisition, directly or indirectly (by merger or otherwise) of assets (whether tangible or intangible),
including any capital stock of another Person, for consideration in excess of $50,000; 
 (xiii) Contracts involving the
issuance or repurchase of any capital stock or other equity interest of the Company; 
 (xiv) performance or payment
guarantees, keep well arrangements and other similar credit support obligations or arrangements; 
 (xv) leases or subleases in
respect of (A) any Real Property or (B) any material rights, assets or property; 
 (xvi) Contracts under which
(A) the Company has granted exclusive or non-exclusive rights to Products or (B) another party processes, produces or manufactures, or will process, produce or manufacture, Products; 

(xvii) Contracts concerning Intellectual Property, including any agreements described in Sections 4.16(h) and 4.16(k)
of this Agreement; 
 (xviii) stockholders’ rights plan or agreement, “poison pill” or similar plan or Contract;

 (xix) any settlement agreement entered into within the last three (3) years; 

(xx) Contracts with customers, suppliers and distributors involving amounts in excess of $50,000; and 

(xxi) Except for those Contracts that will be terminated prior to the Closing, any Contract containing an obligation that is related to
any business or operation of Seller (or a Subsidiary or Affiliate thereof, other than the Company) and unrelated to the business or operations of the Company. 
 (b) Seller has made available to Buyer true and complete copies of each Material Contract, together with all amendments and supplements thereto, or, if no written Contract exists, an accurate and complete
description of such Material Contract. Except as set forth in Section 4.6(b)-1 of the Seller Disclosure Schedule, other than Material Contracts that have terminated or expired in accordance with their terms, each Material Contract is in
full force and effect, is a valid and binding obligation of the Company and, to the Knowledge of Seller, of each other party thereto and is enforceable against the Company and, to the Knowledge of Seller, against each other party thereto, and such
Material Contracts will continue to be (i) valid, binding and enforceable against the Company and, to the Knowledge of Seller, of each other party thereto, and (ii) in full force and effect immediately following the Closing, with no
alteration or acceleration or increase in fees or liabilities, payments, obligations or burdens. The 

  
 26 

 
Company is not alleged to be and, to the Knowledge of Seller, no other party is or is alleged to be in, or has received notice of any, default under, or breach or violation of, any Material
Contract and, to the Knowledge of Seller, no event has occurred which, with the giving of notice or passage of time or both, would constitute such a default, breach or violation and Seller has no reasonable basis for suspecting that any such
default, breach or violation exists or will be forthcoming. No break-up or other similar fee is due or owing by the Company in connection with any prior negotiations, discussions or arrangements regarding any transaction, similar to the Contemplated
Transaction or otherwise, or other Contract. Except as set forth in Section 4.6(b)-2 of the Seller Disclosure Schedule, the Company is not currently involved, nor has it been involved since December 31, 2010, in any dispute with any
counterparty to any Material Contract, and the Company has not received written or, to the Knowledge of Seller, oral notice since December 31, 2010 from any such counterparty to the effect that such counterparty intends to terminate or
otherwise alter or modify the terms of any such Material Contract. 
 (c) Section 4.6(c) of the Seller Disclosure
Schedule sets forth any Material Contract which, by its terms, will be modified or adjusted, will become terminable by any other party thereto, or will require consent by or notification to any other party thereto, in each case, as a result of the
execution of this Agreement or the consummation of the Contemplated Transactions. 
 (d) The Company has no liability pursuant
to any grant from the National Institutes of Health, and no event has occurred which, with the giving of notice or the passage of time or both, would cause any liability to Buyer or any of its Affiliates with respect to any such grant, and the
Company has no reasonable basis for suspecting that any such liability exists or will be forthcoming (whether as a result of the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby). 

Section 4.7 Compliance. 
 (a) The Company is in compliance with, and is not in default or violation of (i) its Charter or Bylaws, (ii) any Law or Order by which the Company or its properties, rights or assets are bound
or affected, and (iii) the terms of all bonds, indentures, Contracts, permits, franchises and other instruments or obligations to which the Company or by which the Company or its properties, rights or assets are bound or affected, except in the
case of clauses (ii) and (iii) for immaterial noncompliance, defaults or violations. The Company is in material compliance with the terms of all applicable Approvals. 

(b) The Company (i) is not, to the Knowledge of Seller, under investigation by any Governmental Authority with respect to any
violation of any Approval or any Law or Order and (ii) has not been charged with, has not received notice of, or to the Knowledge of Seller, has not been threatened to be charged with, any revocation, withdrawal, suspension, cancellation,
termination or modification of any Approval or any Law or Order applicable to the Company. 
 (c) Section 4.7(c) of
the Seller Disclosure Schedule sets forth a complete and accurate list of all material permits issued to or held by the Company. Such listed permits are the only material permits that are required for the Company to conduct its business as presently

  
 27 

 
conducted. Each such permit is in full force and effect; the Company is in material compliance with the terms of each such permit; and, to the Knowledge of Seller, no suspension or cancellation
or material modification of such permit is threatened. 
 Section 4.8 Absence of Certain Changes or Events. 

(a) During the period from December 31, 2010 to the date hereof, the Company has conducted its business only in the ordinary course
of business consistent with past practice, and, since December 31, 2010, there has not been any change, development, circumstance, condition, event, occurrence, damage, destruction or loss that has had or would reasonably be expected to have,
individually or in the aggregate, a Material Adverse Effect on the Company. 
 (b) Except as described in
Section 4.8(b) of the Seller Disclosure Schedule, during the period from December 31, 2010 to the date hereof: 
 (i) there has not been (A) any change by the Company in its accounting or cash management methods, principles or practices (including with respect to reserves, revenue recognition, timing for
payments of accounts payable, collections of accounts receivable and depreciation or amortization policies or rates) or (B) any revaluation by the Company of any of its assets, including writing down the value of inventory or writing off notes
or accounts receivable; 
 (ii) the Company has not amended or otherwise modified its Charter or Bylaws, or altered through
merger, liquidation, reorganization, restructuring or in any other fashion the structure or ownership of the Company; 
 (iii)
the Company has not declared, set aside or paid any dividend or other distribution (whether in cash, stock (or similar equity interest) or property or any combination thereof) in respect of any of its capital stock; or amended the terms of,
repurchased, redeemed or otherwise acquired any of its securities; 
 (iv) the Company has not sold, transferred, delivered,
leased, subleased, licensed, sublicensed, mortgaged, pledged, encumbered, impaired or otherwise disposed of (in whole or in part), or created, incurred, assumed or caused to be subjected to any Lien on, any of the rights, assets or properties of the
Company (including any Intellectual Property or accounts receivable), except for the sale of inventory and disposal of obsolete assets in the ordinary course of business consistent with past practice; 

(v) the Company has not acquired any rights, assets or properties other than in the ordinary course of business consistent with past
practice; 
 (vi) there has not been any damage, destruction or loss (whether or not covered by insurance) with respect to any
material rights, assets or properties of the Company; 
 (vii) the Company has not (A) incurred or modified any
Indebtedness or issued any debt securities or any warrants or rights to acquire any debt security, (B) assumed, guaranteed or endorsed or otherwise become responsible for, the obligations of any Person,

  
 28 

 
(C) entered into any off-balance sheet financing arrangement or any accounts receivable or payable financing arrangement, or (D) made any loans or advances (except for advances of reasonable
business expenses in the ordinary course of business consistent with past practice); 
 (viii) the Company has not authorized
or made any capital expenditures outside of the ordinary course of business consistent with past practice and in excess of $50,000; 
 (ix) there has not been any (A) increase in, acceleration of or provision for compensation, benefits (fringe or otherwise) or other rights to any employee, contractor or subcontractor of the Company
except in the ordinary course of business consistent with past practice, (B) grant, agreement to grant, or amendment or modification of any grant or agreement to grant, any severance, bonus, termination, retention or similar payment to any
employee, contractor or subcontractor of the Company except in the ordinary course of business consistent with past practice, (C) loan or advance of money or other property by the Company to any of its employees, contractors or subcontractors
(except for advances of business expenses in the ordinary course of business consistent with past practice), or (D) establishment, adoption, entrance into, amendment or termination of any Employee Plan (except as otherwise required by
applicable Law), collective bargaining agreement or other labor agreement; 
 (x) there has not been any termination, lay off,
or resignation of any executive or management employee or key employee at the Company, or any hiring to fill any executive or management position or key employee position at the Company; and to the Knowledge of Seller, there is no impending
resignation or termination of employment of any such executive or management employee or key employee; 
 (xi) there has not
been any labor dispute, other than routine individual grievances, or any activity or proceeding by a labor union or representative thereof to organize any employees of the Company, or any lockouts, strikes, slowdowns, work stoppages or threats
thereof by or with respect to such employees; 
 (xii) the Company has not (A) made or changed any Tax election or changed
any method of Tax accounting, (B) settled or compromised any federal, state, local or foreign Tax liability, (C) filed any amended Tax Return, (D) entered into any closing agreement relating to any Tax, (E) agreed to an extension
of a statute of limitations, or (F) surrendered any right to claim a Tax refund; and 
 (xiii) there has not been any
other event or condition of any character that, either individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect on the Company. 

Section 4.9 Liabilities. The Company does not have any liabilities or obligations of any nature (whether known or unknown,
absolute or contingent, liquidated or unliquidated, due or to become due, accrued, fixed or otherwise), and there is no existing fact, condition or circumstance which could reasonably be expected to result in such liabilities or obligations, except
liabilities or obligations (a) disclosed in the unaudited listing of assets and liabilities of the Company as of June 30, 2011, (b) not required to be disclosed under GAAP or (c) incurred since June 30, 2011 in the ordinary
course of business consistent with past practice (excluding 

  
 29 

 
any incurrence of Indebtedness), except as described in Section 4.9 of the Company Disclosure Schedule. 
 Section 4.10 Absence of Litigation. Except as described in Section 4.10 of the Seller Disclosure Schedule, since the “Effective Time” (as defined in the LipoSonix Agreement),
there have been no (a) Claims pending on behalf of or against or, to the Knowledge of Seller, Claims threatened on behalf of or against the Company (or Seller or its Affiliates with respect to the Company) or its properties, rights or assets
(including cease and desist letters or requests for a license), (b) Order outstanding to which the Company or its properties, rights or assets is subject, (c) Claim which questions or challenges (i) the validity of this Agreement or
(ii) any action taken or to be taken by the Company pursuant to this Agreement or in connection with the Contemplated Transactions. No director, officer, employee, consultant or agent of the Company has asserted a Claim or demand for payment or
has a basis for a Claim or demand for payment against the Company in respect of the period prior to and including the Closing (other than accrued and unpaid compensation earned in the ordinary course of business). 

Section 4.11 Employee Benefit Plans. 
 (a) As of the date of this Agreement, Section 4.11(a) of the Seller Disclosure Schedule lists and, in the case of employee benefit plans not reduced to writing, describes all employee benefit
plans (as defined in Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”)), including, without limitation, multiemployer plans within the meaning of Section 3(37) of ERISA, and all
incentive and compensation plans, including without limitation all cash (including without limitation bonus) and equity (including without limitation stock option, restricted stock, stock purchase, stock appreciation rights), incentive, deferred
compensation, retirement or supplemental retirement, severance, golden parachute, vacation, cafeteria, dependent care, medical care, employee assistance program, education or tuition assistance programs, insurance and other similar fringe or
employee benefit plans, programs or arrangements, whether written or oral, and any employment or executive compensation or severance Contracts, written or otherwise, for the benefit of, or relating to, any present or former employee, director or
independent contractor of the Company, (i) which is or has been entered into, contributed to, established by, participated in and/or maintained by the Company or any trade or business (whether or not incorporated) which is a member of a
controlled group or which is under common control with the Company (an “ERISA Affiliate”) within the meaning of Section 414 of the Code, or (ii) under which the Company or ERISA Affiliate has any liability whether or not
such plan is terminated (together, the “Employee Plans”). Seller has provided to Buyer correct and complete copies of (where applicable) (i) summary plan descriptions related to each Employee Plan, (ii) the most recent
determination letters or opinion letters received from the IRS for each Employee Plan, (iii) the three most recent IRS Forms 5500 Annual Report for each Employee Plan, (iv) the most recent audited financial statement and actuarial
valuation report for each Employee Plan, (v) the most recent discrimination testing results for each Employee Plan and (vi) all correspondence with, rulings by or opinions by the United States Internal Revenue Service (the
“IRS”) or the U.S. Department of Labor for each Employee Plan. No Employee Plans are maintained, sponsored, or contributed to by the Company and the Company does not have, and following the Closing will not have, any liability with
respect to any Employee Plans, except as set forth in (i) the Unaudited Financial Statements or (ii) the Statement of Working Capital. 

  
 30 

 (b)(i) There has been no “prohibited transaction,” as such term is defined in
Section 406 of ERISA and Section 4975 of the Code, with respect to any Employee Plan (and which is not otherwise exempt); (ii) there has been no breach of fiduciary obligations imposed under Title I of ERISA with respect to any
Employee Plan; (iii) there are no Claims pending (other than routine claims for benefits) or, to the Knowledge of Seller, threatened against any Employee Plan or against the assets of any Employee Plan; (iv) all Employee Plans conform to,
and in their operation and administration are in all material respects in compliance with, the terms thereof and requirements prescribed by any and all statutes (including ERISA and the Code), Orders and governmental Regulations currently in effect
with respect thereto and any other applicable Laws; (v) the Company and ERISA Affiliates have performed in all material respects all obligations required to be performed by them under each Employee Plan and are not in default under or in
violation of, and Seller Company has no Knowledge of any default or violation by any other Person with respect to, any of the Employee Plans; and (vi) each Employee Plan intended to qualify under Section 401(a) of the Code is so qualified
(and each corresponding trust is exempt under Section 501 of the Code), and has received or is the subject of a favorable determination or opinion letter from the IRS, and nothing has occurred which may reasonably be expected to cause the loss
of such qualification (or exemption). 
 (c) No Employee Plan is an “employee pension benefit plan” (within the
meaning of Section 3(2) of ERISA) subject to Title IV of ERISA or a “multiemployer plan” (within the meaning of Section 3(37) of ERISA), and neither the Company nor any ERISA Affiliate has or has ever had an obligation to
contribute, or incurred any liability in respect of a contribution, to any such employee pension benefit plan or multiemployer plan. 
 (d) No Employee Plan is (i) a “voluntary employees’ beneficiary association” (within the meaning of Section 501(c)(9) of the Code), (ii) an “employee stock ownership
plan” (within the meaning of Section 4975(e)(7) of the Code) or otherwise invests in “employer securities” (within the meaning of Section 409(l) of the Code), (iii) a “multiple employer plan,” as described in
Code Section 413(c) or Sections 4063 or 4064 of ERISA, or (iv) a “multiple employer welfare arrangement” as defined in Section 3(40)(A) of ERISA (a “MEWA”). If any Employee Plan is a MEWA, the benefits
thereunder are fully insured. 
 (e) Each Employee Plan that is a “group health plan” (within the meaning of Code
Section 5000(b)(1)) has been operated in compliance in all material respects with the group health plan continuation coverage requirements of Section 4980B of the Code and Sections 601 through 608 of ERISA (“COBRA
Coverage”), Section 4980D of the Code and Sections 701 through 713 of ERISA, Title XXII of the Public Health Service Act and the provisions of the Social Security Act, as amended, to the extent such requirements are applicable. No
Employee Plan or other written or oral agreement exists which obligates the Company to provide health care coverage or medical, surgical, hospitalization, death or similar benefits (whether or not insured) to any current or former employee, director
or consultant of the Company following such current or former employee’s, director’s or consultant’s termination of employment, service or consultancy with the Company, other than COBRA Coverage or similar state law coverage.

 (f) Except as set forth in Section 4.11(f) of the Seller Disclosure Schedule, no Employee Plan exists that, as a
result of the execution and delivery of this Agreement or the Contemplated Transactions (whether alone or in connection with any subsequent event(s)), could 

  
 31 

 
result in (i) severance pay or any increase in severance pay upon any termination of employment after the date of this Agreement, (ii) accelerating the time of payment or vesting or
result in any payment or funding (through a grantor trust or otherwise) of compensation or benefits under, increase the amount payable or result in any other material obligation pursuant to, any of the Employee Plans or (iii) any breach or
violation of, or default under, any of the Employee Plans. The Company has not made any payments, is not obligated to make any payments, and is not a party to any agreements that as a result of the Contemplated Transactions (whether alone or in
connection with any subsequent event(s) could obligate it to make any payments, that will not be deductible under Section 280G of the Code. 
 (g) All contributions and payments with respect to each Employee Plan that are required to be made by the Company with respect to periods ending on or prior to the Closing Date have been, or will be, made
or accrued before the Closing Date in accordance with the terms of the applicable Employee Plan. 
 Section 4.12
Employment and Labor Matters. 
 (a) As of the date of this Agreement, Section 4.12(a) of the Seller Disclosure
Schedule identifies (i) all current directors and officers of the Company and (ii) all current employees, consultants and agents (including sales representatives and distributors) employed or engaged by the Company and, for each individual
identified in clauses (i) or (ii), sets forth each such individual’s rate of pay or annual compensation, job title and date of hire. As of the date of this Agreement, except as set forth in Section 4.12(a) of the Seller
Disclosure Schedule, there are no employment, consulting, commission, incentive or bonus pay, severance pay, retention or continuation pay, termination or indemnification agreements or other similar Contracts of any nature (whether in writing or
not) between the Company and any current or former stockholder, officer, director, employee, consultant, labor organization or other representative of the Company’s employees providing for payments in an aggregate amount of $50,000 or greater,
nor is any such Contract presently being negotiated. There are no collective bargaining agreements or other similar Contracts (whether in writing or not) between the Company and any current or former officer, employee, labor organization or other
representative of the Company’s employees, nor is any such Contract presently being negotiated. Seller has provided to Buyer complete and correct copies of all such agreements and Contracts. The Company has not failed to make or is not
otherwise delinquent in payments to any of its employees or consultants for any wages, salaries, overtime pay, commissions, bonuses, benefits or other compensation for any services or otherwise arising under any policy, practice, Contract, plan,
program or Law. Except as set forth in Section 4.12(a) of the Seller Disclosure Schedule, none of the Company’s employment policies or practices is currently being audited or investigated by any Governmental Authority or Court.
Except as set forth in Section 4.12(a) of the Seller Disclosure Schedule, there is no pending or, to the Knowledge of Seller, threatened Claim, unfair labor practice charge, or other charge or inquiry against the Company brought by or on
behalf of any employee, prospective employee, former employee, retiree, labor organization or other representative of the employee, or other individual or any Governmental Authority with respect to employment practices brought by or before any Court
or Governmental Authority. 
 (b) Except as set forth in Section 4.12(b) of the Seller Disclosure Schedule,
(i) there are no controversies pending or, to the Knowledge of Seller, threatened, between the 

  
 32 

 
Company, on the one hand, and its employees or consultants, on the other hand; (ii) the Company is not a party to any collective bargaining agreement or other labor union Contract applicable
to Persons employed by the Company nor are there any activities or proceedings of any labor union to organize any such employees of the Company; (iii) since December 31, 2009, there have been no strikes, slowdowns, work stoppages,
lockouts, or threats thereof, by or with respect to any employees of the Company; and (iv) there are no employment-related grievances pending or, to the Knowledge of Seller, threatened. Except as set forth in Section 4.12(b)-1 of
the Seller Disclosure Schedule, the Company is not a party to, or otherwise bound by, any consent decree with, or citation or other Order by, any Governmental Authority relating to employees or employment practices. The Company is in compliance in
all material respects with all applicable Laws, Contracts and policies relating to employment, employment practices, wages, hours and terms and conditions of employment, including the obligations of the Worker Adjustment and Retraining Notification
Act of 1988, as amended (the “WARN Act”), and similar Laws, and all other notification and bargaining obligations arising under any collective bargaining agreement, by Law or otherwise. The Company has not effectuated a “plant
closing” or “mass layoff” as those terms are defined in the WARN Act and similar Laws, affecting in whole or in part any site of employment, facility, operating unit or employee of the Company, without complying with all provisions of
the WARN Act or implemented any early retirement, separation or window program within the past two (2) years, nor has the Company planned or announced any such action or program for the future. 

Section 4.13 Title to Assets; Leases; Sufficiency of Assets. 

(a) The Company has good and marketable title to all of its real or personal properties (whether owned or leased), rights and assets,
free and clear of all Liens. The Company does not currently own nor has ever owned any real property or interest therein, nor has received any notice of any Lien with respect to any of its leasehold interests. 

(b) Section 4.13(b) of the Seller Disclosure Schedule contains a complete and accurate list of all leases of real property to
which the Company is a party or by which it holds a leasehold interest or is otherwise obligated (collectively, “Real Property”). Seller has provided to Buyer complete and accurate copies of all such leases for Real Property. Each
Real Property lease to which the Company is a party is legal, valid, binding and in full force and effect in accordance with its terms, and all rents and additional rents due to date from the Company on each such lease have been paid. As of the date
of this Agreement, the Company has not received written notice that it is in material default under any Real Property lease to which the Company is a party, and there exists no material default by the Company, or to the Knowledge of Seller, by any
other party under any such lease. Except as set forth in Section 4.13(b) of the Seller Disclosure Schedule, there are no leases, subleases, licenses, concessions or any other Contracts to which the Company is a party granting to any
Person other than the Company any right to possession, use occupancy or enjoyment of any of the Real Property or any portion thereof and the Company is not obligated under or bound by any option, right of first refusal, purchase Contract, or other
Contract to sell or otherwise dispose of any Real Property or any other interest in any Real Property. 

  
 33 

 (c) Section 4.13(c) of the Seller Disclosure Schedule contains a complete and
accurate list of all leases of all property (other than Real Property) to which the Company is a party or by which it holds a leasehold interest. 
 (d) Except as set forth in Section 4.13(d) of the Seller Disclosure Schedule, the tangible assets of the Company constitute all of the properties, assets, rights and facilities owned, used,
held for use, intended for use, leased or licensed by the Company, Seller or its Affiliates in the operation of the business of the Company. To the Knowledge of Seller, the tangible assets of the Company constitute all of the properties, assets,
rights and facilities necessary and sufficient to enable the Company, immediately following the Closing, to continue to conduct the business of the Company in the same manner as currently conducted. 

Section 4.14 Taxes. For purposes of this Agreement, “Tax” or “Taxes” shall mean taxes, duties,
fees, premiums, assessments, imposts, levies and governmental impositions of any kind, payable to any federal, state, local or foreign Governmental Authority, including, but not limited to, those on or measured by or referred to as income,
franchise, profits, gross receipts, goods and services, capital, ad valorem, advance, corporation, custom duties, alternative or add-on minimum taxes, estimated, environmental, disability, registration, value added, sales, use, service, real
or personal property, capital stock, license, payroll, withholding, employment, social security, workers’ compensation, unemployment compensation, utility, severance, production, excise, stamp, occupation, premiums, windfall profits, transfer
and gains taxes, and interest, penalties and additions to tax imposed with respect thereto; and “Tax Returns” shall mean returns, reports, forms and information statements, including any schedule or attachment thereto, with respect
to Taxes required to be filed with the IRS or any other Governmental Authority or taxing authority or agency, domestic, state, local or foreign, including consolidated, combined and unitary tax returns. Except as set forth in
Section 4.14 of the Seller Disclosure Schedule: 
 (a) All Tax Returns required to be filed by or on behalf of the
Company have been timely filed, and all such Tax Returns are true, complete and correct in all material respects. 
 (b) All
Taxes shown as due on such Tax Returns and payable by or with respect to the Company and all other material Taxes payable by or with respect to the Company have been timely paid. All assessments for Taxes due and owing by or with respect to the
Company with respect to completed and settled examinations or concluded litigation have been paid. The Company has not incurred a Tax liability since December 31, 2010 other than a Tax liability in the ordinary course of business consistent
with past practice. There are no Tax Liens on any assets, properties or rights of the Company except Liens for current Taxes not yet due and payable. 
 (c) No Claim or, to the Knowledge of Seller, audit has commenced and no notice has been given that such audit or other proceeding is pending or threatened with respect to the Company or any group of
entities of which the Company is or has been a member in respect of any Taxes (an “Affiliated Group”). No Tax deficiency or claim for additional Taxes has been asserted or, to the Knowledge of Seller, threatened to be asserted
against the Company or any Affiliated Group by any Taxing authority. No Claim has ever been made by a Taxing authority in any jurisdiction in which the Company does not file Tax Returns that the Company is or may be subject to taxation by that
jurisdiction. 

  
 34 

 (d) The Company has not requested or been granted any waiver of any federal, state, local or
foreign statute of limitations with respect to, or any extension of a period for the assessment of, any Tax. No extension or waiver of time within which to file any Tax Return of, or applicable to, the Company has been granted or requested which has
not since expired. 
 (e) The Company is not and, to the Knowledge of Seller, has never been (nor does the Company have any
liability for unpaid Taxes because it once was) a member of an affiliated, consolidated, combined or unitary group. The Company is not a party to any Tax allocation, Tax indemnity or Tax sharing agreement nor is the Company liable for the Taxes of
any other person under Treasury Regulations §1.1502-6 (or any similar provision of state, local or foreign law), as transferee or successor, by Contract, or otherwise. The Company is not and, to the Knowledge of Seller, has never been a partner
in a partnership or a participant in an arrangement or the owner of an entity that is or may be treated as a partnership for federal income Tax purposes. 
 (f) The Company has complied with all applicable Laws relating to the payment and withholding of Taxes (including, without limitation, withholding of Taxes pursuant to Sections 1441, 1442 and 3406 of
the Code or similar provisions under any foreign Laws) and has, within the time and in the manner required by Law, withheld from payments to employees, independent contractors and other persons and paid over to the proper Governmental Authorities
all amounts required to be so withheld and paid over under all applicable Laws. 
 (g) The Company will not be required to
include any item of income in, or exclude any item of deduction from, taxable income for any taxable period or portion thereof ending after the Closing Date as a result of any (i) change in the method of accounting for a taxable period or
portion thereof ending on or prior to the Closing Date, (ii) prepaid amount received on or prior to the Closing Date or (iii) intercompany transaction completed on or prior to the Closing Date. 

(h) The Company has collected all sales, use and value added Taxes required to be collected, and has remitted on a timely basis to the
appropriate taxing authorities all sales, use and value added Taxes required to be paid, or has been furnished properly completed exemption certificates. 
 (i) No closing agreement pursuant to Section 7121 of the Code (or any similar provision of state, local or foreign Law) has been entered into by or with respect to the Company. 

(j) No power of attorney has been executed with respect to any matter relating to Taxes of the Company, which is currently in force.

 (k) The Company has not been a party to any distribution occurring during the last two years in which the parties to such
distribution treated the distribution as one to which Section 355 or Section 361 of the Code is applicable; nor has the Company been a party to any distribution that could constitute part of a “plan” or “series of related
transactions” (within the 

  
 35 

 
meaning of Section 355(e) of the Code) in conjunction with the transactions contemplated by this Agreement. 
 (l) The Company has not entered into any transactions that are part of any “reportable transaction” under Sections 6011, 6111 or 6112 of the Code (or any similar provision under any state
or local Law). 
 (m) The Company has not participated in or cooperated with an international boycott, within the meaning of
Section 999 of the Code, nor has the Company had operations that are or may hereafter become reportable under Section 999 of the Code. 
 (n) The Company has complied in all material respects with tax-related requirements that the arm’s-length nature of the terms of any transactions between and among the Company, Seller or Affiliates
be documented. 
 (o) The Company is not a United States real property holding corporation within the meaning of
Section 897(c)(2) of the Code and has not been a United States real property holding corporation at any time during the applicable period specified in Section 897(c)(1)(A)(ii) of the Code. 

(p) The Company does not have any deferred compensation plan or arrangement that is described in Section 409A(a)(1)(A)(i) of the
Code. 
 Section 4.15 Environmental Matters. 

(a) The Company is in compliance in all material respects with all applicable Environmental Laws. 

(b) The Company has been duly issued and maintains all Environmental Permits necessary to operate the Company as currently operated and a
complete list of all such Environmental Permits, all of which are valid and in full force and effect, is set forth in Section 4.15(b) of the Seller Disclosure Schedule. 

(c) The Company does not have any material liability, known or unknown, contingent or absolute, under any Environmental Law, and the
Company is not responsible for any such liability of any other person under any Environmental Law, whether by contract, by operation of law or otherwise. There are no pending, or to the Knowledge of Seller, threatened, Environmental Claims.

 (d) The Company does not currently own, lease or operate, use or install, and has not formerly owned, leased or operated,
used or installed, and, to Seller’s Knowledge, the Real Property does not contain: (i) underground improvements, including but not limited to treatment or storage tanks, used currently or in the past for the management of Hazardous
Materials; (ii) a dump or landfill; (iii) filled in lands or wetlands; or (iv) PCBs, mold, lead-based paint, toxic mold, or asbestos-containing materials. The Company has not caused a Release of Hazardous Materials, and to
Seller’s Knowledge, there has been no Release of Hazardous Materials, in each case at, on, under, or from the Real Property or any other property currently or 

  
 36 

 
formerly owned, leased or operated by the Company, such that the Company is or could be liable for Remediation with respect to such Hazardous Materials. 

(e) The Company has not arranged, by Contract or otherwise, for the transportation, disposal or treatment of Hazardous Materials at any
location such that it is or would be liable for Remediation of such location pursuant to Environmental Laws. 
 (f) To the
Knowledge of Seller, no Lien in favor of any Person relating to or in connection with any Environmental Claim has been filed or has attached to the Real Property. No authorization, notification, recording, filing, consent, waiting period,
Remediation, or approval is required under any Environmental Law in order to consummate the Contemplated Transactions. 

Section 4.16 Intellectual Property. 
 (a) Section 4.16(a) of the Seller Disclosure Schedule lists all: (i) patents, provisional and non-provisional patent applications, registered trademarks, trade names, and service marks,
registered copyrights and domain names owned by or licensed to the Company (“Scheduled Company Intellectual Property”), including where applicable the jurisdictions, both domestic and foreign, in which each such item of Intellectual
Property has been issued or registered or in which any application for such issuance and registration has been filed; (ii) written licenses, sublicenses and other agreements to which the Company is a party and pursuant to which any Person is
authorized to use any Scheduled Company Intellectual Property and any other Intellectual Property owned by the Company; (iii) written licenses, sublicenses, and other agreements to which the Company is a party (other than licenses related to
commercial off-the-shelf software programs) and pursuant to which the Company is authorized to use any Intellectual Property of any third party, including patents, patent applications, Trade Secrets, trademarks, and copyrights (“Third Party
Intellectual Property Rights”) which are incorporated in, are, or form a part of, or cover any Product or the second generation of LipoSonix Product, part number P005700-01 or which are material to the Company’s operations, including
any fully-paid, royalty-free, worldwide, irrevocable, perpetual, nonexclusive licenses in and to the Intellectual Property of any Person pursuant to consulting agreements between the Company and such Person (all of which consulting agreements
are separately identified on Section 4.16(a)(iii) of the Seller Disclosure Schedule as “License Consulting Agreements”); and (iv) all agreements to which the Company is a party that provide for an optional or contingent
license, sublicense, or other agreement as described in clauses (ii) or (iii) above in this paragraph. All ownership interests or encumbrances held by any third parties in the Scheduled Company Intellectual Property (including, but not
limited to licenses, Liens, or security interests) are noted in Section 4.16(a)-2 of the Seller Disclosure Schedule. All (x) Scheduled Company Intellectual Property and (y) Trade Secrets that are used in and material to the
business, Products and the second generation of LipoSonix Product, part number P005700-01 of the Company (the “Material Company Trade Secrets”), are, except where otherwise noted in Section 4.16(a)-3 of the Seller
Disclosure Schedule, valid, enforceable, have been duly maintained, are in full force and effect, and have not been cancelled, expired, withdrawn, lapsed, invalidated, or abandoned. The Company is not obligated to, and Buyer shall not be obligated
as a result of the consummation of the transactions contemplated herein to, pay any royalties and/or fees to any third party under 

  
 37 

 
any patent, trademark, copyright, or other Intellectual Property license, other than as set forth in Section 4.16(a) of the Seller Disclosure Schedule. 

(b) The Company has taken all action necessary in its reasonable discretion to obtain and/or maintain the enforceability and registration
of all Scheduled Company Intellectual Property. 
 (c) Except as set forth in Section 4.16(c) of the Seller
Disclosure Schedule, the Company has not sent to any third party or otherwise communicated to another Person since the “Effective Time” (as defined in the LipoSonix Agreement), any charge, complaint, Claim, demand or notice asserting that
such Person has infringed, misappropriated, or acted in conflict with any of the Scheduled Company Intellectual Property or any other Intellectual Property owned by the Company or that any charge, complaint, Claim, demand, or notice asserting any
such other Person has conducted any acts of unfair competition against the Company, nor, to the Knowledge of Seller, is any such infringement, misappropriation, conflict or act of unfair competition occurring or threatened. 

(d) Except as set forth in Section 4.16(d) of the Seller Disclosure Schedule, since the “Effective Time” (as
defined in the LipoSonix Agreement), neither Seller or the Company has received and Seller does not have Knowledge of any allegations, assertions, or suggestions of any charge, complaint, Claim, demand or notice that the Company has infringed,
misappropriated, or acted in conflict with any Intellectual Property owned by any third party, that the Company has conducted any acts of unfair competition or other legal wrong against any third party and to its Knowledge there is no basis for any
such allegations, assertions, or suggestions of any charge, complaint, Claim, demand or notice. Except as set forth in Section 4.16(d) of the Seller Disclosure Schedule, neither Seller or the Company has received and Seller does not have
Knowledge of any notice (i) that the Scheduled Company Intellectual Property and the Material Company Trade Secrets are invalid, unenforceable or otherwise defective, inoperable, unregisterable, or unpatentable, except for communications from
patent offices received in the normal course of patent prosecution or (ii) that the Company needs a license under any patents, trademarks, copyrights or other Intellectual Property of any third party. Neither Seller or the Company has received
any offer to take a license for any patents, trademarks, copyrights, or other Intellectual Property of any third party to carry on its business as it is now being conducted or contemplated to be conducted including the development, manufacture, sale
and other commercialization of Products or the second generation of LipoSonix Product, part number P005700-01. 
 (e) Except as
set forth in Section 4.16(e) of the Seller Disclosure Schedule, to the Knowledge of Seller, there is no unauthorized use, disclosure, infringement or misappropriation of any rights of the Company in the Scheduled Company Intellectual
Property and the rights of the Company in any other Intellectual Property, or any Third Party Intellectual Property Rights licensed to the Company, by any third party, including any employee or former employee of the Company, and, except as set
forth in Section 4.16(e) of the Seller Disclosure Schedule, there are no royalties, fees, or other payments or compensation payable to the Company by any third party by reason of the Company’s ownership, use, sale, or disposition of
Intellectual Property. 

  
 38 

 (f) Except as set forth in Section 4.16(f) of the Seller Disclosure Schedule,
the Company is not nor will the Company be, as a result of the execution and delivery of this Agreement, or the performance of its obligations hereunder, in breach of any license, sublicense, or Material Contract involving Intellectual Property, or
violate any Third Party Intellectual Property Rights thereby. 
 (g) Any Product currently being manufactured in the United
States for export to any other jurisdiction foreign to the United States, including Europe, any Product currently being developed by the Company for sale in the United States, including the second generation of LipoSonix Product, part number
P005700-01, and the business of the Company as presently conducted in the United States and in any jurisdiction foreign to the United States, including Europe, do not interfere with, conflict with, infringe upon, misappropriate, or otherwise violate
any Intellectual Property of any third party. No action or Claim is pending or, to the Knowledge of Seller, threatened alleging that the Product, the second generation of LipoSonix Product, part number P005700-01 or the operation of such business
interferes with, conflicts with, infringes upon, misappropriates, or otherwise violates the Intellectual Property rights of any third party and, to the Knowledge of Seller, there is no basis therefore. 

(h) Each current and former officer, employee, and consultant of the Company has executed and provided to the Company an agreement
sufficient to ensure that the Company becomes, will become or may elect to become the owner or assignee of any Intellectual Property such current or former officer, employee, or consultant of the Company creates within the scope of his or her
employment, or, in the case of a non-employee, from the services such current or former officer, employee, or consultant of the Company, performs for the Company, unless or except to the extent that the Company is entitled to become or elects to
become the owner or assignee of such Intellectual Property by operation of Law. 
 (i) Except as set forth in
Section 4.16(i) of the Seller Disclosure Schedule, no former stockholder, equityholder, partner, director, officer or employee of the Company (or any predecessor in interest) has or will have, after giving effect to the transactions
contemplated by this Agreement, any legal or equitable right, title, or interest in or to, or any right to use, directly or indirectly, in whole or in part, any Scheduled Company Intellectual Property and any other Intellectual Property of the
Company. 
 (j) The Intellectual Property that is used by the Company in the conduct of its business was either:
(i) developed by employees of the Company within the scope of their employment; (ii) developed on behalf of the Company by a third party, and all ownership rights therein have been assigned or otherwise transferred to or vested in the
Company pursuant to written agreements; or (iii) licensed or acquired from a third party pursuant to a written license, assignment, or other contract that is in full force and effect and under which the Company is not in material breach.

 (k) The Company has entered into written confidentiality agreements with all employees and third parties to whom the Company
has disclosed material Company-owned confidential Intellectual Property. 

  
 39 

 (l) The Company has taken reasonable measures to protect the confidentiality of its Trade
Secrets, including requiring its former and current officers, employees, consultants, and all other Persons having access thereto to execute written non-disclosure agreements. No Material Company Trade Secret has been disclosed or authorized to be
disclosed to any third party other than pursuant to a written non-disclosure agreement that adequately protects the Company’s proprietary interests in and to such Trade Secrets. To the Knowledge of Seller, no party to any non-disclosure
agreement with the Company is in breach or default thereof. 
 (m) To the Knowledge of Seller, there is no patent, patent
application, publication, knowledge, use, sale, or offer for sale of or by the Company or any third party, that prevents or interferes with the enforcement of the Company’s Intellectual Property or that affects the validity of the issued claims
or the patentability of the pending claims of any of the Company’s patents or patent applications, except for any information cited to, from or communicated with patent authorities. 

(n) Section 4.16(n) of the Seller Disclosure Schedule sets forth a list of all licenses, sublicenses, or other agreements
pursuant to which the Company has in-licensed or acquired rights to any Intellectual Property together with a list of all milestones therein and whether such milestones have been completed or not as of the date of this Agreement. 

(o) The Company has taken commercially reasonable steps to regularly scan its computer systems and all owned or licensed computer
software with up-to-date virus detection software. To the Knowledge of Seller, neither its computer systems nor any owned or licensed computer software contain any viruses. For the purposes of this Agreement, “viruses” includes any
computer code intentionally designed to disrupt, disable, or harm in any manner the operation of any software or hardware. To the Knowledge of Seller, neither its computer systems nor any owned or licensed computer software contain any worms, bombs,
backdoors, disabling device code, or any design or routine which causes software to be erased, rendered inoperable, or otherwise become incapable of being used, either automatically or upon command by any party. 

(p) The Company has taken commercially reasonable steps to restrict access to its computer systems to only those parties authorized by
the Company and have further taken steps to detect and limit any unauthorized access of its computer systems. The Company has taken commercially reasonable steps to patch, fix, or otherwise update its own computer software and/ or close any security
holes that it has discovered in its own computer systems and computer software. The Company has further taken commercially reasonable steps to install all updates, patches, or fixes released by the licensor to maintain up-to-date licensed computer
software and to close any security holes found in its licensed computer software. To the extent that the Company is not itself authorized to modify or fix any licensed computer software in which it discovers a security issue, the Company has taken
commercially reasonable steps to notify the licensor of such software and obtain updated licensed computer software from the licensor. 
 (q) The Company does not maintain any proprietary software for use in or with, or contemplated to be used in or with, its Products or the second generation of LipoSonix Product, part number P005700-01,
which is subject to any open source licensing agreement and 

  
 40 

 
which thereby requires the Company to disclose the source code of said proprietary software. The use of any open source software in conjunction with its Products or the second generation of
LipoSonix Product, part number P005700-01 (i) is de minimis; (ii) is wholly separable therefrom; or (iii) otherwise exempts the Company from having to disclose any proprietary software. 

(r) [Reserved.] 

(s) No Intellectual Property covered by, or that is the subject of, the ***, is currently used in, or is necessary to, any Product or the
second generation of LipoSonix Product, part number P005700-01 of the Company. The commercialization, marketing, licensing, use, or sale of any Product or the second generation of LipoSonix Product, part number P005700-01 (as it currently exists) of
the Company does not and will not result in any obligation on the part of the Company or Buyer, or any of their respective Affiliates, to pay any royalties or fees or to issue any securities pursuant to the terms of the ***. To the Knowledge of
Seller, no Future Inventions (as such term is defined in the ***) have been made or conceived, whether individually or jointly, by any one or more of the parties to the ***. 
 (t) No Intellectual Property covered by, or that is the subject of, the ***, will be used in, or will be necessary to, any Product or the second generation of LipoSonix Product, part number P005700-01 of
the Company subsequent to the termination of the *** due to the expiration of the Licensed Patents as defined in Section 1.2 therein. The commercialization, marketing, licensing, use, or sale of any Product or the second generation of LipoSonix
Product, part number P005700-01 of the Company will not result in any obligation on the part of the Company or Buyer, or any of their respective Affiliates, to pay any royalties or fees or to issue any securities pursuant to the terms of the ***
subsequent to the expiration of the Licensed Patents as defined in Section 1.2 therein. To the Knowledge of Seller, no Future Inventions (as such term is defined in the ***) have been made or conceived, whether individually or jointly, by any
one or more of the parties to the ***. 
 Section 4.17 Insurance. Section 4.17-1 of the Seller Disclosure
Schedule sets forth a complete and accurate list of all primary insurance policies and fidelity bonds covering the assets, business, equipment, properties, rights and operations of the Company. As of the date of this Agreement,
Section 4.17-2 of the Seller Disclosure Schedule also contains (a) a list of all claims filed by the Company since the “Effective Time” (as defined in the LipoSonix Agreement) which are covered by the insurance policies
maintained by the Company and (b) a list of all claims (including any pending claims subject to a reservation of rights) made by the Company since the “Effective Time” (as defined in the LipoSonix Agreement) for which coverage was
denied by any insurer, and, to the Knowledge of Seller, the estimated amounts of such claims as listed in Section 4.17-2 of the Seller Disclosure Schedule as have been reasonably determined. Each insurance policy listed in
Section 4.17-1 of the Seller Disclosure Schedule that was renewed on or after December 31, 2010 was renewed on substantially the same terms and conditions as the corresponding expiring policy. There is no Claim by or against the
Company pending under any of such policies or bonds as to which coverage has been questioned, denied or disputed by the underwriters of such policies or bonds or which exceeds coverage limitations. No reservation of rights or denial of coverage has
been issued by the underwriters of such policies or bonds with respect to any Claim pending against the Company. All premiums 

  
 41 

 
payable under all such policies and bonds have been paid and the Company is otherwise in full compliance with the terms of such policies and bonds (or other policies and bonds providing
substantially similar insurance coverage). The Company has not taken any action or failed to take any action which, with notice or the lapse of time or both, would constitute a breach or default, or permit termination or modification, of any of such
insurance policies or bonds. The Company maintains insurance for the business and operations of the Company in amounts and on such terms as are (i) in compliance with applicable Law and any Contract(s) to which the Company is a party and
(ii) reasonable and customary for businesses of the type conducted by the Company and covering risks which are normally insured by companies possessing similar assets and carrying on businesses of the type conducted by the Company. No insurer
under any such policy or bond has cancelled or generally disclaimed liability under any such policy or bond or, to the Knowledge of Seller, indicated any intent to do so or to materially increase the premiums payable under or not renew any such
policy. To the Knowledge of Seller, there is not any threatened termination of, notice of cancellation of, notice of non-renewal of or material premium increase with respect to any of such policies or bonds. With respect to incidents known to Seller
that occurred prior to the Closing and which would reasonably result in a claim after the Closing, Seller has provided the relevant underwriters of such policies or bonds with notice of such incidents or will do so prior to the Closing. The Company
has complied in all material respects with all applicable requirements (including contractual, statutory and regulatory requirements) governing the purchase of insurance (including the requirements to provide and/or retain evidence of such
insurance). 
 Section 4.18 Brokers. Other than Deutsche Bank, no broker (including real estate brokers), financial
advisor, finder or investment banker or other Person is entitled to any broker’s, financial advisor’s, finder’s or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf
of Seller or the Company. 
 Section 4.19 Certain Business Practices. None of the Company or any of its directors,
officers, employees or, to the Knowledge of Seller, consultants, sales representatives, distributors or agents, in such capacity and on behalf of the Company, has (a) used any funds for unlawful contributions, gifts, entertainment or other
unlawful payments relating to political activity or (b) violated any applicable money laundering or anti-terrorism Law. The Company and its directors, officers, employees and, to the Knowledge of Seller, consultants, sales representatives,
distributors, agents and business partners have complied at all times, and are in compliance, with all applicable U.S. and non-U.S. anti-corruption laws with respect to the Company, including but not limited to the U.S. Foreign Corrupt Practices
Act, as amended (15 U.S.C. §§ 78dd-1 et seq.). In this regard, the Company and its directors, officers, employees and, to the Knowledge of Seller, consultants, sales representatives, distributors, agents and business partners, in such
capacity and on behalf of the Company, have not given, offered, agreed or promised to give, or authorized the giving directly or indirectly, of any money or other thing of value to anyone as an inducement or reward for favorable action or
forbearance from action or the exercise of influence.
 Section 4.20 Interested Party Transactions. Except as disclosed
in Section 4.20 of the Seller Disclosure Schedule, there are no existing, and since the “Effective Time” (as defined in the LipoSonix Agreement) there have been no, Contracts, transactions, Indebtedness or other 

  
 42 

 
arrangements, or any related series thereof, between the Company, on the one hand, and any of the directors, officers or other Affiliates (including Seller and its Subsidiaries), or any of their
respective Affiliates or family members, on the other hand (except for amounts (i) due as salaries and bonuses in the ordinary course of business consistent with past practice, (ii) in reimbursement of ordinary expenses in the ordinary
course of business consistent with past practice or (iii) in the case of Seller, for accounts payables and accrued liabilities paid, or accounts receivable received, in the ordinary course of business consistent with past practice). There is no
Indebtedness owed to the Company by any employee, consultant, officer, director, sales representative, distributor or agent of the Company, other than salary advances or travel expenses in the ordinary course of business consistent with past
practice. To the Knowledge of Seller, no officer or director of the Company has any direct or indirect ownership interest in any Affiliate of the Company (other than stock ownership interest in Seller) or any firm or corporation with which the
Company has a business relationship, or any firm or corporation that competes with the Company, except that officers or directors of the Company and members of their immediate families may own stock in publicly-traded companies that may compete with
the Company. No member of the immediate family of any officer or director of the Company is directly or indirectly interested in any Material Contract. 
 Section 4.21 Health Regulatory. 
 (a) The Company has not engaged, and no
other Person (i) who has a direct or indirect ownership interest (as defined in 42 C.F.R. § 1001.1001(a)(2)) in the Company, or (ii) who has an ownership or control interest (as defined in 42 C.F.R. § 420.201) in the Company, or
(iii) who is an officer, director, agent (as defined in 42 C.F.R. § 1001.1001(a)(2)), or managing employee (as defined in 42 C.F.R. § 420.201) of the Company, has engaged on behalf of the Company in any activities which are prohibited
by, or are cause for civil penalties or mandatory or permissive exclusion from any Federal Health Care Program under, any applicable Law, including, without limitation, 42 U.S.C. §§ 1320a-7, 1320a-7a, 1320a-7b, 1395nn or 31 U.S.C.
§ 3729, or the regulations promulgated pursuant to such statutes, in each case to the extent applicable to the Company. 
 (b) Neither the Company, nor any officer, director, managing employee, or, to Seller’s Knowledge, agent of the Company is a party to, or bound by, any order, individual integrity agreement, corporate
integrity agreement or other similar formal agreement with any Governmental Authority resulting from a failure, or alleged failure, to comply with applicable Laws. 
 (c) To Seller’s Knowledge, no person has filed or has threatened to file a whistleblower action against the Company under any Law, including under the False Claims Act of 1863 (31 U.S.C. 3729 et
seq.). 
 (d) The Company has an operational healthcare compliance program, including a code of ethics or has adopted a code of
ethics that governs all employees, including sales representatives, which interact with physician and hospital customers, and such employees’ interactions with their physician and hospital customers. 

  
 43 

 (e) The Company is not a “covered entity,” nor a “Business Associate” as
those terms are defined under the Health Insurance Portability and Accountability Act of 1996 and the regulations promulgated thereunder, as each is amended from time to time (“HIPAA”). 

(f) The Company has not engaged in any activities, or otherwise acted in a manner, prohibited by or in violation of any Law governing the
maintenance, use, disclosure, privacy, and/or security of, and standard transactions related to, Personal Information, including, but not limited to, the Gramm-Leach-Bliley Act and its implementing regulations (“GLBA”), HIPAA, as
amended by HITECH, state health information privacy laws, and state data breach notification laws (collectively, “Privacy and Security Laws”); there is no charge, proceeding or, to the Knowledge of Seller, investigation by any
Governmental Authority with respect to a violation of any applicable Privacy and Security Laws that is now pending or, to the Knowledge of Seller, threatened with respect to the Company; and the Company has not received any requests or demands from
a Governmental Authority or any other party to make available its internal practices, books, and/or records relating to its use and disclosure of health information for purposes of determining a covered entity’s or the Company’s compliance
with HIPAA or with other applicable privacy laws. 
 (g) There are no facts, circumstances or conditions that would reasonably
be expected to form the basis for any Action against or affecting the Company relating to or arising under Privacy and Security Laws; and the Company has not acted in a manner regarding the maintenance, use, disclosure, privacy, or security of
Personal Information that, to the Knowledge of Seller, would trigger a notification or reporting requirement under any Contract. 
 (h) For purposes of this Section 4.21, (i) “Action” means any suit, claim, action, proceeding, arbitration, mediation or investigation; and (ii) “Personal
Information” means all financial, health, and/or other personal information, including, but not limited to, “nonpublic personal information” as defined under GLBA and “individually identifiable health information” as
defined under HIPAA, that identifies, relates to, describes, is capable of being associated with, or with respect to which there is a reasonable basis to believe the information can be used to identify, an individual. 

Section 4.22 FDA and International Regulatory and Related Matters. 

(a) FDA Legal Compliance and Permits. 
 (i) General Compliance. The Company is conducting and has conducted its business and operations in compliance in all material respects with the Federal Food, Drug, and Cosmetic Act (the
“FD&C Act”), 21 U.S.C. § 301 et. seq., and all applicable regulations promulgated by the United States Food and Drug Administration (“FDA”) (collectively, “FDA Law and Regulation”).

 (ii) Inspections. Except as set forth in Section 4.22(a)(ii) of the Seller Disclosure Schedule, the
Company’s Bothell, Washington facility has not been inspected by the FDA or any state regulatory authority. 
 (iii)
Enforcement. The Company has not received any written notice or, to the Knowledge of Seller, other communication from the FDA or any state regulatory 

  
 44 

 
authority alleging noncompliance with any applicable FDA Law and Regulation. The Company is not subject to any enforcement proceedings by the FDA or any state regulatory authority and, to the
Knowledge of Seller, no such proceedings have been threatened. There is no civil, criminal or administrative action, suit, demand, claim, complaint, hearing, investigation, demand letter, warning letter, untitled letter or proceeding pending against
the Company and the Company has no liability (whether actual or contingent) for failure to comply with any FDA Law and Regulation. There is no act, omission, event, or circumstance of which Seller has Knowledge that would reasonably be expected to
give rise to or lead to any such action, suit, demand, claim, complaint, hearing, investigation, notice, demand letter, warning letter or proceeding or any similar liability. There has not been any violation of any FDA Law and Regulation by the
Company in its product development efforts, submissions, record keeping and reports to FDA or any state regulatory authority that would reasonably be expected to require or lead to investigation, corrective action or regulatory enforcement action.
There is no civil or criminal proceeding pending or, to the Knowledge of Seller, threatened relating to the Company or any Company employee which involves a matter within the FDA or any state regulatory authority’s jurisdiction. To the
Knowledge of Seller, no director, officer, employee, consultant or agent of the Company has: (A) made any untrue statement of material fact or fraudulent statement to the FDA or any other Governmental Authority; (B) failed to disclose a
material fact required to be disclosed to the FDA or any other Governmental Authority; or (C) committed an act, made a statement, or failed to make a statement that would reasonably be expected to provide the basis for the FDA or any other
Governmental Authority to invoke its policy respecting “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,” as set forth in 56 Fed.Reg. 46191 (September 10, 1991), or similar policy. The Company has never
been and is not now subject to FDA’s Application Integrity Policy or similar policy by any other Government Entity. No director, officer or employee of the Company, and to the Knowledge of Seller, no consultant or agent of the Company has been
convicted of any crime or, to the Knowledge of Seller, engaged in any conduct for which debarment is mandated or permitted by 21 U.S.C. § 335a. No director, officer or employee of the Company, and to the Knowledge of Seller, no consultant or
agent of the Company has been convicted of any crime or engaged in any conduct for which such Person or entity could be excluded from participating in the federal health care programs under Section 1128 of the Social Security Act, as amended,
or any similar law or regulation. No current director, officer, employee, consultant or agent of the Company, or, to the Knowledge of Seller, former director or officer of the Company is listed on an “Exclusion List,” meaning the current
(x) HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://www.oig.hhs.gov), (y) General Services Administration’s List of Parties Excluded from Federal Programs (available through the Internet at
http://www.epls.gov) and (z) FDA Debarment List (available through the Internet at http://www.fda.gov/ora/compliance_ref/debar/). 
 (iv) Registration and Listing. The Company has designed, and currently manufactures the Products at its Bothell, Washington facility for distribution exclusively outside of the United States. The
Company has not and does not market or commercially distribute the Products in the United States. The Company’s facility is registered with the FDA and the Company has listed the LipoSonix Product with the FDA under the applicable FDA
registration and listing regulations and such registration and listing is current as of the Closing. 

  
 45 

 (v) Quality System Regulation. To the Knowledge of Seller, the Company has designed
and developed the LipoSonix Product and all other Products in commercial distribution in material compliance with the applicable provisions of the Quality System Regulation set forth in 21 C.F.R. § 820.30, including Design Control provisions.

 (vi) No Adulteration or Misbranding. The Company has not introduced in U.S. commercial distribution during the period
of six (6) calendar years immediately preceding the date hereof any of the Products which were upon their shipment by the Company adulterated or misbranded in violation of 21 U.S.C. § 331. 

(vii) Clinical Trials. All studies, tests, including preclinical tests, and clinical trials in respect of the Company’s
business being conducted by or on behalf of the Company that have been or will be submitted to any Governmental Authority, including the FDA and its counterparts worldwide, including in the European Union, in connection with any approval or
authorization to market the Products, are being or have been conducted in compliance in all material respects with applicable Laws and Regulations, including those Laws and Regulations designed to protect patients. The Company has not received any
written notices, correspondence or, to the Knowledge of Seller, other communication in respect of the Company’s business from the FDA or other Governmental Authority requiring the termination or suspension of any clinical trials conducted by,
or on behalf of, the Company, and, to the Knowledge of Seller, neither the FDA nor any other Governmental Authority is considering such action. The Company has not received written notification from a Governmental Authority of the rejection of data
obtained from any clinical trial conducted by, or on behalf of, the Company with respect to the Company’s business or the Products, which data were submitted to the Governmental Authority and which were necessary to obtain regulatory approval
or clearance of a particular Product. 
 (viii) Exportation of Products. All Products that have been exported from the
United States by the Company have been exported in compliance in all material respects with the applicable export requirements of the FDA Law and Regulation. The Company has complied in all material respects with all notification and reporting
requirements applicable to the export requirements of the FDA Law and Regulation. 
 (ix) Labeling, Promotion, and
Advertising. To the extent applicable, the Company has complied in all material respects with all FDA Law and Regulation pertaining to product labeling, advertising and promotion. 

(x) List of Permits. Section 4.22(a)(x) of the Seller Disclosure Schedule sets forth a true and complete list of all
required permits, licenses, registrations, certificates, orders, clearances or approvals issued under the FD&C Act (“FD&C Permits”) and held by the Company. Each such FD&C Permit is in full force and effect and, to the
Knowledge of Seller, no suspension, revocation, cancellation or material modification of such FD&C Permit is threatened and there is no basis for believing that such FD&C Permit will not be renewable upon expiration. Each such FD&C
Permit will continue in full force and effect immediately following the Closing. 
 (b) International Regulatory and Related
Matters. 

  
 46 

 (i) General Compliance. The Company is conducting and has conducted its business and
operations in all EU member states and in other countries in which it currently is marketing the Products in compliance in all material respects with all applicable Laws and Regulations, including the essential requirements for affixing the CE mark
to Products and related guidelines, as well as provisions in European Union (“EU”) and EU member state legislation governing the disposal of waste electrical products and, where applicable, governing product liability, electrical
safety, and electromagnetic compatibility (collectively, “Applicable Non-U.S. Laws and Regulations” with respect to all legislation described in this paragraph (i) as applicable to the Products or activities of the Company).

 (ii) Enforcement. Except as set forth in Section 4.22(b)(ii) of the Seller Disclosure Schedule, the
Company has not received any written notice or, to the Knowledge of Seller, other communication from any non-U.S. regulatory agency/conformity assessment body (“Non-U.S. Regulatory Agency”) or other national authority alleging
noncompliance with any Applicable Non-U.S. Laws and Regulations. The Company is not subject to any enforcement proceedings by a Non-U.S. Regulatory Agency or other national authority and, to Seller’s Knowledge, no such proceedings have been
threatened. There is no civil, criminal or administrative action, suit, demand, claim, complaint, hearing, investigation, demand letter, warning letter or proceeding pending against the Company and the Company has no liability (whether actual or
contingent) for failure to comply with any Applicable Non-U.S. Laws and Regulations. There is no act, omission, event, or circumstance of which the Company has Knowledge that would reasonably be expected to give rise to or lead to any such action,
suit, demand, claim, complaint, hearing, investigation, notice, demand letter, warning letter or proceeding or any similar liability. There has not been any violation of any Applicable Non-U.S. Laws and Regulations by the Company in its product
development efforts, submissions, record keeping and reports to any Non-U.S. Regulatory Agency or other national authority, or any declaration of conformity that it may have made that would reasonably be expected to require or lead to investigation,
corrective action or regulatory enforcement action. There is no civil or criminal proceeding relating to the Company or any employee of the Company which involves a matter within or related to the jurisdiction of such Non-U.S. Regulatory Agency or
other national authority. 
 (iii) Facilities Licenses and Permits. The Company has complied with all Applicable
Non-U.S. Laws and Regulations pertaining to licenses and permits including requirements as to facilities where the Products are manufactured, processed, or held in any country, other than the U.S., where the Products are marketed. 

(iv) CE Marking/Premarket Clearance. Each Product owned or distributed by the Company and in current commercial distribution is
in compliance in all material respects with applicable marketing authorization, conformity assessments and quality systems requirements of the relevant country, and, in the EU member states, is marketed under, and is covered by, a medical device CE
mark. Each Product is marketed in compliance with the regulatory requirements in each country where the Product is commercialized, and in the EU member states, on the basis of which the CE mark was affixed under the following EU legislation: Council
Directive 93/42/EEC of 14 June 1993 concerning medical devices, Directive 2004/108/EC of the European Parliament and of the Council of 15 December 2004 on the approximation of the laws of the EU member states relating to electromagnetic
compatibility 

  
 47 

 
and repealing Directive 89/336/EEC of the European Parliament and of the Council of 12 December 2006 on the harmonisation of the laws of EU member states relating to electrical equipment
designed for use within certain voltage limits and any applicable national legislation in any EU member state implementing Council Directive 93/42/EEC, Directive 2004/108/EC and Directive 2006/95/EC. 

(v) Commercial Distribution in EU and Other Countries Outside the United States. Section 4.22(b)(v) of the Seller
Disclosure Schedule lists all Products that are in current commercial distribution or aimed for future distribution in the EU or other countries outside the United States. 
 (vi) Compliance with EU WEEE Directive. Regarding any Product that is in current commercial distribution in the EU the Company complies with (A) the requirements set forth by the Directive
2002/96/EC on waste electrical and electronic equipment and (B) any national legislation implementing Directive 2002/96/EC in any EU member state where such Product is marketed; in particular, to the extent possible under the national
legislation in the respective EU member states, the Company (x) concluded agreements with all Persons distributing such Products in the EU securing compliance with Directive 2002/96/EC or (y) joined systems enabling purchasers of the
products to return any electronic or electric waste from or in connection with the products free of charge to the distributor. 

(vii) Quality Management System Regulation and Reporting. 

(A) The Company has been audited by BSI Management Systems, its registrar and found to be in compliance with ISO 13485 and continues to
operate in material compliance with ISO 13485. 
 (B) With the exception of those suppliers identified in
Section 4.22(b)(vii)(B) of the Seller Disclosure Schedule, the Company and its suppliers that are subject to such requirements are, and have been since July 2007, in compliance with, and the Product in commercial distribution is
designed, manufactured, prepared, assembled, packaged, labeled, stored, installed, serviced, and processed in compliance with, ISO 13485 and all other applicable quality standards. 

(C) The Company is in compliance with record-keeping and reporting requirements for adverse event reporting under Applicable Non-U.S.
Laws and Regulations of countries in which the Products are investigated or marketed. Section 4.22(b)(vii)(C) of the Seller Disclosure Schedule sets forth all adverse event reports submitted to Governmental Authorities under Applicable
Non-U.S. Laws and Regulations. 
 (viii) No Unlawful Shipments. The Company has not introduced into commercial
distribution, in the six (6) years prior to the date of this Agreement, any Products that are, or that were, upon their shipment by the Company, in violation of Applicable Non-U.S. Laws and Regulations. 

(ix) Labeling, Promotion, and Advertising. All Products are and have been labeled, promoted, and advertised in all material
respects accordance with their marketing authorization (if any), within the scope of their exemption from such authorization, or in 

  
 48 

 
accordance with applicable Non-U.S. Laws and Regulations, including EU or national legislation and guidelines governing the labeling, promotion and marketing of products falling within the
category governing the Products. 
 (x) List of Permits. Section 4.22(b)(x) of the Seller Disclosure
Schedule sets forth a list of all permits, licenses, registrations, certificates, orders, clearances or approvals which are held by the Company and which relate to the Company’s activities outside the U.S. (“Non-U.S. Permits”).
Such Non-U.S. Permits are the only permits that are required for the Company to conduct its business outside the U.S. as presently conducted. Each such Non-U.S. Permit is in full force and effect and, to the Knowledge of Seller, no suspension,
revocation, cancellation or material modification of such Non-U.S. Permit is threatened and there is no basis for believing that such Non-U.S. Permit will not be renewable upon expiration. Each such Non-U.S. Permit will continue in full force and
effect immediately following the Closing. 
 Section 4.23 Product Liability; Product Warranties. Except as set forth in
Section 4.23 of the Seller Disclosure Schedule, all Products and services sold, rented, leased, provided or delivered by the Company to customers conform, in all material respects, to applicable contractual commitments, express and
implied warranties, product and service specifications, and, to the Knowledge of Seller, and other than as reserved for in the ordinary course of business, the Company has no liability for replacement or repair thereof or other damages in connection
therewith. Except as set forth in Section 4.23 of the Seller Disclosure Schedule, no Product or service sold, leased, rented, provided or delivered by the Company to customers on or prior to the Closing is subject to any guaranty,
warranty (other than warranties imposed by law) or other indemnity beyond the applicable standard terms and conditions of sale, rent or lease. Except as set forth in Section 4.23 of the Seller Disclosure Schedule, the Company does not
have any liability arising out of any injury to a Person or property as a result of the ownership, possession, provision or use of any equipment, Product or service sold, rented, leased, provided or delivered by the Company on or prior to the
Closing. All product liability claims that have been asserted against the Company, whether covered by insurance or not and whether litigation has resulted or not, are listed and summarized in Section 4.23 of the Seller Disclosure
Schedule. 
 Section 4.24 Inventories. The inventories of the Company are in good and merchantable condition, are
suitable and usable for the purposes for which they are intended and are in a condition such that they can be sold or used in the ordinary course of the business consistent with past practice. The Company has good and marketable title to its
inventories free and clear of all Liens. Except as reserved against by the Company (which reserve is set forth in Section 4.24 of the Seller Disclosure Schedule), the inventories of the Company do not consist, in any material amount, of
items that are obsolete or damaged. 
 Section 4.25 Trade Compliance Matters. 

(a) The Company is in compliance in all material respects with all applicable export control and economic sanctions laws and regulations
of the United States and other countries, including but not limited to the U.S. Export Administration Regulations (“EAR”) (15 C.F.R. 730 et seq.), the EAR’s rules on Restrictive Trade Practices or Boycotts (15
C.F.R. Part 760, the so-called “Anti-boycott Regulations”), and the economic sanctions rules and regulations 

  
 49 

 
implemented under statutory authority and/or Presidential Executive Orders and administered by the U.S. Treasury Department’s Office of Foreign Assets Control (31 C.F.R. Part 500 et
seq.; collectively, the “OFAC Regulations”). 
 (b) The Company has not, directly or indirectly,
exported, re-exported, sold or otherwise transferred any goods, software, or technology subject to the EAR in violation of the EAR or any OFAC Regulations. In the five (5) year period immediately preceding the date of this Agreement, the
Company has not been a party to or a beneficiary under any contract under which goods have been sold or services provided, directly or indirectly, to customers in countries subject to sanctions under the OFAC Regulations without the proper license
or other authorization from the U.S. Government. In addition, the Company has not engaged in any other transactions, or otherwise dealt, with any Person or entity with whom U.S. persons are prohibited from dealing under the EAR or the OFAC
Regulations, including but not limited to any person or entity designated by OFAC on the list of Specially Designated Nationals and Blocked Persons. 
 (c) There has been and is no charge, proceeding or, to the Knowledge of Seller, investigation by any Governmental Authority with respect to a violation of any applicable U.S. or non-U.S. export, import
control or economic sanctions Laws and Regulations including the EAR and the OFAC Regulations that is now pending or, to the Knowledge of Seller, has been asserted or threatened with respect to the Company. 

(d) Except as set forth in Section 4.25(d) of the Seller Disclosure Schedule, the Company is in compliance in all material
respects with all applicable U.S. and non-U.S. customs Laws and Regulations, including any export or import declaration filing, payment of customs duties, compliance with import quotas, import registration or any other similar requirements related
to the exportation or importation of goods or services by the Company. As of the date of this Agreement, Section 4.25(d) of the Seller Disclosure Schedule lists each special import or export program in which the Company participates,
including any temporary importation, bonded warehouse, expedited customs clearance or processing, drawback or similar program entitling the Company to customs or Tax benefits related to the importation or exportation of its goods or services. The
Company is in compliance in all material respects with all requirements imposed under any such programs. Except as set forth in Section 4.25(d) of the Seller Disclosure Schedule, there is no charge, proceeding or, to the Knowledge of
Seller, investigation by any Governmental Authority with respect to a material violation of any applicable U.S. or non-U.S. customs Laws or Regulations that is now pending or, to the Knowledge of Seller, threatened with respect to the Company.

 (e) Neither the Company nor its representatives nor any person acting for, or on behalf of the Company, has paid, promised to
pay, or authorized the payment of any money, or offered, given, promised to give, or authorized the giving of anything of value to any Government Official or to any person, in each case, under the circumstances where the Company, its representative
or such person knew or reasonably ought to have known (after due and proper inquiry) that all or a portion of such money or thing of value would be offered, given or promised, directly or indirectly, to a Government Official: (i) for the
purpose of (a) influencing any act or decision of a Government Official in their official capacity; (b) inducing a Government Official to do or omit to do any act in violation of their lawful duties; (c) securing

  
 50 

 
any improper advantage; (d) inducing a Government Official to influence or affect any act or decision of any Governmental Authority, any company, business, enterprise or other entity owned,
in whole or part, or controlled by an Governmental Authority, or any political party; or (e) assisting the Company or its representative or any person acting on behalf of the Company in obtaining or retaining business for or with, or directing
business to, the Company, its representative or such person; and (ii) in a manner which would constitute or have the purpose or effect of public or commercial bribery, acceptance of or acquiescence in extortion, kickbacks or other unlawful or
improper means of obtaining business or any improper advantage in violation of an anticorruption Laws and Regulations. 

Section 4.26 Manufacturing and Marketing Rights. Except as set forth in Section 4.26 of the Seller Disclosure
Schedule, the Company has not granted rights to manufacture, produce, assemble, license, market, or sell its Products to any other Person and is not bound by any agreement that affects the Company’s exclusive right to develop, manufacture,
assemble, distribute, market or sell its Products. 
 Section 4.27 Corporate Records. The minute books and other similar
records of the Company contain accurate records, in all material respects, of actions taken at any meeting of the Board of Directors of the Company or any committee thereof and of written consents executed in lieu of the holding of any such meeting.

 Section 4.28 Financial Statements. Section 4.28-1 of the Seller Disclosure Schedule sets forth the
unaudited listing of assets and liabilities of the Company as of December 31, 2010, and the unaudited statements of revenue and direct expenses for the year ended December 31, 2010 (the “Unaudited 2010 Financial
Statement”). Section 4.28-2 of the Seller Disclosure Schedule sets forth the unaudited listing of assets and liabilities of the Company as of June 30, 2011, and the unaudited statements of revenue and direct expenses for
the six month period ended June 30, 2011 (the “Unaudited Interim Financial Statements”, and together with the Unaudited 2010 Financial Statement, the “Unaudited Financial Statements”). The Unaudited Financial
Statements (x) fairly present the financial condition and results of operations of the Company at and as of the date and for the period indicated and (y) were compiled from books and records regularly maintained by management of Seller
used to prepare the financial statements of Seller. 
 Section 4.29 LipoSonix Agreement. 

(a) Seller has made available to Buyer a true and complete copy of the LipoSonix Agreement, together with all schedules, exhibits,
amendments, supplements, modifications and waivers. The LipoSonix Agreement is in full force and effect, is a valid and binding obligation of Seller and of each other party thereto and is enforceable against Seller and each other party thereto, and
the LipoSonix Agreement will continue to be (i) valid, binding and enforceable against Seller and each other party thereto, and (ii) in full force and effect immediately following the Closing, with no alteration or acceleration or increase
in fees or liabilities, payments, obligations or burdens. Seller is not alleged to be and no other party is or is alleged to be in, or has received notice of any, default under, or breach or violation of the LipoSonix Agreement and, to the Knowledge
of Seller, no event has occurred which, with the giving of notice or passage of time or both, would constitute such a default, breach or violation 

  
 51 

 
and Seller has no reasonable basis for suspecting that any such default, breach or violation exists or will be forthcoming. Seller is not currently involved, nor has it been involved since the
“Effective Time” (as defined in the LipoSonix Agreement), in any dispute with any counterparty to the LipoSonix Agreement, and the Company has not received or provided written or, to the Knowledge of Seller, oral notice since the
“Effective Time” (as defined in the LipoSonix Agreement), from or to any counterparty to the effect with respect to any such dispute. Seller has made no claims for indemnification under the LipoSonix Agreement, and to the Knowledge of
Seller, there were no representations and warranties made by the Company under the LipoSonix Agreement that were inaccurate, and no breaches of any covenants made by the Company under the LipoSonix Agreement. 

(b) No fees or payments of any kind will be due from either Seller or Buyer under the LipoSonix Agreement as a result of the consummation
of the Contemplated Transactions. No “Mandatory Prepayment Amount” (as defined in the LipoSonix Agreement) will be payable from either Buyer or Seller under the LipoSonix Agreement, at the Closing or at any time in the future. 

Section 4.30 [Reserved]. 
 Section 4.31 Exclusivity of Representations and Warranties. Except as expressly set forth in this Article 4, Seller makes no representations or warranties, express or implied, with respect
to the Company or any of the business, assets, liabilities or operations of the Company, and any such other representations or warranties are hereby expressly disclaimed. 
 ARTICLE 5 
 REPRESENTATIONS AND WARRANTIES 

OF BUYER 

Buyer hereby represents and warrant to Seller as follows: 
 Section 5.1 Organization and Good Standing. Buyer is a corporation duly organized, validly existing and in good standing under the Laws of the State of Delaware, the state of its incorporation, and
has all corporate power and authority to own, lease and operate its properties and assets and to carry on its business as now conducted. 
 Section 5.2 Authority; Enforceability. Buyer has all requisite corporate power and authority to execute and deliver this Agreement and each other instrument and document required to be executed and
delivered by it at or prior to the Closing, and to perform its obligations hereunder and thereunder and to consummate the Contemplated Transactions. The execution and delivery by Buyer of this Agreement and the performance of its obligations
hereunder and thereunder have been duly and validly authorized by the Board of Directors of Buyer. No other corporate proceedings on the part of Buyer are necessary to authorize the consummation of the Contemplated Transactions. This Agreement has
been duly and validly executed and delivered by Buyer, or will be duly and validly executed and delivered by Buyer at or prior to Closing, and assuming the due authorization, execution and delivery thereof by Seller, 

  
 52 

 
constitutes a legal, valid and binding obligation of Buyer enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance,
reorganization, moratorium and other similar Laws relating to or affecting creditors’ rights generally, general equitable principles (whether considered in a proceeding in equity or at law) and an implied covenant of good faith and fair
dealing. 
 Section 5.3 No Conflict; Required Filings and Consents. 

(a) The execution and delivery by Buyer of this Agreement and each other instrument and document required by this Agreement to be
executed and delivered by Buyer do not, and the performance of this Agreement and each other instrument and document required by this Agreement to be executed and delivered by Buyer, shall not, (i) conflict with or violate the certificate of
incorporation or bylaws of Buyer, (ii) any resolution adopted by the Board of Directors or stockholders of Buyer or (ii) subject to the filings and other matters referred to in Section 5.3(b), conflict with or violate in any
material respect any Law or Order in each case applicable to Buyer or by which it or any of its properties, rights or assets are bound or affected. 
 (b) The execution and delivery by Buyer of this Agreement and each other instrument and document required by this Agreement to be executed and delivered by Buyer at or prior to the Closing do not, and the
performance by Buyer of this Agreement and each instrument required by this Agreement to be executed and delivered by Buyer at or prior to the Closing shall not, require Buyer to obtain any Approval of any Person, observe any waiting period imposed
by, or make any filing with or notification to, any Governmental Authority, except for compliance with any applicable requirements of the pre-merger notification requirements of the HSR Act and applicable Foreign Competition Laws, and except as
would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on Buyer. 

Section 5.4 Absence of Litigation. As of the date hereof, there is no Claim pending against or, to the Knowledge of Buyer,
threatened against Buyer which questions or challenges (a) the validity of this Agreement, or (b) any action taken or to be taken by Buyer pursuant to this Agreement or in connection with the Contemplated Transactions. 

Section 5.5 Available Funds. Buyer has as of the date of this Agreement, and will have on the Closing Date and on the date on
which the FDA Milestone Payment is due, a sufficient amount of cash (without giving effect to any unfunded financing regardless of whether any such financing is committed) to satisfy Buyer’s payment obligations required to be made at the
Closing under this Agreement and upon the achievement of the FDA Milestone in the form of the FDA Milestone Payment, (ii) the resources and capabilities (financial or otherwise) to perform its obligations hereunder, and (iii) has not
incurred any obligation, commitment, restriction or liability of any kind, which would impair or adversely affect such resources and capabilities. 
 Section 5.6 No Brokers. Other than Morgan Keegan & Co., there is no investment banker, broker, finder or other intermediary which has been retained by or is authorized to act on
behalf of Buyer who is or might be entitled to any fee or commission in connection with the consummation of the Contemplated Transactions. 

  
 53 

 Section 5.7 Investment Representation. Buyer has such knowledge and experience
in financial and business matters that it is capable of evaluating the risks and merits associated with the acquisition of the Shares, and Buyer is purchasing the Shares for its own account and not with a view to the sale or distribution thereof
(within the meaning of securities Laws). 
 Section 5.8 Buyer Review. Buyer represents that it is a sophisticated
entity that was advised by knowledgeable counsel and, to the extent it deemed necessary, other advisors in connection with this Agreement and has conducted its own independent review and evaluation of the Company and its business. Buyer acknowledges
that the Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities law and Buyer must bear the economic risk of its investment in the Shares until and unless the
offer and sale of such Shares is subsequently registered under the Securities Act and all applicable state securities laws or an exemption from such registration is applicable. Buyer is an “accredited investor” within the meaning of
Regulation D under the Securities Act. 
 Section 5.9 No Outside Reliance. Buyer expressly acknowledges and agrees
that (i) the representations and warranties contained in Article 4 are the only representations and warranties Seller is making regarding the Company and that Seller is not making any representations and warranties with respect to any
other information about the Company provided to Buyer in the course of its due diligence investigation of the Company; (ii) except as specifically set forth in this Agreement, Seller is transferring the Shares and the properties and assets held
by the Company “as is, where is, and with all faults;” (iii) except for the representations and warranties expressly set forth in Article 4, Buyer is not relying on any representations or warranties of any kind whatsoever,
whether oral or written, express or implied, arising out of any statute, regulation or common law right or remedy, or otherwise, from Seller or the Company or directors, officers, employees, agents, stockholders, affiliates, consultants, counsel,
accountants, investment bankers or representatives of any of them, as to any matter, concerning the Company or the properties or assets of the Company, or set forth, contained or addressed in any due diligence materials (including the completeness
thereof). Without limiting the generality of the foregoing, Buyer expressly acknowledges and agrees that, except to the extent expressly addressed by Article 4, any financial information, projections or other information contained in any
documents or other materials (including the “Confidential Information Memorandum” or documents in the “virtual data room”) or management presentations that have been or are in the future provided to Buyer or any of its
Affiliates, agents, lenders or representatives are not and will not be deemed to be representations or warranties of Seller. 

ARTICLE 6 

COVENANTS 

Section 6.1 Conduct of Business by the Company Pending the Closing. Seller covenants and agrees that, between the date of
this Agreement and the earlier to occur of the Closing and the termination of this Agreement pursuant to its terms, unless Buyer shall otherwise specifically consent in writing in advance (provided that such consent shall only be requested
and provided if consistent with applicable Law and provided further that such consent shall not be unreasonably withheld, conditioned or delayed), or unless otherwise expressly provided for by 

  
 54 

 
this Agreement, Seller shall cause the Company to (i) conduct its business only in the ordinary course of business and in a manner consistent with past practice and (ii) conduct its
business in compliance with all applicable Laws and Orders. Seller shall cause the Company to use its commercially reasonable efforts to (A) preserve intact the business organization and assets and Intellectual Property of the Company,
(B) keep available the services of the Company’s present officers, employees, consultants, sales representatives, distributors and sales agents (other than terminations in the ordinary course of business consistent with past practice),
(C) maintain in effect Material Contracts (other than those Material Contracts that expire in accordance with their terms or terminations expressly provided for by this Agreement), and (D) preserve the Company’s present relationships
with advertisers, publishers, sponsors, customers, licensees, suppliers, sales representatives, distributors and other Persons with which the Company has business relations. By way of amplification and not limitation, Seller shall cause the Company
to not, between the date of this Agreement and the earlier to occur of the Closing and the termination of this Agreement pursuant to its terms, directly or indirectly do, or propose to do, any of the following without the prior written consent of
Buyer (provided that such consent shall only be requested and provided if consistent with applicable Law and provided further that such consent shall not be unreasonably withheld, conditioned or delayed), unless otherwise
expressly provided for by this Agreement or otherwise expressly set forth in Section 6.1 of the Seller Disclosure Schedule: 
 (a) amend or otherwise change the Charter or Bylaws or alter through merger, liquidation, reorganization, reclassification, recapitalization, restructuring or in any other fashion the corporate structure
or capital structure or ownership of the Company; 
 (b)(i) issue, grant, sell, transfer, deliver, pledge, promise, dispose
of or encumber, or authorize the issuance, grant, sale, transfer, deliverance, pledge, promise, disposition or encumbrance of, or alter or modify the terms of rights or obligations under any shares of capital stock of any class or series (common or
preferred) or securities or other instruments (including notes or other evidences of Indebtedness) convertible into, or subscription rights, options or warrants to acquire, or other agreements or commitments of any character obligating it to issue
any such shares or other convertible instruments or securities or any other ownership interest or stock-based rights of the Company, (ii) adopt, ratify or effectuate a stockholders’ rights plan or agreement or similar plan or Contract, or
(iii) redeem, purchase or otherwise acquire, directly or indirectly, any of the capital stock of the Company; 

(c)(i) other than cash dividends or other cash distributions to Seller in the ordinary course of business consistent with past
practice, declare, set aside or pay any dividend or other distribution (whether in cash, stock or property or any combination thereof) in respect of any of its capital stock, (ii) split, combine or reclassify any of its capital stock,
(iii) effect a recapitalization; issue or authorize the issuance of any other securities in respect of, in lieu of or in substitution for, shares of its capital stock, or (iv) amend the terms of, repurchase, redeem or otherwise acquire,
directly or indirectly, any of its securities; 
 (d) sell, transfer, assign, lease, sublease, license, sublicense, mortgage,
pledge, encumber, impair or otherwise dispose of (in whole or in part), or create, incur, assume or cause to be subjected to any Lien on, any of the assets, properties or securities of the Company

  
 55 

 
(including any Intellectual Property or accounts receivable), except for the sale of inventory in the ordinary course of business consistent with past practice; 

(e)(i) acquire (by merger, consolidation, acquisition of stock or assets or otherwise) or organize or form any corporation, limited
liability company, partnership, association, joint venture, trust or other entity or Person or any business organization or division thereof, or (ii) acquire any rights, assets or properties other than in the ordinary course of business
consistent with past practice; 
 (f)(i) incur or modify any Indebtedness or issue any debt securities or any warrants or
rights to acquire any debt security, (ii) assume, guarantee or endorse or otherwise become responsible for, the obligations of any other Person, (iii) enter into any off-balance sheet financing arrangement or any accounts receivable or
payable financing arrangement, or (iv) make any loans, advances or enter into any other financial commitments other than advances of reasonable expenses to employees in the ordinary course of business consistent with past practice; 

(g) authorize or make any capital expenditures outside of the ordinary course of business consistent with past practice, or in excess of
$100,000; 
 (h)(i) increase, accelerate or provide for additional compensation or fringe benefits of, or grant, agree to
grant, pay or otherwise make payable any incentive, bonus or similar compensation or rights, to any present or former director, officer, employee, consultant, sales representative, distributor or agent of the Company, (ii) grant any severance,
retention, continuation or termination pay to any present or former director, officer, employee, consultant, sales representative, distributor or agent of the Company outside of the ordinary course of business consistent with past practice,
(iii) loan or advance any money or other property to any present or former director, officer, employee, consultant, sales representative, distributor or agent of the Company (except for advances of business expenses in the ordinary course of
business consistent with past practice), (iv) establish, adopt, enter into, amend or terminate any Employee Plan or any plan, agreement, program, policy, trust, fund or other arrangement that would be an Employee Plan if it were in existence as
of the date of this Agreement (except as may otherwise be required pursuant to Applicable Law), (v) terminate or lay off any executive or management employee or key employee (except for termination for “cause”), or (vi) grant any
equity or equity-based awards or stock-based rights; 
 (i) fail to give any notices or other information required to be given
to the employees of the Company, any collective bargaining unit representing any group of employees of the Company or any applicable Governmental Authority under the WARN Act, the National Labor Relations Act, the Code, COBRA, or other applicable
Law in connection with the Contemplated Transactions; 
 (j) hire or retain, or continue to retain or employ, any employee or
consultant having access to confidential or proprietary information of the Company unless such employee or consultant enters into, or has entered into, a proprietary information and inventions agreement in the form customarily used by the Company or
an agreement containing substantially similar and no less restrictive confidentiality and inventions assignment provisions, or amend or 

  
 56 

 
otherwise modify, or grant a waiver under, any such confidentiality or proprietary information agreement with any such Person; 

(k) change any accounting or cash management policies, procedures or practices used by the Company (including with respect to reserves,
revenue recognition, timing for payments of accounts payable and collection of accounts receivable) unless required by a change in Law or GAAP; 
 (l)(i) enter into any Contract that if entered into prior to the date hereof would be a Material Contract other than in the ordinary course of business consistent with the past practices of the
Company and not exceeding $50,000, (ii) modify, amend, extend or supplement in any material respect, transfer or terminate any Material Contract or waive, release or assign any rights or Claims thereto or thereunder other than in the ordinary
course of business consistent with the past practices of the Company and not exceeding $50,000, (iii) enter into or extend any lease or sublease with respect to Real Property with any third party, (iv) modify, amend or transfer in any way
or terminate any license agreement, standstill or confidentiality agreement with any third party, or waive, release or assign any rights or Claims thereto or thereunder, (v) enter into any agreement or arrangement that limits or otherwise
restricts or that could by its terms be reasonably expected to restrict the Company or its Affiliates or successors or that by its terms could, after the Effective Time, limit or restrict Buyer or any of its respective Subsidiaries or Affiliates or
successors thereto, from engaging or competing in any line of business or in any geographic area, (vi) enter into or amend any agreement pursuant to which any other party is granted manufacturing, marketing or other development or distribution
rights of any type or scope with respect to any Product or any of the Company’s technologies or (vii) enter into, modify, amend or supplement any Contract to provide exclusive rights or obligations or any non-competition or similar
obligations or restrictions; 
 (m)(i) make or change any Tax election or change any method of tax accounting,
(ii) settle or compromise any federal, state, local or foreign Tax liability, (iii) file any amended Tax Return, (iv) enter into any closing agreement relating to any Tax, (v) agree to an extension or waiver of any limitation
period applicable to any claim or assessment in respect of Taxes, or (vi) surrender any right to claim a Tax refund; 
 (n)
enter into any operating leases; 
 (o) except as required by Law, modify or change in any material respect any existing permit
or operating license listed in Section 4.7(c) of the Seller Disclosure Schedule; 
 (p) pay, discharge, satisfy or
settle any Claim or waive, assign or release any material rights or claims, except any Claim which settlement would not impose any injunctive or similar Order on the Company or restrict in any way the business of the Company, or exceed $50,000 in
cost, liability or value to the Company; 
 (q) commence, join, make an appeal with respect to or settle a lawsuit, action,
Claim or similar proceeding other than (i) for the routine collection of bills, (ii) to enforce its rights with respect to Intellectual Property, (iii) in such cases where Seller in good faith determines that failure to commence suit
would result in the material impairment of a valuable 

  
 57 

 
aspect of its business, provided, that Seller consults with Buyer prior to the Company filing or taking of any action with respect to such lawsuit, action, Claim or similar proceeding, or
(iv) pursuant to this Agreement; 
 (r) engage in, enter into or modify or amend any Contract, transaction, Indebtedness,
commitment or other arrangement with, directly or indirectly, any of the directors, officers, employees, consultants, agents, or other Affiliates of the Company, or any of their respective Affiliates or family members, other than offer letters and
other standard documents, in the Company’s forms (and not providing any rights to severance or similar payments), which have been provided to Buyer, with any new employees or consultants hired or retained after the date of this Agreement;

 (s) fail to maintain in full force and effect all self-insurance and insurance, as the case may be, currently in effect,
except that existing policies may be replaced by new or successor policies of substantially similar coverage and at a substantially similar cost; 
 (t) commence any proceeding for any voluntary liquidation, dissolution, or winding up of the Company, including but not limited to initiating any bankruptcy proceedings on its behalf; 

(u) fill any orders for, or conduct any further business with, any third parties that are subject to a United States trade embargo;

 (v) take any action if such action would or would reasonably be expected to have, individually or in the aggregate, a
Material Adverse Effect on the Company; 
 (w) fail to maintain in full force and effect all material permits, licenses,
registrations, certificates, orders, clearances or approvals held by the Company; or 
 (x) authorize any of the foregoing, or
agree or enter into or amend any Contract or commitment to do any of the foregoing. 
 Section 6.2 No Solicitation of
Other Proposals. 
 (a) From the date hereof until the earlier to occur of the Closing and the termination of this Agreement
pursuant to its terms, Seller shall not, nor shall Seller permit the Company or any of its Affiliates to, nor shall it authorize, direct or permit any of their respective directors, officers, employees, consultants, advisors, representatives or
agents (collectively, the “Seller Representatives”) to, directly or indirectly, (i) solicit, facilitate, initiate, knowingly encourage or take any action to solicit, facilitate, initiate or knowingly encourage, any inquiries or
communications regarding or the making of any proposal or offer that constitutes or may constitute an Acquisition Proposal, or (ii) participate or engage in any discussions or negotiations with, or provide any information to or take any other
action with the intent to facilitate the efforts of, any Person concerning any possible Acquisition Proposal or any inquiry or communication which would reasonably be expected to result in an Acquisition Proposal. For purposes of this Agreement, the
term “Acquisition Proposal” shall mean any inquiry, proposal or offer from any Person (other than Buyer or any of its Affiliates) relating to (i) any merger, consolidation, reorganization or other direct or indirect business
combination, recapitalization, liquidation, 

  
 58 

 
winding-up of, or similar transaction, involving the Company, (ii) the issuance or acquisition of shares of capital stock or other equity securities of the Company, (iii) the sale,
lease, exchange, license (whether exclusive or not), or other disposition of a substantial portion of the Intellectual Property of the Company or a substantial portion of the business or other assets of the Company, or (iv) any other
transaction, the consummation of which would reasonably be expected to impede, interfere with, prevent or materially delay the Closing or any of the other transactions contemplated hereby or which would reasonably be expected to diminish
significantly the benefits to Buyer or its Affiliates of the transactions contemplated hereby; provided, however, that an Acquisition Proposal shall not include any of the foregoing relating to Seller or any of its Subsidiaries other
than the Company. Seller shall immediately cease and cause to be terminated, and shall cause all Seller Representatives to immediately terminate and cause to be terminated, all existing discussions or negotiations with any Persons conducted
heretofore with respect to, or that could reasonably be expected to lead to, an Acquisition Proposal. Seller shall take all reasonable actions to ensure that each Seller Representative complies with the provisions of this Section 6.2(a).
Without limiting the foregoing, any action or conduct by any Seller Representative that would be a violation of this Section 6.2(a) if taken by Seller, whether or not such Person is purporting to act on behalf of Seller, shall be deemed
to be a breach of this Section 6.2(a) by Seller. 
 (b) Nothing in this Section 6.2 shall permit Seller
to enter into any agreement, orally or in writing, with respect to an Acquisition Proposal during the term of this Agreement. In addition to the other obligations of Seller set forth in this Section 6.2, Seller shall immediately advise
Buyer orally and in writing of any request for information with respect to any Acquisition Proposal, or any inquiry with respect to or which could result in an Acquisition Proposal, the material terms and conditions of such request, Acquisition
Proposal or inquiry, and the identity of the Person making the same. 
 Section 6.3 Access to Information;
Confidentiality. 
 (a) From the date hereof until the earlier to occur of the Closing and the termination of this Agreement
pursuant to its terms, consistent with applicable Law, upon reasonable notice, Seller shall afford to the officers, employees, accountants, counsel and other representatives and agents of Buyer and its Affiliates (collectively “Buyer
Representatives”) reasonable access (with reasonable prior notice, and during regular business hours) to the Company’s properties, records, databases, source code, books, Contracts, commitments and other information, and, during such
period, Seller shall make available to Buyer and the Buyer Representatives the appropriate individuals for discussion of the Company’s business, properties and personnel as Buyer or the Buyer Representatives may reasonably request.
Notwithstanding the foregoing, in exercising Buyer’s access rights under this Section 6.3, (i) Buyer and the Buyer Representatives shall not be permitted to interfere unreasonably with the conduct of the business of the
Company, Seller or any of its Affiliates, (ii) the auditors and accountants of the Company, Seller or any of its Affiliates shall not be obligated to make any work papers available to any Person unless and until such Person has signed a
customary agreement relating to such access to work papers in form and substance reasonably acceptable to such auditors or accountants and (iii) if the Parties are in an adversarial relationship in litigation or arbitration, the furnishing of
information, documents or records in accordance with this Section 6.3(a) shall be subject to applicable rules relating to discovery. 

  
 59 

 (b) Buyer shall keep all non-public information obtained pursuant to
Section 6.3(a) confidential in accordance with the terms of the Confidentiality Agreement, dated April 7, 2011, between Seller and Buyer (the “Confidentiality Agreement”). The Confidentiality Agreement shall
continue in full force and effect prior to the Closing and after any termination of this Agreement. The Confidentiality Agreement shall be deemed to have been terminated at the Closing Date solely with respect to information relating to the Company
and its products and business; provided, however, that Buyer acknowledges that any and all other information provided to it by Seller or its representatives concerning Seller and its Affiliates shall remain subject to the terms and
conditions of the Confidentiality Agreement. Anything contained in the Confidentiality Agreement to the contrary notwithstanding, Seller and Buyer hereby agree that each such Party may issue press release(s) or make other public announcements
regarding the transactions contemplated in this Agreement only in accordance with Section 6.7. 
 (c) Buyer hereby
agrees that it shall, and shall cause Buyer Representatives to, keep confidential any Confidential Information not related to the Company, its products or business that Buyer obtains as a result of the Contemplated Transactions and to promptly
deliver to Seller or destroy (upon Seller’s request) any such Confidential Information, including all copies, reproductions, and extracts thereof. 
 (d) Seller hereby agrees that it shall, and shall cause Seller Representatives to, keep confidential any Confidential Information related to the Company, its assets (tangible and intangible), employees,
finances, businesses and operations. 
 Section 6.4 Commercially Reasonable Efforts; Further Assurances. 

(a) Upon the terms and subject to the conditions set forth in this Agreement, each Party shall use its commercially reasonable efforts to
take, or cause to be taken, all actions, and do, or cause to be done, and to assist and cooperate with the other Parties in doing, all things necessary, proper or advisable under applicable Law to consummate and make effective, in the most
expeditious manner practicable, the Contemplated Transactions. Each Party shall use its commercially reasonable efforts to (i) as promptly as practicable, obtain all Approvals necessary to consummate the Contemplated Transactions,
(ii) make all filings required by applicable Law required in connection with the authorization, execution and delivery of this Agreement by Buyer and Seller and the consummation by them of the Contemplated Transactions, (iii) furnish all
information required for any application or other filing to be made pursuant to any Law or any applicable Regulations of any Governmental Authority in connection with the Contemplated Transactions and all information reasonably requested by any
Governmental Authority in connection with the Contemplated Transactions, and (iv) obtain the expiration or termination of any applicable waiting period and any required clearances under the HSR Act or any applicable Foreign Competition Laws.

 (b) Subject to the terms and conditions herein provided and without limiting the foregoing, Seller and Buyer shall promptly
(but in no event later than fifteen (15) days after the date hereof) make or cause their “ultimate parent entities,” as that term is defined in the HSR Act and the Regulation promulgated thereunder to make, in consultation and
cooperation with the other Party, (i) an appropriate filing of a notification and report form pursuant to the HSR Act relating to the Contemplated Transactions and (ii) all other necessary registrations, declarations,

  
 60 

 
notices and filings relating to the Contemplated Transactions with other Governmental Authorities under any applicable Foreign Competition Laws. 

(c) Subject to applicable confidentiality restrictions or restrictions required by Law, Buyer and Seller shall notify the other promptly
upon the receipt of (i) any comments or questions from any officials of any Governmental Authority in connection with any filings made pursuant to this Section 6.4 or the Contemplated Transactions and (ii) any request by any
officials of any Governmental Authority for amendments or supplements to any filings made pursuant to any Laws or Regulations of any Governmental Authority or answers to any questions, or the production of any documents, relating to an investigation
of the Contemplated Transactions by any Governmental Authority. Whenever any event occurs that is required to be set forth in an amendment or supplement to any filing made pursuant to this Section 6.4, each Party will promptly inform the
other of such occurrence and cooperate in filing promptly with the applicable Governmental Authority such amendment or supplement. Without limiting the generality of the foregoing, each Party shall provide to the other (or the other’s
respective advisors) upon request copies of all correspondence (including any submissions and document productions) between such Party and any Governmental Authority relating to the Contemplated Transactions. The Parties may, as they deem advisable
and necessary, designate any competitively sensitive materials provided to the other under this Section 6.4 as “outside counsel only.” Such materials and the information contained therein shall be given only to outside counsel
of the recipient and will not be disclosed by such outside counsel to employees, officers, or directors of the recipient without the advance written consent of the Party providing such materials. In addition, to the extent reasonably practicable,
all discussions, telephone calls, and meetings with a Governmental Authority regarding the Contemplated Transactions shall include representatives of both Parties. Subject to applicable Law, the Parties will consult and cooperate with each other in
connection with any analyses, appearances, presentations, memoranda, briefs, arguments, and proposals made or submitted to any Governmental Authority regarding the Contemplated Transactions by or on behalf of any Party. 

(d) Without limiting the foregoing, Buyer shall use reasonable best efforts to promptly take, in order to consummate the Contemplated
Transactions by the End Date, all actions necessary to (i) secure the expiration or termination of any applicable waiting period and any required clearances under the HSR Act or any applicable Foreign Competition Laws and (ii) resolve any
objections asserted with respect to the Contemplated Transactions raised by any Governmental Authority, and to prevent the entry of any court Order and to have vacated, lifted, reversed or overturned any Order that would prevent, prohibit, restrict,
or delay the consummation of the Contemplated Transactions, including: (A) executing settlements, undertakings, consent decrees, stipulations, or other agreements with any Governmental Authority, (B) selling, divesting, licensing, or
otherwise conveying particular assets or categories of assets or businesses of Buyer, (C) agreeing to sell, divest, license, or otherwise convey any particular assets or categories of assets or businesses of Buyer contemporaneously with or
subsequent to the Closing, and (D) permitting Seller to sell, divest, license, or otherwise convey any particular assets or categories of assets or businesses of the Company prior to the Closing; provided, however, that Buyer
shall not be required to take any action that would be material to the business or financial condition of Buyer and its Subsidiaries, taken as a whole, or material to the business or financial condition of the Company. No actions taken pursuant to
this Section 6.4 shall be considered for purposes of determining whether a Material Adverse Effect on the 

  
 61 

 
Company or Buyer has occurred. Buyer shall, in consultation with Seller, respond to and seek to resolve as promptly as reasonably practicable any objections asserted by any Governmental Authority
with respect to the Contemplated Transactions. 
 (e) Buyer shall not, and shall cause its Affiliates not to, acquire or agree
to acquire, by merging with or into or consolidating with, or by purchasing a substantial portion of the assets of or equity in, or by any other manner, any business or any corporation, partnership, association or other business organization or
division thereof, or otherwise acquire or agree to acquire any assets, if the entering into of a definitive agreement relating to, or the consummation of such acquisition, merger or consolidation would reasonably be expected to: (i) impose any
material delay in the obtaining of, or materially increase the risk of not obtaining, any consents of any Governmental Authority necessary to consummate the Contemplated Transactions or the expiration or termination of any applicable waiting period;
(ii) materially increase the risk of any Governmental Authority seeking or entering an Order prohibiting the consummation of the Contemplated Transactions; (iii) materially increase the risk of not being able to remove any such Order on
appeal or otherwise; or (iv) materially delay or prevent the consummation of the Contemplated Transactions. 
 (f) The
Parties shall use their commercially reasonable efforts to satisfy or cause to be satisfied all of the conditions precedent that are set forth in Article 7, as applicable to each of them, and to cause the Contemplated Transactions to be
consummated in the most expeditious manner practicable. Each Party, at the reasonable request of another Party, shall promptly execute and deliver such other instruments and do and perform such other acts and things as may be necessary or desirable
for effecting completely the consummation of this Agreement and the Contemplate Transactions. 
 Section 6.5 Employee
Benefits. 
 (a) From and after the Closing, Buyer shall provide employees of the Company (the “Employees”)
with employee benefits (including hourly wage or salary level) that are substantially similar in the aggregate to those employee benefits provided to similarly situated employees of Buyer. Nothing in this Section 6.5(a) shall restrict in
any way the ability of Buyer or the Company to terminate any Employee at any time. 
 (b) To the extent permitted by an
applicable Buyer employee benefit plan or arrangement, Buyer shall give Employees full credit for purposes of eligibility to participate and vesting under the employee benefit plans or arrangements maintained by Buyer or its U.S. Affiliates in which
such Employees participate for such Employees’ service with the Company to the same extent recognized by comparable plans of the Company immediately prior to the Closing Date. Notwithstanding the foregoing, with respect to any welfare benefit
plans maintained by Buyer or its U.S. Affiliates for the benefit of Employees on and after the Closing Date, Buyer shall use commercially reasonable efforts to (i) cause to be waived any eligibility requirements or pre-existing condition
limitations to the same extent waived under comparable plans of the Company immediately prior to the Closing Date and (ii) give effect, in determining any deductible and maximum out-of-pocket limitations, to amounts paid by such Employees in
the year of the Closing Date with respect to similar plans maintained by the Company. 

  
 62 

 (c) Nothing contained in this Agreement shall (i) constitute or be deemed to be an
amendment to any Employee Plan or any other compensation or benefit plan, program or arrangement of the Company, (ii) prevent the amendment or termination of any Employee Plan or interfere with the right or obligation of Buyer or the Company to
make such changes as are necessary to conform with applicable Law or (iii) create any third-party beneficiary rights in any Employee (including any beneficiary or depending thereof) in respect of any compensation or benefits that may be
provided under any plan or arrangement of Buyer. 
 Section 6.6 Notification of Certain Matters. 

(a) Seller shall give prompt notice to Buyer, and Buyer shall give prompt notice to Seller, of the occurrence or non-occurrence of any
fact, condition or event of which Seller has Knowledge or which Buyer has Knowledge, as applicable, the occurrence or non-occurrence of which would result in any representation or warranty contained in this Agreement being untrue or inaccurate in
any material respect (or, in the case of any representation or warranty qualified by its terms by materiality (including the words “material” or “Material Adverse Effect”), then untrue or inaccurate in any respect) had such
representation or warranty been made as of the time of occurrence or discovery of such fact, condition or event and any failure of Seller or Buyer, as the case may be, to comply with or satisfy in any material respect any covenant, condition or
agreement to be complied with or satisfied by it hereunder; provided, however, that the delivery of any notice pursuant to this Section 6.6 shall not limit or otherwise affect the remedies available hereunder to the Party
receiving such notice, including the right to indemnification. 
 (b) Each of Buyer and Seller shall give prompt notice to the
other Party of (i) any notice or other communication from any Person alleging that the Approval of such Person is or may be required in connection with this Agreement or the Contemplated Transactions, (ii) any notice, document, request,
court papers or other communication from any Governmental Authority or other third party in connection with this Agreement or the Contemplated Transactions, (iii) any Claim relating to or involving or otherwise affecting such Party that relates
to this Agreement or the Contemplated Transactions, or (iv) any fact, event, change, development, circumstance, condition or effect that such Party has determined would reasonably be expected to delay or impede the ability of such Party to
consummate the Contemplated Transactions or to fulfill their respective obligations set forth herein or therein. 
 (c) Seller
shall give prompt notice to Buyer of (i) the occurrence of a default, breach or violation or event that, with notice or lapse of time or both, would become a default, breach or violation under any Material Contract of the Company, (ii) any
fact, event, change, development, circumstance, condition or effect that has had or would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on the Company, and (iii) any of its representations or
warranties contained herein failing to be true and correct in all material respects (or, in the case of any representation or warranty qualified by its terms by materiality (including the words “material” or “Material Adverse
Effect”), failure to be true or accurate in any respect). 
 (d) Seller shall give any notices to third parties, and use
commercially reasonable efforts to obtain any Approvals from third parties, (i) necessary to consummate the 

  
 63 

 
Contemplated Transactions (including but not limited to those Approvals set forth on Sections 4.5(a) and 4.5(b) of the Seller Disclosure Schedule), and (ii) otherwise required
under any Contracts in connection with the consummation of the Contemplated Transactions. If Seller shall fail to obtain any such Approval from a third party, Seller shall use its commercially reasonable efforts to take such actions as are
reasonably requested by Buyer (and Buyer agrees to cooperate therewith as reasonably requested) to limit the adverse effect upon Seller and Buyer, their respective Subsidiaries and Affiliates, and their respective businesses resulting, or which
would result after the Closing, from the failure to obtain such consent. Notwithstanding the foregoing, Seller and Buyer shall cooperate with each other and shall use commercially reasonable efforts to have the guarantee described in
Section 6.6(d) of the Seller Disclosure Schedule released prior to the Closing. 
 Section 6.7 Public
Announcements. On or prior to Closing, no Party hereto will make any press release, public statement, public announcement or public filing with any Governmental Authority (including any exhibit thereto containing a copy of this Agreement) with
respect to this Agreement or any of the Contemplated Transactions (including with respect to the matters set forth in Section 6.7 of the Seller Disclosure Schedule) without the prior written consent of the other Party; provided,
however, that either Party may make any press release, public statement, public announcement or public filing which such Party determines is required by applicable Law or stock listing requirements and provided further, that the
Party making such press release, public statement, public announcement or public filing shall provide to the other Party a copy of such press release, public statement, public announcement or public filing as early as is reasonably practicable prior
to the making thereof, and will consult with the other Party regarding the contents thereof prior to making any such press release, public statement, public announcement or public filing. 

Section 6.8 Claims. Prior to the Closing, Seller shall not settle or compromise any Claim brought in connection with the
Contemplated Transactions by any present, former or purported holder of any securities of the Company or other present, former or purported counterparty to a Material Contract with the Company without the prior written consent of Buyer;
provided, that such consent shall not be unreasonably withheld, conditioned or delayed. 
 Section 6.9 Delivery of
Corporate Records. At or before the Closing, Seller shall deliver to Buyer or its designee correct and complete copies of all of the Company’s minute books of all stockholders, Board of Directors and committee meetings, unanimous or other
consents, corporate seals, stock ledgers, true and complete copies of the Charter and Bylaws, and other similar records and items reasonably requested by Buyer from Seller. 
 Section 6.10 Certain Litigation Matters. After the Closing, with respect to the legal proceedings described in paragraph 2 of Section 4.10(a) of the Seller Disclosure Schedule, Buyer
shall assume and continue to perform all of the obligations of the Company and Seller to coordinate the defense of the defendants, engage legal counsel (whether it continues to engage Clifford Chance LLP or otherwise), and pay for and reimburse any
legal costs and expenses (including court costs and attorneys’ fees) of the defendants; provided, however, that all costs and expenses incurred by Buyer or the Company in connection with such legal proceedings shall be borne
equally by Buyer and Seller; provided, further, that Seller’s obligations with respect to the legal proceedings described in paragraph 2 of Section 4.10(a) of the Seller Disclosure 

  
 64 

 
Schedule shall be limited to the amount set forth in Section 6.10 of the Seller Disclosure Schedule and, following the reimbursement by Seller to Buyer of such amount in accordance
with Section 6.10 of the Seller Disclosure Schedule, Seller shall be deemed to have paid such amount in full and shall have no additional obligations or liability of any kind whatsoever with respect thereto. 

Section 6.11 Post-Closing Books and Records of the Company. Until the end of the Contingent Payment Termination Date, Buyer shall
maintain all books and records of the Company relating to periods ending on or prior to the Closing. If at any time after the Closing, Seller requires access to certain of such book(s) or record(s), Buyer shall, at its option, (i) deliver
copies of such book(s) and/or record(s) specified in reasonable detail by Seller at Seller’s cost or (ii) make available such book(s) and/or record(s) as are specified in reasonable detail by Seller to Seller
during normal business hours at a mutually agreed time and place, which information Seller agrees to keep confidential and not to disclose to any Person except to its representatives on a “need to know” basis. 

Section 6.12 FDA Approval Matters. 
 (a) Prior to the Closing, Seller shall notify Buyer of any communications with the FDA or any Governmental Authority in any other jurisdiction, including outside of the United States, or any other
Governmental Authority, whether written or oral, as soon as reasonably practicable, but in no event later than three (3) Business Days after the receipt of such communication, and within such same time period, Seller shall provide Buyer with
copies of any such written communications and written summaries of any such oral communications. 
 (b) Prior to the Closing,
from time to time and at the reasonable request of Buyer, Seller shall provide Buyer with updates concerning the progress of the Company’s regulatory filings and strategy for obtaining necessary regulatory Approvals to market and sell the
LipoSonix Product. Seller shall reasonably consult with Buyer regarding any regulatory filing prior to finalizing such filings and delivering them to the relevant Governmental Authorities. 

Section 6.13 Additional Covenants Regarding LipoSonix Agreement. 

(a) Notwithstanding anything to the contrary in this Agreement (including Article 9), this Section 6.13 shall govern
the rights and obligations of the Parties with respect to matters involving indemnification claims under Article 9 of the LipoSonix Agreement. In the event of any inconsistency between this Section 6.13 and Article 9 of this
Agreement, the provisions of this Section 6.13 shall be controlling. 
 (b) In the event that (i) Seller (as
“Parent” under the LipoSonix Agreement) or a “Parent Indemnified Person” (as defined in the LipoSonix Agreement) affiliated with Seller (a “Medicis Indemnitee”) submits an indemnification claim under Article 9 of
the LipoSonix Agreement (a “LipoSonix Indemnification Claim”) or (ii) Buyer (or another Buyer Indemnified Person) provides notice of an indemnification claim under Article 9 of this Agreement with respect to Losses
arising out of or resulting from the same or a substantially similar matter (or the same or substantially similar facts, events or circumstances) as those forming the basis for a 

  
 65 

 
LipoSonix Indemnification Claim by a Medicis Indemnitee (whether such Buyer indemnification claim is submitted before or after such Medicis Indemnitee submits such LipoSonix Indemnification
Claim), Buyer and Seller agree as follows: 
 (i) Buyer shall, as reasonably requested by Seller, cooperate with such Medicis
Indemnitee in connection with such Medicis Indemnitee’s efforts to seek recovery under Article 9 of the LipoSonix Agreement with respect to such LipoSonix Indemnification Claim (it being understood that Seller shall reimburse Buyer for its
reasonable out of pocket expenses incurred in providing such cooperation); 
 (ii) Buyer shall set off against Contingent
Payments then payable, or that become payable in the future, under the LipoSonix Agreement an amount equal to the amount of Losses with respect to such LipoSonix Indemnification Claim which “Parent” or the “Surviving Corporation”
(as such terms are defined in the LipoSonix Agreement) is entitled to off-set against such Contingent Payments in accordance with Section 3.11(h) and Article 9 of the LipoSonix Agreement; it being understood that, as between Seller and Buyer,
Buyer shall be responsible for making the determination whether Losses are “more likely than not to be incurred or suffered” for purposes of the LipoSonix Agreement, including Section 3.11(h) and Article 9 of the LipoSonix Agreement,
and such determination shall be controlling for purposes of Section 3.11(h) and Article 9 of the LipoSonix Agreement with respect to such LipoSonix Indemnification Claim; 
 (iii) Buyer agrees to provide (or if requested by Seller, join with Seller or such Medicis Indemnitee in providing) such notices or other communications reasonably requested by Seller or such Medicis
Indemnitee for purposes of complying with and/or preserving rights under Article 9 of the LipoSonix Agreement (including Section 9.11 of the LipoSonix Agreement) and Section 3.11(h) of the LipoSonix Agreement with respect to such LipoSonix
Indemnification Claim and in order to preserve and effectuate the off-set rights set forth in the LipoSonix Agreement with respect thereto; 
 (iv) in the event that it is finally determined that such Medicis Indemnitee is entitled to indemnification under Article 9 of the LipoSonix Agreement with respect to such LipoSonix Indemnification Claim
and that “Parent” or the “Surviving Corporation” (as such terms are defined in the LipoSonix Agreement) are entitled to retain some or all of the amounts previously off-set prior to such final determination under
Section 3.11(h) and Article 9 of the LipoSonix Agreement (or which Buyer was otherwise entitled to off-set pursuant to the terms of the LipoSonix Agreement) with respect to such LipoSonix Indemnification Claim, Buyer agrees to promptly pay to
Seller an amount equal to such off-set amount, less the sum of (x) any reasonable and documented out-of-pocket expenses incurred by Buyer as contemplated in clause (i) above (provided such documentation is promptly provided to Seller) in
connection with such LipoSonix Indemnification Claim and (y) any amount to which Buyer is finally determined to be entitled to recover from Seller, if any, pursuant to a valid indemnification claim timely submitted in accordance with Article
9 of this Agreement with respect to Losses arising out of or resulting from the same or a substantially similar matter (or the same or substantially similar facts, events or circumstances) as those forming the basis for the LipoSonix
Indemnification Claim; 

  
 66 

 (v) in the event that it is finally determined that such Medicis Indemnitee is entitled to
indemnification under Article 9 of the LipoSonix Agreement with respect to such LipoSonix Indemnification Claim and that “Parent” or the “Surviving Corporation” (as such terms are defined in the LipoSonix Agreement) are entitled
to off-set some or all of such Losses against future Contingent Payments under Section 3.11(h) and Article 9 of the LipoSonix Agreement with respect to such LipoSonix Indemnification Claim, but no Contingent Payments (or an insufficient amount
of Contingent Payments to fully offset such Losses) had otherwise become payable under the LipoSonix Agreement prior to such final determination against which such Losses could be off-set under Section 3.11(h) and Article 9 of the LipoSonix
Agreement with respect to such LipoSonix Indemnification Claim, Buyer agrees to off-set such Losses against future Contingent Payments (up to an amount equal to the aggregate amount of such Losses) in accordance with Section 3.11(h) and Article
9 of the LipoSonix Agreement and to, thereafter, promptly pay to Seller an amount equal to such off-set amount, less the sum of (x) any reasonable and documented out-of-pocket expenses incurred by Buyer as contemplated in clause (i) above
(provided such documentation is promptly provided to Seller) in connection with such LipoSonix Indemnification Claim and (y) any amount to which Buyer is finally determined to be entitled to recover from Seller, if any, pursuant to a valid
indemnification claim timely submitted in accordance with Article 9 of this Agreement with respect to Losses arising out of or resulting from the same or substantially similar matter (or the same or substantially similar facts, events or
circumstances) as those forming the basis for the LipoSonix Indemnification Claim; 
 (vi) to the extent that Buyer (or another
Buyer Indemnified Person) provides notice of an indemnification claim under Article 9 of this Agreement with respect to Losses arising out of or resulting from the same or a substantially similar matter (or the same or substantially similar
facts, events or circumstances) as those forming the basis for a LipoSonix Indemnification Claim by a Medicis Indemnitee (whether such Buyer indemnification claim is submitted before or after such Medicis Indemnitee submits such LipoSonix
Indemnification Claim), Buyer agrees that, notwithstanding anything in Article 9 of this Agreement to the contrary, (x) resolution of, and any recovery with respect to, the portion of such Buyer indemnification claim that arises out of
or results from the same or a substantially similar matter (or the same or substantially similar facts, events or circumstances) as those forming the basis for a LipoSonix Indemnification Claim shall be tolled under this Agreement pending a final
determination of such LipoSonix Indemnification Claim, (y) such Buyer indemnification claim shall remain subject to all other limitations on and conditions to indemnification set forth in Article 9 of this Agreement, and (z) such
Buyer Indemnified Persons shall not be entitled to recover any Losses from Seller under Article 9 of this Agreement with respect to such Buyer indemnification claim (or the applicable portion thereof that is tolled hereunder) unless and until
a final determination is made with respect to such LipoSonix Indemnification Claim and then only to the extent that the amount of Losses to which such Buyer Indemnified Person is otherwise entitled to recover from Seller with respect to such Buyer
indemnification claim (or applicable portion thereof that is tolled hereunder) pursuant to the terms of Article 9 of this Agreement exceeds the amount which “Parent” or the “Surviving Corporation” (as such terms are
defined in the LipoSonix Agreement) are entitled to off-set against Contingent Payments under Section 3.11(h) and Article 9 of the LipoSonix Agreement; 

  
 67 

 (vii) Buyer agrees to provide written notification to Seller of any indemnification claim
it intends to assert under Article 9 of the LipoSonix Agreement prior to submitting any such claim under the LipoSonix Agreement and to allow Seller to participate, at its sole expense, in any such indemnification claim (it being understood that the
other provisions of this Section 6.13 shall apply in the event Buyer also submits an indemnification claim against Seller under Article 9 of this Agreement and/or a Medicis Indemnitee also submits a LipoSonix Indemnification Claim
under Article 9 of the LipoSonix Agreement with respect to Losses arising out of or resulting from the same or a substantially similar matter (or the same or substantially similar facts, events or circumstances) as those forming the basis for such
LipoSonix Indemnification Claim; 
 (viii) in the event any indemnification claim under the LipoSonix Agreement involves a
“Third Party Claim” (as defined in the LipoSonix Agreement), the procedure with respect to third party claims set forth in Section 9.10 of the LipoSonix Agreement shall govern to the extent inconsistent with the procedures for Third
Party Claims under Section 9.5 of this Agreement; it being understood that, if both Buyer and a Medicis Indemnitee have asserted indemnification claims under Article 9 of the LipoSonix Agreement with respect to Losses arising out of or
resulting from the same or a substantially similar matter (or the same or substantially similar facts, events or circumstances), Buyer shall be entitled to make the determination as to (and to control) the defense of such “Third Party
Claim” under Article 9 of the LipoSonix Agreement; 
 (ix) if Buyer complies with all of its obligations under this
Section 6.13 with respect to indemnification claims and off-set rights under the LipoSonix Agreement, Seller agrees to indemnify Buyer for any Losses actually incurred or suffered as a result of any actions taken or not taken at the
direction of Seller pursuant to this Section 6.13; it being understood that, to the extent Buyer’s failure to comply with its obligations under this Section 6.13 with respect to any indemnification claim under the
LipoSonix Agreement results in Seller’s or Buyer’s inability to off-set all or a portion of any Losses against amounts under Section 3.11(h) or Article 9 of the LipoSonix Agreement that it would otherwise have been entitled to off-set
had Buyer timely complied with all of its obligations hereunder and under the LipoSonix Agreement (the “Lost Offset Amount”), such Lost Offset Amount shall reduce dollar-for-dollar the amount of any Losses to which Seller is
otherwise obligated to indemnify Buyer under Article 9 of this Agreement with respect to any indemnification claims thereunder; 
 (x) consistent with the foregoing provisions of this Section 6.13, for the avoidance of doubt, Buyer shall not be deemed to have suffered a Loss for purposes of Article 9 of this
Agreement, to the extent that: (I) Buyer off-sets such Losses against Contingent Payments under Section 3.11(h) and Article 9 of the LipoSonix Agreement (including future Contingent Payments) or (II) Buyer was otherwise entitled to off-set
such Losses against the Contingent Payments under Section 3.11(h) and Article 9 of the LipoSonix Agreement (including future Contingent Payments) but failed to timely and properly exercise such off-set rights; and 

(xi) the Parties agree to provide each other with copies of all notices provided under Article 9 or Section 3.11(h) of the
LipoSonix Agreement to any third Person with respect to any indemnification claims or effort to exercise off-set rights thereunder. 

  
 68 

 (c) In the event that Buyer submits an indemnification claim under Article 9 of the
LipoSonix Agreement, including on behalf of the “Surviving Corporation” (as such term is defined in the LipoSonix Agreement), Seller agrees to provide (or if requested by Buyer, join with Buyer in providing) such notices as reasonably
requested by Buyer in order to preserve and effectuate the off-set rights set forth in the LipoSonix Agreement with respect thereto. 
 Section 6.14 Control of Business. Subject to the terms of this Agreement, Buyer acknowledges on behalf of itself and its Affiliates and its and their directors, officers, employees, Affiliates,
agents, representatives, successors and assigns that the operation of the Company remain in the dominion and control of Seller, as applicable, until the Closing and that none of the foregoing Persons will provide, directly or indirectly, any
directions, orders, advice, aid, assistance or information to any director, officer or employee of the Company, as applicable, except as specifically contemplated or permitted by this Article 6 or as otherwise consented to in advance by an
executive officer of Seller, as applicable. 
 Section 6.15 Seller Marks. Notwithstanding anything in this Agreement to
the contrary, Buyer acknowledges and agrees that Buyer does not possess and is not obtaining pursuant to this Agreement, any rights in, or to use (whether by license or otherwise), the name “Medicis” or any service marks, trademarks,
trade names, identifying symbols, logos, emblems, signs, insignia or Internet domain names related thereto or containing or comprising any of the foregoing, including any transliterations thereof or any name or mark confusingly similar thereto
(collectively, the “Seller Marks”). Buyer acknowledges and agrees that as between Buyer, on the one hand, and Seller and its Affiliates, on the other hand, all right, title and interest in and to the Seller Marks are owned
exclusively by Seller and its Affiliates. Upon the Closing, Buyer shall (a) cease any and all use of all Seller Marks in any and all forms (whether used alone, in a stylized version or with other marks or designs), on any and all items and
materials including, without limitation, any websites, Internet domain names, business cards, schedules, stationery, packaging materials, displays, signs, promotional materials, manuals, forms, computer software and other business documents and
materials (“Documents and Materials”); and (b) destroy, remove or replace all Seller Marks from all Documents and Materials of any type and regardless of form or format that are in the possession or control of Buyer.

 Section 6.16 Audit and Preparation of Company Financial Statements. From and after the date hereof, Seller and Buyer
shall cooperate in the negotiation of a letter agreement to be entered into by Seller and Buyer governing the terms and conditions of Seller’s cooperation with Buyer in connection with Buyer’s obligation (if any) to prepare and file a
Current Report on Form 8-K containing the information required therein, including the audited and unaudited financial statements of the Company required by Rule 3-05 of Regulation S-X of the Securities and Exchange Commission (the
“SEC”) together with the unqualified audit opinion of Ernst & Young LLP, Seller’s registered independent accounting firm, and the pro forma financial information with respect to the transactions contemplated by this
Agreement to the extent required by Article 11 of Regulation S-X of the SEC. 
 Section 6.17 Buyer Financing. From and
after the date hereof, Buyer shall use commercially reasonable efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable to arrange and obtain the proceeds of the revolving line of
credit and term loan as described in the letter from Silicon Valley Bank dated 

  
 69 

 
September 7, 2011 and addressed to Buyer, including using its commercially reasonable efforts to: (i) enter into definitive agreements with respect thereto on the terms and conditions
contained in the letter as promptly as practicable after the date hereof and (ii) satisfy on a timely basis all conditions applicable to Buyer that are within Buyer’s control in such definitive agreements. 

Section 6.18 Transition Services Agreement. Prior to the Closing, the Parties shall use commercially reasonable efforts to
negotiate and enter into a transition services agreement on terms reasonably acceptable to the Parties, pursuant to which Seller would provide certain temporary services to the Company after the Closing on a transitional basis in order to avoid
interruption of the Company’s business. 
 Section 6.19 No Use of Corporate Name. On the Closing Date or the first
Business Day after the Closing Date, Buyer shall cause the Company to change its name from “Medicis Technologies Corporation” to a name that does not contain the word “Medicis” or any transliterations thereof or any name
confusingly similar thereto, and deliver evidence that Buyer has made the filing required pursuant to this sentence with the Secretary of State of the State of Delaware and that the filing has become effective as of the Closing Date or such first
Business Day in accordance with the DGCL. 
 ARTICLE 7 

CONDITIONS 
 Section 7.1 Conditions to Each Party’s Obligations. The respective obligations of each Party to consummate the Contemplated Transactions shall be subject to the satisfaction or waiver at or
prior to the Closing of the following conditions: 
 (a) HSR Act; Foreign Competition Laws. Any applicable waiting period
under the HSR Act relating to the Contemplated Transactions, if any, shall have expired or been terminated and any approvals required under applicable Foreign Competition Laws shall have been obtained. 

(b) No Governmental Restriction, Etc. There shall not be in effect any Order asserted by any Governmental Authority of competent
jurisdiction restraining, enjoining or otherwise prohibiting the consummation of the Contemplated Transactions; provided, that prior to asserting the failure of this condition the Party asserting its failure shall have used its reasonable best
efforts to have such Order vacated. 
 Section 7.2 Additional Conditions to Obligations of Buyer. The obligations of
Buyer to consummate the Contemplated Transactions shall also be subject to the satisfaction or waiver at or prior to the Closing of the following conditions: 
 (a) Representations and Warranties. The representations and warranties of Seller contained in this Agreement (which shall, for purposes of this Section 7.2(a), be read without any
qualification contained therein as to materiality, including the words “material” or “Material Adverse Effect”) shall be true and correct on the date hereof and on and as of the Closing, with the same effect as if made on and as
of the Closing (other than such representations 

  
 70 

 
that are made as of a specified date, which shall be true and correct as of such date), except where failures of such representations and warranties to be so true and correct have not had, and
would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on the Company; provided, however, that the representations and warranties of Seller contained in Sections 4.1, 4.2, 4.3(a)
and 4.4 shall be true and correct in all material respects on the date hereof and on and as of the Closing, with the same effect as if made on and as of the Closing (other than such representations that are made as of a specified date, which
shall be true and correct in all material respects as of such date). Buyer shall have received a certificate to such effect signed by an authorized officer of Seller. 
 (b) Agreements and Covenants. Seller shall have performed and complied in all material respects with all agreements and covenants required by this Agreement to be performed or complied with by it
on or prior to the Closing; and Buyer shall have received a certificate to such effect signed by an authorized officer of Seller. 
 (c) No Material Adverse Change. There shall not have occurred any fact, event, change, development, circumstance or effect which, individually or in the aggregate, has had or would reasonably be
expected to have a Material Adverse Effect on the Company. 
 (d) Resignation of Directors and Officers. Seller shall
have received letters of resignation, effective as of the Closing, from each of the directors and officers of the Company. 

(e) FIRPTA. Seller shall have delivered to Buyer written certification of the non-foreign status of Seller within the meaning of,
and in accordance with the provisions of, Treasury Regulations § 1.1445-2(h)(2). 
 (f) No Governmental Restriction,
Etc. There shall not be any pending action, suit or proceeding asserted by any Governmental Authority (i) challenging or seeking to restrain or prohibit the consummation of the Contemplated Transactions or (ii) seeking to require Buyer
to take any of the actions specified in clauses (A) through (D) of Section 6.4(d) that would be material to the business or financial condition of Buyer and its Subsidiaries, taken as a whole, or material to the business or
financial condition of the Company. 
 Section 7.3 Additional Conditions to Obligations of Seller. The obligation of
Seller to consummate the Contemplated Transactions by this Agreement shall also be subject to the satisfaction or waiver at or prior to the Closing of the following conditions: 

(a) Representations and Warranties. The representations and warranties of Buyer contained in this Agreement (which shall, for
purposes of this Section 7.3(a), be read without any qualification contained therein as to materiality, including the words “material” or “Material Adverse Effect”) shall be true and correct on the date hereof and on
and as of the Closing, with the same effect as if made on and as of the Closing (other than such representations that are made as of a specified date, which shall be true and correct as of such date), except where failures of such representations
and warranties to be so true and correct have not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on Buyer. Seller shall have received a certificate to such effect signed by an
authorized officer of Buyer. 

  
 71 

 (b) Agreements and Covenants. Buyer shall have performed and complied in all material
respects with all agreements and covenants required by this Agreement to be performed or complied with by it on or prior to the Closing; and Seller shall have received a certificate to such effect signed by an authorized officer of Buyer.

 ARTICLE 8 
 TERMINATION, AMENDMENT AND WAIVER 
 Section 8.1 Termination. This
Agreement may be terminated and the Contemplated Transactions may be abandoned at any time prior to the Closing: 
 (a) By
mutual written consent of the Parties; 
 (b) By either Buyer or Seller if the Closing shall not have occurred on or before
January 11, 2012 (as the same may be extended pursuant to this Section 8.1(b), the “End Date”); provided, that the right to terminate this Agreement under this Section 8.1(b) shall not be
available to any Party whose willful failure to fulfill any obligation under this Agreement has been the cause of, or resulted in, the failure of the Closing to have occurred on or before such date; and provided, further, that if the
consummation of the Contemplated Transactions is subject to the notification requirement and waiting period under the HSR Act or any applicable Foreign Competition Laws and the expiration of the applicable waiting period under the HSR Act or any
applicable Foreign Competition Laws has not been obtained by the End Date, the End Date shall be automatically extended, without further action of the Parties, until March 12, 2012; or 

(c) By either Buyer or Seller, if a Court or Governmental Authority shall have issued an Order or taken any other action, in each case
which has become final and non-appealable and which restrains, enjoins or otherwise prohibits the transactions contemplated herein; provided, that the issuance of such final, non-appealable Order shall not be attributable to the breach of
this Agreement by the Party seeking termination pursuant to this Section 8.1(c); 
 (d) By Buyer, if Buyer is not in
breach of its obligations under this Agreement, and if (i) at any time that any of the representations and warranties of Seller herein become untrue or inaccurate such that Section 7.2(a) would not be satisfied (treating such time
as if it were the Closing for purposes of this Section 8.1(d)) or (ii) there has been a breach on the part of Seller of any of its covenants or agreements contained in this Agreement such that Section 7.2(b) would not be
satisfied (treating such time as if it were the Closing for purposes of this Section 8.1(d)), and, in both case (i) and case (ii), such breach (if curable) has not been cured within thirty (30) days after notice to Seller
by Buyer; provided, however, that no such cure period shall be required for a breach which by its nature cannot be cured; or 
 (e) By Seller, if it is not in breach of its obligations under this Agreement, and if (i) at any time that any of the representations and warranties of Buyer herein become untrue or inaccurate such
that Section 7.3(a) would not be satisfied (treating such time as if it were the Closing for purposes of this Section 8.1(e)) or (ii) there has been a breach on the part of Buyer of any of their respective covenants or
agreements contained in this Agreement such that Section 7.3(b) would not be satisfied (treating such time as if it were the Closing for purposes of 

  
 72 

 
this Section 8.1(e)), and, in both case (i) and case (ii), such breach (if curable) has not been cured within thirty (30) days after written notice to Buyer by Seller;
provided, however, that no such cure period shall be required for a breach which by its nature cannot be cured. 

Section 8.2 Effect of Termination. 
 (a) In the event of the termination of this Agreement pursuant to Section 8.1 (which termination will be effective immediately upon the delivery of written notice of the terminating Party to
the other Parties hereto), this Agreement (other than this Section 8.2 (Effect of Termination) and Sections 6.3 (Access to Information; Confidentiality), 6.7 (Public Announcements) and 11.1 through 11.10
(Miscellaneous) and any related definitional provisions herein, which shall survive such termination) will forthwith become void and be of no further force and effect, and there will be no liability on the part of the Parties or any of their
respective officers or directors to the other and all rights and obligations of any Party hereto will cease, except that nothing herein will relieve any Party from liability for any Intentional Breach by such Party, prior to termination of this
Agreement in accordance with its terms, of any representation, warranty, covenant or agreement contained in this Agreement. 

Section 8.3 Amendment. Any provision of this Agreement may be amended or waived prior to the Closing if, and only if, such
amendment or waiver is in writing and signed, in the case of an amendment, by Seller and Buyer or in the case of a waiver, by the Party against whom the waiver is to be effective. 

Section 8.4 Waiver. At any time prior to the Closing, Buyer, on the one hand, and Seller, on the other, may, to the extent
permitted by Law, extend the time for the performance of any of the obligations or other acts required by the other Party hereunder, waive any inaccuracies in the representations and warranties made to such Party and contained herein or in any
document delivered pursuant hereto and waive compliance with any of the agreements or conditions for the benefit of such Party contained herein. Any such extension or waiver shall be valid only if set forth in an instrument in writing signed by the
Party or Parties to be bound thereby. For the avoidance of doubt, no such waiver granted pursuant to the foregoing shall limit an Indemnified Person’s right to indemnification under Article 9 with respect to the matter waived,
except to the extent specified in such waiver. 
 ARTICLE 9 

INDEMNIFICATION 
 Section 9.1 Survival; Time Limitation. All representations, warranties, covenants and obligations in this Agreement will survive the Closing and the consummation of the Contemplated Transactions,
subject to the following: 
 (a) If the Closing occurs, Seller will have indemnification obligations under this Article
9, subject to Section 9.7, with respect to (i) any breach, untruth or inaccuracy of any representation or warranty of Seller contained in Article 4 of this Agreement (other than the representations and warranties in
Sections 4.3, 4.4, 4.18 and 4.29 of this Agreement, as to which a Claim may be made at any time, and the representations and warranties in Section 4.14, as to

  
 73 

 
which a Claim may be made until ninety (90) days after the expiration of the applicable statute of limitations) or (ii) any Claim for indemnification pursuant to
Section 9.2(a)(ii) (except in respect of an Intentional Breach by Seller of the covenants or agreements described in such Section), Section 9.2(a)(vii) or Section 9.2(a)(viii), only if on or before the twelve
(12) month anniversary of the Closing Date, Buyer notifies Seller as set forth in Sections 9.4 or 9.5, as applicable, of this Agreement. 
 (b) If the Closing occurs, Buyer will have indemnification obligations under this Article 9, subject to Section 9.7, with respect to any breach, untruth or inaccuracy of any
representation or warranty of Buyer contained in Article 5 of this Agreement (other than the representations and warranties in Sections 5.2, 5.5 through 5.9 of this Agreement, as to which a Claim may be made at
any time), only if on or before the twelve (12) month anniversary of the Closing Date, Seller notifies Buyer as set forth in Sections 9.4 or 9.5, as applicable, of this Agreement. 

Section 9.2 Indemnification; Remedies. 
 (a) Subject to the limitations set forth in this Article 9, Buyer and its Affiliates (including, from and after the Closing, the Company) and each of their respective officers, directors,
agents, representatives, employees, successors and permitted assigns (hereinafter referred to individually as a “Buyer Indemnified Person” and collectively as “Buyer Indemnified Persons”) shall be indemnified by
Seller, as set forth in this Article 9, from and against any and all amounts payable, payments, losses, damages, claims, demands, actions or causes of action, liabilities, settlements, judgments, costs and expenses, including interest,
penalties, fines and fees (including reasonable attorneys’ fees and costs of Claims) (collectively, “Losses”), arising out of or resulting from any of the following matters: 

(i) the breach, untruth or inaccuracy of any representation or warranty of Seller contained in Article 4 of this Agreement
or in any schedule, exhibit or certificate delivered by Seller pursuant hereto, determined in each case and for all purposes without regard to any materiality (including the word “material”), Material Adverse Effect or similar qualifier
contained therein (other than Sections 4.6(a) and 4.8(a), for which breaches, untruths or inaccuracies shall be determined without disregarding any materiality (including the word “material”), Material Adverse Effect or
similar qualifier contained therein); 
 (ii) the breach or nonperformance by Seller of any of its covenants or agreements
contained in this Agreement to be performed prior to or at the Closing, determined in each case and for all purposes without regard to any materiality (including the word “material”), Material Adverse Effect or similar qualifier contained
therein; 
 (iii) the breach or nonperformance by Seller of any of its covenants or agreements contained in this Agreement to
be performed after the Closing, determined in each case and for all purposes without regard to any materiality (including the word “material”), Material Adverse Effect or similar qualifier contained therein; 

(iv) the following Taxes and, except as otherwise provided in Section 10.3, any Losses incurred in contesting or otherwise
in connection with any such Taxes: (A)

  
 74 

 
Taxes imposed on the Company with respect to Tax periods ending on or before the Closing Date; (B) with respect to Tax periods beginning before the Closing Date and ending after the Closing
Date, Taxes imposed on the Company which are allocable, pursuant to Section 10.1, to the portion of such period ending on the Closing Date; (C) Taxes of any Person attributable to any taxable period for which the Company (or any
predecessor or subsidiary thereof) is held liable under Treasury Regulations Section 1.1502-6 (or any similar provision of state, local or foreign law) by reason of the Company (or any predecessor or subsidiary) being (or having been) included
in any consolidated, affiliated, combined, aggregate or unitary group at any time before the Closing Date; (D) Taxes imposed on any Person other than the Company for which the Company is liable under an agreement entered into on or before the
Closing Date; (E) any Taxes imposed in connection with the transactions contemplated by this Agreement (including by reason of the Company ceasing to be a member of any Affiliated Group); and (F) Taxes imposed on the Company, as a result
of any breach of warranty or misrepresentation under Section 4.14; provided, that payments under this paragraph shall only be made to the extent that the amount exceeds any accrual or reserve for Taxes included in the calculation
of Final Working Capital; 
 (v) the breach or nonperformance by Seller of its obligations set forth in the LipoSonix
Agreement; 
 (vi) matters with respect to which and to the extent that Seller or its Affiliates are entitled to
indemnification pursuant to Article 9 of the LipoSonix Agreement, only if and to the extent that (A) a Buyer Indemnified Person is not otherwise entitled to indemnification under the LipoSonix Agreement and (B) such Losses are off-set
against Contingent Payments under Section 3.11(h) and Article 9 of the LipoSonix Agreement; 
 (vii) the breach, untruth
or inaccuracy of any representation or warranty of Seller, or the breach or nonperformance by MAC, of any of its covenants or agreements, contained in the Asset Purchase Agreement; 

(viii) any claim based upon breach of product warranty, strict liability in tort, negligent design or manufacture of product, or any
other product liability claim (whether in tort, contract or otherwise), arising from the materials, design, testing, manufacture, packaging or labeling (including instructions for use) with respect to any Product sold or manufactured by the Company
prior to Closing; and 
 (ix) any amounts payable to any director, officer, employee, agent, consultant or advisor of the
Company as a result of announcement or the consummation of the transactions contemplated hereby, including change-in-control payments (whether triggered by the change-in-control alone or in combination with a later termination of employment),
severance payments, retention or “stay” bonuses, special or closing bonuses or similar payments, in each case that the Company or Buyer is or will become contractually obligated to pay under any Contract with the Company or Seller.

 (b) Subject to the limitations set forth in this Article 9, Seller and its Affiliates and each of their
respective officers, directors, agents, representatives, employees, successors and permitted assigns (hereinafter referred to individually as a “Seller Indemnified Person” and collectively as “Seller Indemnified
Persons”) shall be indemnified by Buyer, as set forth in this 

  
 75 

 
Article 9 from and against any and all Losses arising out of or resulting from any of the following matters: 
 (i) the breach, untruth or inaccuracy of any representation or warranty of Buyer contained in Article 5 of this Agreement or in any schedule, exhibit or certificate delivered by Buyer pursuant
hereto, determined in each case and for all purposes without regard to any materiality (including the word “material”), Material Adverse Effect or similar qualifier contained therein; 

(ii) the breach or nonperformance by Buyer of any of its covenants or agreements contained in this Agreement, determined in each case
and for all purposes without regard to any materiality (including the word “material”), Material Adverse Effect or similar qualifier contained therein; and 
 (iii) the breach or nonperformance by Buyer of the obligations set forth in the LipoSonix Agreement to make the Contingent Payments as set forth in the LipoSonix Agreement. 

(c) Nothing in this Agreement shall limit the liability of any Party for any breach of any representation, warranty, covenant or
agreement in this Agreement if this Agreement is terminated. 
 Section 9.3 Calculation of Losses; Indemnification
Limitations. 
 (a) For the purposes of calculating the amount of Losses pursuant to Section 9.2(a)(i) and
Section 9.2(b)(i), the representations and warranties in this Agreement shall be read without any materiality (including the word “material”), Material Adverse Effect or similar qualifiers. 

(b) Subject to Section 9.7, the Buyer Indemnified Persons or the Seller Indemnified Persons (each, an “Indemnified
Person”), as the case may be, shall not be entitled to indemnification pursuant to Sections 9.2(a)(i) (except in respect of the representations and warranties made under Sections 4.3, 4.4, 4.14,
4.18 and 4.29, as to which the limitation in this Section 9.3(b) shall not apply), 9.2(a)(ii) (except in respect of an Intentional Breach by Seller of the covenants or agreements described in such Section, as to
which the limitation in this Section 9.3(b) shall not apply), 9.2(a)(iii) (except in respect of an Intentional Breach by Seller of the covenants or agreements described in such Section, as to which the limitation in this
Section 9.3(b) shall not apply), 9.2(a)(vii), 9.2(a)(viii) and 9.2(b)(i) (except in respect of the representations and warranties made under Sections 5.2, 5.5 through 5.9, as to which the limitation in
this Section 9.3(b) shall not apply) for any Losses until the aggregate amount of all Losses incurred by the Buyer Indemnified Persons or the Seller Indemnified Persons, as the case may be, exceeds *** (the “Threshold”),
in which case the Indemnified Persons shall be entitled to indemnification for the full amount of Losses including the Threshold (i.e., back to dollar one); provided, however, that only individual Claims with a value in excess
of *** shall be included in the Threshold or be counted for determining the amount of Losses to be indemnified to the Buyer Indemnified Persons or the Seller Indemnified Persons, as the case may be. 

  
 76 

 (c) For the avoidance of doubt, the limitations in Section 9.3(b) shall not
apply to any Claim for indemnification pursuant to Sections 9.2(a)(ii) and 9.2(a)(iii) in respect of an Intentional Breach by Seller of the covenants or agreements described in such Sections, Sections 9.2(a)(iv) through
(vi), Section 9.2(a)(ix) and Sections 9.2(b)(ii) and 9.2(b)(iii). 
 (d) Notwithstanding
anything in this Agreement to the contrary, subject to Section 9.7, the right of the Buyer Indemnified Persons to seek indemnification (i) pursuant to Section 9.2(a)(i) (except in respect of the representations and
warranties made under Sections 4.3, 4.4, 4.14, 4.18 and 4.29), Section 9.2(a)(ii) (except in respect of an Intentional Breach by Seller of the covenants or agreements described in such Section),
Section 9.2(a)(iii) (except in respect of an Intentional Breach by Seller of the covenants or agreements described in such Section), Section 9.2(a)(vii) and Section 9.2(a)(viii), shall be limited to and capped at
an amount equal to the sum of (x) *** of the sum of the Purchase Price and the FDA Milestone Payment (to the extent actually paid by Buyer to Seller) and (y) *** of the Seller Contingent Payments, other than the FDA Milestone Payment,
actually paid by Buyer to Seller hereunder and shall be satisfied exclusively by off-setting against the Seller Contingent Payments; and (ii) pursuant to (A) Section 9.2(a)(i) with respect to the representations and warranties
made under Sections 4.3(a), 4.4, 4.18 and 4.29 and (B) Section 9.2(a)(v), shall be limited to and capped at an amount equal to *** of the sum of (x) the Purchase Price and (y) the Seller
Contingent Payments actually paid by Buyer to Seller hereunder; provided, that, in the event that Buyer is entitled to indemnification pursuant to Articles 9, but its recovery is limited by clause (i) or (ii) of this sentence, Buyer
shall be entitled to recover any unrecovered amount as to which Buyer is entitled to indemnification pursuant to Article 9 from future Contingent Payments, subject to limitations set forth in clauses (i) and (ii) of this sentence.

 (e) Subject to Section 9.7, any Claim required to be made by Seller or Buyer, as the case may be, on or prior to
the expiration of the applicable survival period set forth in Section 9.1, and not made, shall be irrevocably and unconditionally released and waived by such party. 

(f) The amount of any Losses for which indemnification is provided under this Article 9 shall be net of any amounts actually
recovered or recoverable by the Indemnified Party under insurance policies or otherwise with respect to such Losses and, to the extent applicable, shall be subject to the obligations and limitations set forth in Section 6.13. The
Indemnified Party shall use commercially reasonable efforts to obtain full recovery under all insurance policies covering any Losses to the same extent as it would if such Losses were not subject to indemnification hereunder. In the event that an
insurance or other recovery is made by any party with respect to any Losses for which any such person has been indemnified hereunder and has received funds in the amount of the Losses or portion thereof (including under the off-set provisions of the
LipoSonix Agreement), then a refund equal to the aggregate amount of the recovery shall be made promptly to the Indemnifying Party. 
 Section 9.4 Notice of Claims. In the event any Indemnified Person wishes to pursue its, his or her rights to indemnification under this Article 9, if the matter does not involve a Third
Party Claim under Section 9.5 hereof, the Indemnified Person shall give written notice thereof to the Indemnifying Party stating that an indemnification Claim or Claims pursuant to Section 9.2 or any other provision of this
Agreement is being made, describing the basis for such Claim with 

  
 77 

 
reasonable specificity and specifying in reasonable detail the Losses in respect of such Claim (provided that the Indemnified Person shall not be bound by any estimate of Losses made in good
faith and contained in such description). Within thirty (30) days from the receipt of such notice, the Indemnifying Party shall provide a written notice to such Indemnified Person indicating whether the Indemnifying Party objects to such Claim.
If no such objection notice is received by such Indemnified Person within such thirty (30) day period, the Indemnifying Party waives any objection to such Indemnified Person being indemnified for such Claim pursuant to this Agreement under this
Article 9. If such notice of objection is provided within such period, the Indemnifying Party and the Indemnified Person or its, his or her representative(s) shall then attempt in good faith for thirty (30) days to agree upon the rights
of the respective parties with respect to each of such Claims. If no such resolution can be reached after good faith negotiation, such Indemnified Person or the Indemnifying Party may institute proceedings in a court of competent jurisdiction (in
accordance with Section 11.8) to resolve any such dispute, and each such Indemnified Person and the Indemnifying Party, subject to Section 6.13, shall seek to resolve such dispute in as expeditious a manner as practicable. In
the case of any such proceeding, the Indemnified Person and the Indemnifying Party shall each be responsible for the payment of its own fees and expenses. 
 Section 9.5 Third Party Claims. 
 (a) In the event that an Indemnified
Person is made a defendant in or party to any Claim instituted by any third party, the liability or the costs or expenses of which are Losses indemnifiable pursuant to this Article 9 (any such third party Claim being referred to as a
“Third Party Claim”), such Indemnified Party shall give the party from whom indemnification hereunder is sought (the “Indemnifying Party”) prompt written notice thereof specifying in reasonable detail the Losses
with respect to such Third Party Claim (including a good faith estimate of such Losses, if reasonably available); provided, however, that the delay or failure to give such notice shall only relieve the Indemnifying Party of its
indemnification obligations under this Article 9 to the extent, if at all, that the Indemnifying Party is materially prejudiced by reasons of such delay or failure; and provided further, that such written notice must in all
events be provided on or before the expiration of the applicable survival period set forth in Section 9.1. Thereafter, the Indemnified Party shall deliver to the Indemnifying Party, promptly following the Indemnified Party’s receipt
thereof, copies of all notices and documents (including court papers) received by the Indemnified Party relating to the Third Party Claim, other than privileged documents and those notices and documents separately addressed to the Indemnifying
Party. 
 (b) The Indemnifying Party will have the right to assume the defense, at its own expense and by counsel reasonably
acceptable to the Indemnified Party, of the Indemnified Party against any Third Party Claim so long as (i) the Indemnifying Party gives written notice to the Indemnified Party within thirty (30) days after it first receives notice of such
Third Party Claim pursuant to Section 9.5(a) that it will defend the Indemnified Party against the Third Party Claim, (ii) the Third Party Claim involves only money damages and does not seek an injunction or other equitable relief
against the Indemnified Party, (iii) the Indemnified Party has not been advised by counsel that a conflict is likely to exist if the same counsel were to represent the Indemnified Party and the Indemnifying Party in connection with conducting
the defense of the Third Party Claim, (iv) the Third Party Claim does not relate to or otherwise arise in connection any criminal or regulatory enforcement action, (v) the Third Party Claim does not relate to the

  
 78 

 
payment or non-payment of Taxes and (vi) the Indemnifying Party conducts the defense of the Third Party Claim diligently. If the Indemnifying Party does not, within fifteen (15) days of
it first receiving notice of a Third Party Claim pursuant to Section 9.5(a), elect to assume the defense of such Third Party Claim, or if the Indemnified Party assumes such defense and, thereafter, any of the conditions in subclauses
(i) through (vi) above of this Section 9.5(b) exist, the applicable Indemnified Party may assume the defense of, defend against, negotiate, settle or otherwise deal with such Third Party Claim, at the Indemnifying Party’s
expense. If the applicable Indemnified Party defends any Third Party Claim pursuant to the preceding sentence or pursuant to subclauses (i) through (vi) above of this Section 9.5(b), then the Indemnifying Party shall reimburse
the applicable Indemnified Party for the reasonable costs and expenses of defending such Third Party Claim upon submission of periodic bills, and the Indemnifying Party shall cooperate in the defense of such Third Party Claim. If the Indemnifying
Party assumes the defense of any Third Party Claim pursuant to and in accordance with this Section 9.5(b), the Indemnifying Party shall keep the Indemnified Parties apprised of the status of such Third Party Claim and any significant
developments with respect thereto and the applicable Indemnified Party may retain separate co-counsel at its sole cost and expense and participate in the defense of the Third Party Claim. 

(c) If the Indemnifying Party assumes the defense of a Third Party Claim pursuant to and in accordance with Section 9.5(b),
the Indemnified Parties shall cooperate in the defense or prosecution thereof and the Indemnified Parties shall agree to any settlement, compromise or discharge of a Third Party Claim that the Indemnifying Party may recommend if such settlement,
compromise or discharge (i) does not require any payment or other action by, or limitation (including injunctive or any other equitable relief) on, any Indemnified Party and (ii) fully releases such Indemnified Parties in connection with
such Third Party Claim. In no event shall the Indemnifying Party admit any liability with respect to such Third Party Claim or settle, compromise, pay or discharge such Third Party Claim without the prior written consent of the Indemnified Parties.

 (d) Notwithstanding the foregoing provisions of Sections 9.5(b) and (c), the provisions of
Section 6.13(b)(viii) shall apply in lieu of the provisions of Sections 9.5(b) and (c) to the extent the same Third Party Claim covered under this Section 9.5(b) is also the basis for an indemnification
claim by a Medicis Indemnitee under the LipoSonix Agreement, as contemplated in Section 6.13. 
 Section 9.6
Other Matters. Notwithstanding anything in this Agreement, any amounts payable pursuant to the indemnification obligations under this Article 9 shall be paid without duplication and in no event shall any Party hereto be indemnified under
different provisions of this Agreement for the same Losses. Without limiting the generality of the foregoing, Buyer shall make no claim for indemnification under this Article 9 in respect of any matter that is taken into account in the
calculation of any adjustment to the Purchase Price pursuant to Section 2.4 or for which Buyer was entitled to offset against Contingent Payments pursuant to Section 3.11(h) and Article 9 of the LipoSonix Agreement. 

Section 9.7 Exclusive Remedies. Notwithstanding anything to the contrary herein, the Parties hereby agree that, except for Claims
based on fraud, from and after the Closing, the exclusive remedy for any breach of a representation or warranty, covenant or agreement 

  
 79 

 
contained in this Agreement shall be the indemnification provisions set forth in this Article 9; provided, however, that nothing in this Article 9 shall prohibit any
Party from seeking specific performance or injunctive relief against any other Party in respect of a breach by such other Party of any covenant hereunder. 
 Section 9.8 No Special, Punitive or Consequential Damages. Notwithstanding anything to the contrary in this Agreement, except in the case of fraud, no Party shall be liable to or otherwise
responsible for special, punitive or consequential damages, other than: (i) special, punitive or consequential damages awarded to a third party pursuant to a Third Party Claim; and (ii) consequential damages awarded to a
Party pursuant to a Claim for indemnification under this Article 9 pursuant to Section 9.2(a)(i) (other than with respect of the representations and warranties made under Sections 4.3, 4.14, 4.18 and
4.29) or pursuant to Section 9.2(b)(i). 
 ARTICLE 10 

TAX 

Section 10.1 Tax Allocation. In the case of Taxes that are payable with respect to a taxable period that begins before the
Closing Date and ends after the Closing Date, the portion of any such Tax that is allocable to the portion of the period ending on the Closing Date shall be: 
 (a) in the case of Taxes that are either (x) based upon or related to income, receipts, payroll or other compensation for services or (y) imposed in connection with any sale or other transfer or
assignment of property (real or personal, tangible or intangible) (other than conveyances pursuant to this Agreement), deemed equal to the amount which would be payable if the taxable year ended with the Closing Date (except that, solely for
purposes of determining the marginal tax rate applicable to income or receipts during such period in a jurisdiction in which such tax rate depends upon the level of income or receipts, annualized income or receipts may be taken into account if
appropriate for an equitable sharing of such Taxes); and 
 (b) in the case of Taxes not described in
Section 10.1(a) that are imposed on a periodic basis and measured by the level of any item, deemed to be the amount of such Taxes for the entire period (or, in the case of such Taxes determined on an arrears basis, the amount of such
Taxes for the immediately preceding period) multiplied by a fraction the numerator of which is the number of calendar days in the period ending on the Closing Date and the denominator of which is the number of calendar days in the entire period.

 Section 10.2 Returns and Payments. 
 (a) Seller shall prepare and file in a timely manner all Tax Returns relating to the Company that are due on or before the Closing Date and all income Tax Returns for Tax years of the Company ended on or
before the Closing Date regardless of whether such income Tax Returns are filed before or after the Closing Date. Seller shall pay in a timely manner all Taxes that are due with respect to such Tax Returns. Such Tax Returns shall be prepared, and
each item thereon treated, in a manner consistent with past practices employed with respect to the Company and shall utilize accounting methods, elections and conventions that do not have the effect of distorting the allocation of income or expense
between the Tax periods covered by 

  
 80 

 
such Tax Returns and subsequent Tax periods. Buyer shall have the right to review such Tax Returns insofar as they pertain to the Company for fifteen (15) days prior to the filing of such
Tax Returns, and Seller agrees to discuss with Buyer in good faith the items reflected on such Tax Return and any adjustments reasonably requested by Buyer. 
 (b) Except as otherwise provided in Section 10.2(a), Buyer shall prepare and file or cause to be prepared and filed in a timely manner all Tax Returns relating to the Company with respect to
Tax periods beginning before the Closing Date (“Pre-Closing Date Tax Returns”), as well as all Tax Returns relating to the Company with respect to Tax periods beginning on or after the Closing Date. Pre-Closing Date Tax Returns
shall be prepared, and each item thereon treated, in a manner consistent with past practices employed with respect to the Company (except to the extent counsel for Buyer determines there is no reasonable basis in Law therefor or determines that a
Tax Return cannot be so prepared and filed or an item so reported without being subject to penalties) and shall utilize accounting methods, elections and conventions that do not have the effect of distorting the allocation of income or expense
between the Tax periods covered by such Tax Returns and subsequent Tax periods. With respect to any Pre-Closing Date Tax Return, Seller shall have the right to review such Tax Return for fifteen (15) days prior to the filing of such Tax Return,
and Buyer shall discuss in good faith the items reflected on such Tax Return and any adjustments reasonably requested by Seller. At the same time that Buyer provides to Seller as copy of a Pre-Closing Date Tax Return for Seller’s review, Buyer
shall also provide to Seller a written schedule of allocation calculations (if applicable) pursuant to Section 10.1. If the Parties are unable in good faith to agree on such allocation, the dispute shall be submitted to a Qualified
Accountant for its determination, which shall be binding upon the Parties (and the Parties shall bear equally the costs of such determination). Buyer shall timely pay any Taxes due with respect to a Pre-Closing Date Tax Return and Seller shall
promptly reimburse Buyer for Taxes allocable (pursuant to Section 10.1) to the portion of the Taxable period occurring on or before the Closing Date, except to the extent the Taxes allocable to the period on or before the Closing Date
have been paid previously by Seller or reflected in the determination of Final Working Capital. 
 Section 10.3
Contests. 
 (a) After the Closing Date, Buyer shall promptly notify Seller in writing of any written notice of a proposed
adjustment or claim in an audit or administrative or judicial proceeding involving Buyer or the Company which, if determined adversely to the taxpayer, would be grounds for indemnification under Article 9; provided,
however, that a failure to give such notice will not affect Buyer’s right to indemnification thereunder except to the extent, if any, that, but for such failure, Seller could have avoided the Tax liability in question. 

(b) In the case of an audit or administrative or judicial proceeding that relates solely to taxable periods ending on or before the
Closing Date, Seller shall have the right at Seller’s expense to participate in and control the conduct of such audit or proceeding. Seller shall keep Buyer informed of the progress of any such audit or proceeding, and Buyer also may
participate in any such audit or proceeding at its expense. Seller shall not settle any proceeding without the consent of Buyer, which consent shall not be unreasonably withheld, if the settlement would adversely affect the Company. If Seller does
not assume the defense of any such audit or 

  
 81 

 
proceeding, Buyer may defend the same in such manner as it may deem appropriate at its expense, including, but not limited to, settling such audit or proceeding. 

(c) With respect to any other audit or proceeding not controlled by Seller, such audit or proceeding shall be controlled by Buyer;
provided, that Buyer shall keep Seller apprised of the status of such audit or proceeding and Seller shall have the right to participate at its own expense in such audit or proceeding. Cooperation and Exchange of Information. 

Section 10.4 Cooperation and Exchange of Information. Seller and Buyer will each provide the other with such cooperation and
information as any of them reasonably may request of the other in filing any Tax Return, amended Tax Return or claim for refund, determining a liability for Taxes or a right to a refund of Taxes, participating in or conducting any audit or other
proceeding in respect of Taxes or making representations to or furnishing information to parties subsequently desiring to purchase either of the Company or a part of the business acquired from the Company by Buyer. Such cooperation and information
shall include providing copies of relevant Tax Returns or portions thereof, together with accompanying schedules, related work papers and documents relating to rulings or other determinations by Tax authorities. Seller and Buyer shall (and Buyer
after the Closing Date will cause the Company and its Subsidiaries, if any, to) retain all Tax Returns, schedules and work papers, records and other documents in their possession relating to Tax matters of the Company and its Subsidiaries, if any,
for the taxable period first ending after the Closing Date and for all prior taxable periods until the later of (i) the expiration of the statute of limitations of the taxable periods to which such Tax Returns and other documents relate, or
(ii) six (6) years following the due date (without extension) for such Tax Returns. Any information obtained under this Section 10.4 shall be kept confidential except as may be otherwise necessary in connection with the filing
of Tax Returns or claims for refund or in conducting an audit or other proceeding. 
 Section 10.5 Characterization of
Payments. Buyer and Seller agree to treat all payments made by any of them to or for the benefit of the others (including any payments to the Company) under the indemnity provisions of this Agreement and for any misrepresentations or breach of
warranties or covenants as adjustments to the purchase price for Tax purposes and that such treatment shall govern for purposes hereof except to the extent that the Laws of a particular jurisdiction provide otherwise, in which case such payments
shall be made in an amount sufficient to indemnify the relevant party on an after-Tax basis. 
 Section 10.6 Transfer
Taxes. All transfer, documentary, sales, use, registration and any other such Taxes and related fees (including any penalties, interest and additions to Tax) (“Transfer Taxes”) arising out of or incurred in connection with this
Agreement shall be borne equally by Seller and Buyer. The Party that is legally required to file a Tax Return relating to Transfer Taxes shall be responsible for preparing and timely filing such Tax Return. 

ARTICLE 11 

MISCELLANEOUS 
 Section 11.1 Fees and Expenses. Except as specifically provided to the contrary in this Agreement, all costs and expenses incurred in connection with this Agreement and the 

  
 82 

 
Contemplated Transactions shall be paid by the Party incurring such expenses, whether or not the transactions contemplated hereby are consummated; provided, however, that Buyer and
Seller shall share equally all out-of-pocket fees and expenses (including fees and expenses of counsel) payable in connection with regulatory filings, including under the HSR Act and any applicable Foreign Competition Laws. Notices. 

Section 11.2 Notices. All notices or other communications which are required or permitted hereunder shall be in writing and
sufficient if delivered personally or sent by nationally recognized overnight courier or by registered or certified mail, postage prepaid, return receipt requested, or by facsimile or telecopier, as follows: 

 

	 	(a)	If to Buyer,to: 

 Solta
Medical, Inc. 
 25881 Industrial Boulevard 
 Hayward, CA 94545 
 Attention: Stephen J. Fanning 

Telecopy: (510) 786-6880 
 with a copy (which shall not constitute notice) to: 
 Wilson Sonsini
Goodrich & Rosati 
 Professional Corporation 
 One Market, Spear Tower, Suite 3300 
 San Francisco, CA 94105 

Attention: Robert T. Ishii 
 Telecopy: (415) 947-2099 
  

	 	(b)	If to Seller, to: 

 Medicis
Pharmaceutical Corporation 
 7720 North Dobson Road 
 Scottsdale, AZ 85256 
 Attention: Mark A. Prygocki and Seth L. Rodner 

Telecopy: (480) 291-8806 
 with a copy (which shall not constitute notice) to: 
 Hogan Lovells US LLP

 Columbia Square 
 555 Thirteenth Street, N.W. 
 Washington, DC 20004-1109 

Attention: Joseph E. Gilligan 
 Telecopy: (202) 637-5910 
 or to such other address as the Party to whom notice is to be
given may have furnished to the other Party in writing in accordance herewith. All such notices or communications shall be 

  
 83 

 
deemed to be received (i) in the case of personal delivery, nationally recognized overnight courier or registered or certified mail, on the date of such delivery, and (ii) in the case
of facsimile or telecopier or electronic mail, upon receipt of the appropriate facsimile or telecopier confirmation. Communications by electronic mail shall not constitute notice. 

Section 11.3 Severability. If any term or other provision of this Agreement, or the application thereof, is invalid, illegal, void
or incapable of being enforced by any rule of Law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect and the application of such term or provision to other Persons or
circumstances will be interpreted so as reasonably to effect the intent of the Parties hereto. Any provision of this Agreement held invalid, illegal, void or unenforceable only in part or degree will remain in full force and effect to the extent not
held invalid, illegal, void or unenforceable. 
 Section 11.4 Entire Agreement. This Agreement (including all exhibits,
annexes and schedules hereto and thereto) and other documents and instruments delivered pursuant hereto or thereto constitute the entire agreement and supersede all prior representations, agreements, understandings and undertakings (other than the
Confidentiality Agreement), both written and oral, among the Parties, or any of them, with respect to the subject matter hereof and thereof and no Party is relying on any prior oral or written representations, agreements, understandings or
undertakings (other than the Confidentiality Agreement) with respect to the subject matter hereof and thereof. 
 Section
11.5 Assignment. This Agreement shall not be assigned by operation of Law or otherwise without the prior written consent of the other Party. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of and be
enforceable by the parties hereto and their respective successors and permitted assigns. 
 Section 11.6 Parties in
Interest. Subject to Section 11.5 hereof, this Agreement shall be binding upon and inure solely to the benefit of each Party and each of their respective permitted successors and assigns, and nothing in this Agreement, express or
implied, is intended to or shall confer upon any other Person, other than the Indemnified Persons who shall be third party beneficiaries hereof, to the extent set forth in Article 9, any right, benefit or remedy of any nature whatsoever
under or by reason of this Agreement. 
 Section 11.7 Failure or Indulgence Not Waiver; Remedies Cumulative. No failure
or delay on the part of any Party in the exercise of any right hereunder will impair such right or be construed to be a waiver of, or acquiescence in, any breach of any representation, warranty or agreement herein, nor will any single or partial
exercise of any such right preclude other or further exercise thereof or of any other right. All rights and remedies existing under this Agreement are cumulative to, and not exclusive of, any rights or remedies otherwise available. 

Section 11.8 Governing Law; Jurisdiction. This Agreement and all disputes controversies or claims relating to, arising out of or
under, or in connection with this Agreement and the Contemplated Transactions, including the negotiation, execution and performance hereunder and thereunder, shall be governed by, and construed in accordance with, the laws of the State of Delaware,
regardless of the laws that might otherwise govern under applicable principles of choice of law or conflicts of law rules or provisions (whether of the State of 

  
 84 

 
Delaware or any other jurisdiction). Each of the Parties hereto irrevocably and unconditionally (a) consents to submit itself to the sole and exclusive personal jurisdiction of the state
courts of the State of Delaware or any court of the United States located in the State of Delaware in connection with any dispute, claim, or controversy arising out of or relating to this Agreement or the Contemplated Transactions, (b) agrees
that it shall not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court, and (c) agrees that it shall not bring any action, suit, or proceeding in connection with any dispute, claim, or
controversy arising out of or relating to this Agreement or the Contemplated Transactions in any court or tribunal other than the state courts of the State of Delaware or any court of the United States located in the State of Delaware. Each of the
Parties hereto further agrees and covenants that if subject matter jurisdiction over any action, suit, or proceeding in connection with any dispute, claim, or controversy arising out of or relating to this Agreement or the Contemplated Transactions
exists in the Court of Chancery of the State of Delaware by reason of Section 111 of the DGCL or if there otherwise exists a good faith basis for concluding that the Court of Chancery of the State of Delaware would have subject matter
jurisdiction in connection with any such action, suit, or proceeding, then any such action, suit, or proceeding shall be brought exclusively in the Court of Chancery of the State of Delaware, and each Party agrees that it shall not attempt to deny
or defeat subject matter jurisdiction over such action, suit, or proceeding in the Court of Chancery of the State of Delaware. Each of the Parties hereto irrevocably and unconditionally consents to service being made through the notice procedures
set forth in Section 11.2. Each of the Parties hereto hereby agrees that service of any process, summons, notice or document by prepaid certified or registered mail to the respective addresses set forth in Section 11.2 shall
be effective service of process for any action, suit, or proceeding in connection with any dispute, claim, or controversy arising out of or relating to this Agreement and any of the Contemplated Transactions. Nothing herein shall be deemed to limit
or prohibit service of process by any other manner as may be permitted by applicable law. Each of the Parties hereto hereby agrees that this Agreement involves at least $100,000 and that this Agreement has been entered into in express reliance on 6
Del. C. § 2708. 
 Section 11.9 Waiver of July Trial. EACH PARTY HEREBY IRREVOCABLY WAIVES TO THE FULLEST EXTENT
PERMITTED BY APPLICABLE LAW ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE CONTEMPLATED TRANSACTIONS OR THE ACTIONS OF SUCH PARTY
IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF. EACH OF THE PARTIES HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD
NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THAT FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE CONTEMPLATED TRANSACTIONS BY, AMONG OTHER THINGS, THE MUTUAL
WAIVERS AND CERTIFICATIONS IN THIS SECTION 11.9. 
 Section 11.10 Enforcement of Agreement; Specific Performance.
The Parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is 

  
 85 

 
accordingly agreed that the Parties shall be entitled to an injunction to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in the state
courts of the State of Delaware or any court of the United States located in the State of Delaware, this being in addition to any other remedy to which such Party is entitled at law or in equity. 

Section 11.11 Counterparts. This Agreement may be executed and delivered in one or more counterparts, and by the different Parties
hereto in separate counterparts, each of which when executed and delivered shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. The exchange of a fully executed Agreement (in counterparts or
otherwise) by facsimile or by electronic delivery in portable document format (PDF) format shall be sufficient to bind the parties to the terms and conditions of this Agreement. 

Section 11.12 Due Diligence Materials; Seller Disclosure Schedule. 

(a) For purposes of this Agreement, the phrase “provided to Buyer” shall mean the posting by Seller of the various
materials, documents and information produced by Seller throughout Buyer’s due diligence review process to a virtual data room managed by Seller or otherwise delivered to Buyer or any of its representatives, up until 5:00 p.m. (Pacific Daylight
Time) on Monday, September 12, 2011. 
 (b) The Seller Disclosure Schedules include descriptions of certain Contracts which
may not meet the threshold requirements for disclosure that are set forth in this Agreement. The inclusion of such Contracts does not mean that all Contracts to which Company is a party are included in the Schedules or that such Contracts are deemed
to be material. Similarly, the Seller Disclosure Schedules may include certain information that does not meet the minimum standards of materiality requiring disclosure thereunder. The inclusion of such information does not mean that all information
contained therein is deemed to be material. 
 [The remainder of this page is intentionally left blank.] 

  
 86 

 IN WITNESS WHEREOF, Seller and Buyer have executed and delivered this Stock Purchase
Agreement or caused this Stock Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized as of the date first written above. 

 

	
	BUYER:
	
	SOLTA MEDICAL, INC.
	
	 /s/   Stephen J. Fanning

	Name: Stephen J. Fanning
	Title:   Chairman, President and Chief Executive
	            Officer
	
	SELLER:
	
	 MEDICIS PHARMACEUTICAL

CORPORATION

	
	 /s/   Mark A. Prygocki

	Name: Mark A. Prygocki
	Title:   President

 ANNEX I 
 DEFINITIONS 
 “Accountant” has the meaning set forth in
Section 2.7(f). 
 “Action” has the meaning set forth in Section 4.21(h)(i).

 “Acquisition Proposal” has the meaning set forth in Section 6.2(a). 

“Acquiring Person” has the meaning set forth in Section 2.8. 

“***” has the meaning set forth in Section ***. 

“Additional LipoSonix Contingent Payment” has the meaning set forth in Section 2.6(a)(i). 

“Affiliate” means, with respect to any Person, any other Person that directly or indirectly, through one or more
intermediaries, controls, is controlled by or is under common control with such Person. 
 “Affiliated Group”
has the meaning set forth in Section 4.14(c). 
 “Agreed Contingent Payment Amount” has the meaning
set forth in Section 2.7(e). 
 “Agreement” has the meaning set forth in the Preamble. 

“Applicable Non-U.S. Laws and Regulations” has the meaning set forth in Section 4.22(b)(i). 

“Appraiser” has the meaning set forth in Section 2.7(f). 

“Approvals” has the meaning set forth in Section 4.1(a). 

“Asset Purchase Agreement” has the meaning set forth in the Recitals. 

“Base Purchase Price” has the meaning set forth in Section 2.2. 

“Business Day” means any day other than a Saturday, Sunday or day on which banks are permitted to close in the State of
New York or the State of Arizona. 
 “Buyer” has the meaning set forth in the Preamble. 

“Buyer Group” means Buyer and its direct and indirect Subsidiaries and Affiliates, including, after the Closing, the
Company. 
 “Buyer Indemnified Person(s)” has the meaning set forth in Section 9.2(a). 

“Buyer Representatives” has the meaning set forth in Section 6.3(a). 

  
 I-1

 “Bylaws” means the Bylaws of the Company. 

“***” has the meaning set forth in Section ***. 

“Charter” means the Certificate of Incorporation of the Company. 

“Claim” means any claim, suit, action, arbitration, cause of action, complaint, allegation, criminal prosecution,
investigation, demand letter, or proceeding, whether at law or at equity, before or by any Court, Governmental Authority, arbitrator, other tribunal, or any other Person, and any information request from a Governmental Authority. 

“Closing” has the meaning set forth in Section 3.1. 

“Closing Date” has the meaning set forth in Section 3.1. 

“COBRA Coverage” has the meaning set forth in Section 4.11(e). 

“Code” means the U.S. Internal Revenue Code of 1986, as amended, from time to time, and the Regulations promulgated and
rulings issued thereunder. 
 “Commercially Reasonable Efforts” has the meaning set forth in
Section 2.6(g)(ii). 
 “Common Stock” means the Common Stock, par value $0.01, of the Company.

 “Company” has the meaning set forth in the Recitals. 

“Company Incremental Amount” has the meaning set forth in Section 2.6(a)(ii). 

“Confidential Information” means any information (in whatever form, whether written, oral, electronic or otherwise)
concerning the businesses and affairs of a Disclosing Party and all analyses, compilations, forecasts, studies or other documents which contain or reflect any such information; provided, however, that the term “Confidential
Information” shall not include (a) information that is or becomes publicly available other than as a direct or indirect result of disclosure by a Receiving Party or its Representatives or (b) information that becomes available to
the Receiving Party on a nonconfidential basis from a source (other than such Disclosing Party or its Representatives) that, to the Knowledge of such Receiving Party, is not prohibited from disclosing such information to such Receiving Party by any
legal, contractual or fiduciary obligation to such Disclosing Party. 
 “Confidentiality Agreement” has the
meaning set forth in Section 6.3(b). 
 “Contemplated Transactions” means all of the transactions
and other matters contemplated by this Agreement. 
 “Contingent Payments” has the meaning set forth in
Section 3.9(b) of the LipoSonix Agreement. 
 “Contingent Payment Audit” has the meaning set forth in
Section 2.7(c). 

  
 I-2

 “Contingent Payment Certificate” has the meaning set forth in
Section 2.7(b)(ii). 
 “Contingent Payment Commencement Date” has the meaning set forth in
Section 2.6(a)(iii). 
 “Contingent Payment Product” has the meaning set forth in
Section 2.6(a)(iv). 
 “Contingent Payment Termination Date” has the meaning set forth in
Section 2.6(a)(v). 
 “Contingent Payment Year” has the meaning set forth in
Section 2.6(a)(vi). 
 “Contract” means any contract, plan, undertaking, understanding, agreement,
license, sublicense, consent, lease, note, mortgage or other binding commitment, whether written or oral. 

“Control” (including the terms “controlled by” and “under common control with”) means
the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ownership of stock or other equity or similar interests, as trustee or executor, by Contract or
credit arrangement or otherwise. 
 “Court” means any court or arbitration tribunal of the United States, any
domestic state, or any foreign country, and any political subdivision or agency thereof. 
 “Credit Agreement”
means that certain Loan and Security Agreement between Silicon Valley Bank and Buyer entered into as of March 9, 2009, as amended. 
 “DGCL” means the General Corporation Law of the State of Delaware. 
 “Disclosing Party” means a Party that discloses Confidential Information to a Receiving Party or to any Representative of such Receiving Party. 

“Dispute Notice” has the meaning set forth in Section 2.7(d). 

“Dispute Period” has the meaning set forth in Section 2.7(d). 

“Disputed Contingent Payment Amount” has the meaning set forth in Section 2.7(e). 

“Documents and Materials” has the meaning set forth in Section 6.13. 

“EAR” has the meaning set forth in Section 4.25(a). 

“Employees” has the meaning set forth in Section 6.5(a). 

“Employee Plans” has the meaning set forth in Section 4.11(a). 

“End Date” has the meaning set forth in Section 8.1(b). 

“Environmental Claims” means all Claims pursuant to Environmental Laws, including but not limited to, those based on,
arising out of or otherwise relating to: (i) the Remediation, presence or Release of, or exposure to, Hazardous Materials or other environmental conditions 

  
 I-3

 
initiated, existing or occurring prior to the Closing Date at, on, under, above, from, or about any Real Property or any other real property currently or formerly owned, leased or operated by the
Company or any of its predecessors or Affiliates; (ii) the off-site Release, treatment, transportation, storage or disposal prior to the Closing Date of Hazardous Materials originating from the Real Property or any other real property currently
or formerly owned, leased or operated by the Company or any of its predecessors or Affiliates; (iii) any violations of Environmental Laws by the Company or any of its predecessors or Affiliates prior to the Closing Date, including reasonable
expenditures necessary to cause the Company to be in compliance with or resolve violations of Environmental Laws. 

“Environmental Laws” means any and all Laws, Orders, codes, or other legally enforceable requirement (including, without
limitation, common law) of the United States, or any state, local, municipal or other U.S. Governmental Authority, regulating, relating to or imposing liability or standards of conduct concerning Hazardous Materials, or the protection of the
environment, human health, employee health and safety, or natural resources, including, without limitation, the Comprehensive Environmental Response, Compensation, and Liability Act, 42 U.S.C. §§ 9601 et seq. 

“Environmental Permits” means any and all permits, licenses, registrations, notifications, exemptions and any other
Approvals under any Environmental Laws. 
 “ERISA” has the meaning set forth in Section 4.11(a).

 “ERISA Affiliate” has the meaning set forth in Section 4.11(a). 

“Estimated Working Capital” has the meaning set forth in Section 2.4(a). 

“Estimated Working Capital Schedule” has the meaning set forth in Section 2.4(a). 

“EU” has the meaning set forth in Section 4.22(b)(i). 

“Exchange Act” means the Securities Exchange Act of 1934, as amended. 

“FD&C Act” has the meaning set forth in Section 4.22(a)(i). 

“FD&C Permits” has the meaning set forth in Section 4.22(a)(x). 

“FDA” has the meaning set forth in Section 4.22(a)(i). 

“FDA Law and Regulation” has the meaning set forth in Section 4.22(a)(i). 

“FDA Milestone” has the meaning set forth in Section 2.6(a)(vii). 

“FDA Milestone Payment” has the meaning set forth in Section 2.6(c). 

“FDA Milestone Payment Amount” has the meaning set forth in Section 2.6(a)(viii). 

“Federal Health Care Program” has the meaning set forth in 42 U.S.C. § 1320a-7b(f). 

  
 I-4

 “Final Working Capital” has the meaning set forth in
Section 2.4(b). 
 “Final Working Capital Schedule” has the meaning set forth in
Section 2.4(b). 
 “Foreign Competition Laws” means any non-U.S. Laws and Orders that are designed
or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization, lessening of competition or restraint of trade. 
 “GAAP” means generally accepted accounting principles in the United States. 
 “GLBA” has the meaning set forth in Section 4.21(f). 

“Governmental Authority” means any governmental agency or authority of the United States, any domestic state, or any
foreign country, and any political subdivision or agency thereof, and includes any authority having governmental or quasi-governmental powers, including any administrative agency or commission. 

“Gross Profit Payment Product” has the meaning set forth in Section 2.6(a)(ix). 

“Hazardous Materials” means any wastes, substances, radiation, or materials (whether solids, liquids or gases):
(i) which are hazardous, toxic, infectious, explosive, radioactive, carcinogenic, or mutagenic; (ii) which are or become defined as “pollutants,” “contaminants,” “hazardous materials,” “hazardous
wastes,” “hazardous substances,” “chemical substances,” “radioactive materials,” “solid wastes,” or other similar designations in, or otherwise subject to regulation under, any Environmental Laws;
(iii) the presence of which on the Real Property cause or threaten to cause a nuisance pursuant to applicable statutory or common law upon the Real Property or to adjacent properties; (iv) which contain without limitation polychlorinated
biphenyls (“PCBs”), mold, methyl-tertiary butyl ether (“MTBE”), asbestos or asbestos-containing materials, lead-based paints, toxic mold, urea-formaldehyde foam insulation, or petroleum or petroleum products
(including, without limitation, crude oil or any fraction thereof); or (v) which pose a hazard to human health, safety, natural resources, employees, or the environment. 
 “HIPAA” has the meaning set forth in Section 4.21(e). 

“HITECH” means the Health Information Technology for Economic and Clinical Health Act provisions of the American
Recovery and Reinvestment Act of 2009, Pub. Law No. 111-5 and its implementing regulations for which compliance is required as of the date of this Agreement. 
 “HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. 
 “Indebtedness” means (i) all indebtedness (whether or not contingent) for borrowed money, (ii) all obligations (contingent or otherwise) for the deferred purchase price of
assets, property or services (other than current trade payables incurred in the ordinary course of business), (iii) all obligations evidenced by notes, bonds, debentures or other similar instruments, (iv) all indebtedness created or
arising under any conditional sale or other title retention 

  
 I-5

 
agreement with respect to property, (v) all obligations under capital leases, (vi) all obligations, contingent or otherwise, as an account party under acceptance, letter of credit or
similar facilities, (vii) all obligations under any currency, interest rate or other hedge agreement or any other hedging arrangement, (viii) all direct or indirect guarantee, support or keep well obligations in respect of obligations of
the kind referred to in clauses (i) through (vii) above, and (ix) all obligations of the kind referred to in clauses (i) through (viii) above secured by (or for which the holder of such obligation has an existing right,
contingent or otherwise, to be secured by) any Lien on property (including, without limitation, accounts and Contract rights) owned by the Company, whether or not the Company has assumed or become liable for the payment of such obligation;
provided, however, that the Contingent Payments under the LipoSonix Agreement shall not be deemed an Indebtedness of the Company or Seller. 
 “Indemnified Person” has the meaning set forth in Section 9.3(b). 
 “Indemnifying Party” has the meaning set forth in Section 9.5(a). 
 “Intellectual Property” means all patents (utility models and inventor’s certificates), provisional and non-provisional patent applications, trademarks, trade names, service marks,
trade dress, copyrights and any applications therefor, domain names, schematics, technology, know-how, Trade Secrets, Confidential Information, customer lists, technical information, technical data, process technology, plans, drawings and blue
prints, inventions, algorithms, devices, systems, processes, computer software programs and applications (source code or object code form), and tangible or intangible proprietary information. 

“Intentional Breach” means a material breach that is a consequence of an act knowingly undertaken by the breaching party
with the intent of causing a breach of this Agreement. 
 “Interest Rate” means the U.S. Prime Rate as
published in the Wall Street Journal from time to time plus one and a half percent (1.5%), on the date that funds were initially set-off by Buyer pursuant to Section 2.7(h). 

“IRS” has the meaning set forth in Section 4.11(a). 

“JSC” has the meaning set forth in Section 2.6(h)(ii). 

“Knowledge” means (i) in the case of Seller, the actual knowledge of a particular fact or other matter of Jens
Quistgaard, Michael Hoffman, Nancy McKinley, Michael Fritts, Charles Desilets, Keith Sullivan and Blake Little; (ii) in the case of Buyer, the actual knowledge of a particular fact or other matter of any individual who is serving as an
executive officer of Buyer as of the date hereof; and (iii) in each case, after the reasonable inquiry of the aforementioned persons. 
 ”Law” means all laws, statutes, ordinances, directives, Regulations and similar mandates of any Governmental Authority, including all Orders of Courts having the effect of law in each
such jurisdiction. 

  
 I-6

 “Lien” means any mortgage, pledge, security interest, attachment,
encumbrance, lien (statutory or otherwise), license, claim, option, conditional sale agreement, right of first refusal, first offer, termination, participation or purchase or charge of any kind (including any agreement to give any of the foregoing);
provided, however, that the term “Lien” shall not include (i) statutory liens for Taxes, which are not yet due and payable, (ii) statutory or common law liens to secure landlords, lessors or renters under leases or
rental agreements confined to the premises rented, (iii) deposits or pledges made in connection with, or to secure payment of, workers’ compensation, unemployment insurance, old age pension or other social security programs mandated under
applicable Laws, (iv) statutory or common law liens in favor of carriers, warehousemen, mechanics and materialmen, to secure claims for labor, materials or supplies and other like liens, and (v) restrictions on transfer of securities
imposed by applicable state and federal securities Laws. 
 “LipoSonix Agreement” has the meaning set forth in
the Recitals. 
 “LipoSonix Indemnification Claim” has the meaning set forth in Section 6.13(b).

 “LipoSonix Product” has the meaning set forth in Section 2.6(a)(x). 

“LipoSonix Technology” has the meaning set forth in Section 2.6(a)(xi). 

“Losses” has the meaning set forth in Section 9.2(a). 

“Lost Offset Amount” has the meaning set forth in Section 6.13(b)(ix). 

“MAC” has the meaning set forth in the Recitals. 

“Material Adverse Effect” means any fact, event, change, development, circumstance or effect (i) that, when such
term is used in relation to the Company (A) is materially adverse to the business, financial condition, assets, liabilities, or results of operations of the Company, or (B) would materially impair or delay the ability of Seller to perform
its obligations hereunder, including the consummation of the Contemplated Transactions or (ii) that, when such term is used in relation to Buyer, would materially impair or delay the ability of Buyer to perform its obligations hereunder,
including the consummation of the Contemplated Transactions. Any fact, event, change, development, circumstance, or effect shall not be deemed to have a Material Adverse Effect if such fact, event, change, development, circumstance or effect results
or arises from (i) changes or conditions generally affecting the Company’s industry, except to the extent such fact, event, change, development, circumstance or effect disproportionately affects (relative to other participants in the
Company’s industry) the Company, (ii) changes in general economic or political conditions (including armed hostilities or terrorist actions), except to the extent such changes or conditions disproportionately affect (relative to other
participants in the Company’s industry) the Company, (iii) changes in accounting requirements or principles or in applicable Law or other legal or regulatory conditions, except to the extent such changes disproportionately affect (relative
to other participants in the Company’s industry) the Company, (iv) any failure, in and of itself, by Seller or the Company to meet internal or external projections or forecasts or revenue or earnings predictions, (v) the public
announcement, or notification to any Person, of 

  
 I-7

 
this Agreement and the Contemplated Transactions or the consummation of the Contemplated Transactions or (vi) the performance of or compliance with the express terms of this Agreement.

 “Material Company Trade Secrets” has the meaning set forth in Section 4.16(a). 

“Material Contracts” has the meaning set forth in Section 4.6(a). 

“Medicis Indemnitee” has the meaning set forth in Section 6.13(b). 

“MEWA” has the meaning set forth in Section 4.11(d). 

“Non-U.S. Permits” has the meaning set forth in Section 4.22(b)(x). 

“Non-U.S. Regulatory Agency” has the meaning set forth in Section 4.22(b)(ii). 

“OFAC Regulations” has the meaning set forth in Section 4.25(a). 

“Order” means any judgment, order, decision, writ, injunction, ruling or decree of, or any settlement under the
jurisdiction of, any Court or Governmental Authority. 
 “Parties” has the meaning set forth in the Preamble.

 “PCBs” has the meaning set forth in the definition of “Hazardous Materials” in
Annex I. 
 “Person” means an individual, corporation, partnership, association, trust, unincorporated
organization, limited liability company, joint venture, other entity or group (as defined in Section 13(d)(3) of the Exchange Act). 
 “Personal Information” has the meaning set forth in Section 4.21(h)(ii). 
 “Pre-Closing Date Tax Returns” has the meaning set forth in Section 10.2(b). 
 “Privacy and Security Laws” has the meaning set forth in Section 4.21(f). 
 “Product” means any product (including any component thereof) manufactured, shipped, sold, marketed, distributed, and/or otherwise introduced into the stream of commerce by or on behalf
of the Company, including any product sold within or outside of the United States by the Company as the distributor, agent, or pursuant to any other contractual relationship with a non-U.S. manufacturer. 

“Purchase Price” has the meaning set forth in Section 2.2. 

“Qualified Accountant” has the meaning set forth in Section 2.4(c). 

“Qualified Acquiring Person” has the meaning set forth in Section 2.8. 

“Quarterly Contingent Payment Certificate” has the meaning set forth in Section 2.7(b)(i). 

  
 I-8

 “Real Property” has the meaning set forth in Section 4.13(b).

 “Receiving Party” means a Party or any Representative of such Party that receives Confidential Information
from a Disclosing Party. 
 “Regulation” means any rule, regulation, policy or interpretation of any
Governmental Authority having the effect of Law. 
 “Release” means any presence or exposure to or emission,
spill, seepage, leak, escape, leaching, discharge, injection, pumping, pouring, emptying, dumping, disposal, migration, release or threatened release of Hazardous Materials into or upon the environment, including the air, soil, improvements, surface
water, groundwater, the sewer, septic system, storm drain, publicly owned treatment works, or waste treatment, storage, or disposal systems. 
 “Remediation” means any investigation, clean-up, removal action, remedial action, restoration, repair, response action, corrective action, monitoring, sampling and analysis, installation,
reclamation, closure, or post-closure in connection with the suspected, threatened or actual Release of Hazardous Materials. 

“Sales Milestone” has the meaning set forth in Section 2.6(a)(xii). 

“Sales Milestone Payment” has the meaning set forth in Section 2.6(d). 

“Sales Milestone Payment Amount” has the meaning set forth in Section 2.6(a)(xiii). 

“Sales Payment Product” has the meaning set forth in Section 2.6(a)(xiv). 

“Sales/Profit Contingent Payment” has the meaning set forth in Section 2.6(e). 

“Sales/Profit Contingent Payment Amount” has the meaning set forth in Section 2.6(a)(xv). 

“Sales/Profit Contingent Payment Percentage” has the meaning set forth in Section 2.6(a)(xvi). 

“Scheduled Company Intellectual Property” has the meaning set forth in Section 4.16(a). 

“Second Generation LipoSonix Product” has the meaning set forth in Section 2.6(a)(vii). 

“SEC” has the meaning set forth in Section 6.16. 

“Securities Act” has the meaning set forth in Section 5.8. 

“Seller” has the meaning set forth in the Preamble. 

“Seller Contingent Payments” has the meaning set forth in Section 2.2. 

“Seller Disclosure Schedule” has the meaning set forth in the preamble to Article 4. 

  
 I-9

 “Seller Indemnified Person(s)” has the meaning set forth in
Section 9.2(b). 
 “Seller Marks” has the meaning set forth in Section 6.13.

 “Seller Representatives” has the meaning set forth in Section 6.2(a). 

“Shares” has the meaning set forth in the Recitals. 

“Statement of Working Capital” has the meaning set forth in Section 2.4(a). 

“Subsidiary” or “Subsidiaries” of the Company, Seller, Buyer or any other Person means any corporation,
partnership, joint venture, limited liability company, trust, unincorporated organization, association or other legal entity of which the Company, Seller, Buyer or such other Person, as the case may be, (i) owns, directly or indirectly, greater
than 50% of the stock or other equity interests the holder of which is generally entitled to vote as a general partner or for the election of the board of directors or other governing body of a corporation, partnership, joint venture, limited
liability company, trust, unincorporated organization, association or other legal entity or (ii) has any arrangement, understanding or agreements entitling the Company, Seller, Buyer or other Person to vote as a general partner or for the
election of a majority of the board of directors or other governing body of a corporation, partnership, joint venture, limited liability company, trust, unincorporated organization, association or other legal entity. 

“Successor Subsidiary” has the meaning set forth in Section 2.8(a). 

“Target Working Capital” shall mean ***. 
 “Tax” has the meaning set forth in Section 4.14. 

“Tax Returns” has the meaning set forth in Section 4.14. 

“Third Party Claim” has the meaning set forth in Section 9.5(a). 

“Third Party Intellectual Property Rights” has the meaning set forth in Section 4.16(a). 

“Threshold” has the meaning set forth in Section 9.3(b). 

“Trade Secrets” means information, including but not limited to, know-how, Confidential Information, customer lists,
software (source code and object code), technical information, data (including pharmacological, toxicological, preclinical and clinical test data and results), process technology, plans, drawings and blue prints, anywhere in the world that derives
independent economic value, actual or potential, from not generally being known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use and that is the subject of efforts
that are reasonable under the circumstances to maintain its secrecy. 
 “Transfer Taxes” has the meaning set
forth in Section 10.6. 
 “Unaudited 2010 Financial Statement” has the meaning set forth in
Section 4.28. 

  
 I-10

 “Unaudited Financial Statements” has the meaning set forth in
Section 4.28. 
 “Unaudited Interim Financial Statements” has the meaning set forth in
Section 4.28. 
 “WARN Act” has the meaning set forth in Section 4.12(b). 

“Worldwide Ancillary Gross Profit” has the meaning set forth in Section 2.6(a)(xvii). 

“Worldwide Ancillary Gross Profit Adjustments” has the meaning set forth in Section 2.6(a)(xviii).

 “Worldwide Gross Profit” has the meaning set forth in Section 2.6(a)(xix). 

“Worldwide Net Sales” has the meaning set forth in Section 2.6(a)(xx). 

“Worldwide Net Sales Adjustments” has the meaning set forth in Section 2.6(a)(xxi). 

  
 I-11Seventh Amendment to Loan and Security Agreement

 Exhibit 10.3 
 SEVENTH AMENDMENT 
 TO 

LOAN AND SECURITY AGREEMENT 
 THIS SEVENTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into this 25th day of October, 2011 by and between SILICON VALLEY BANK (“Bank”) and SOLTA
MEDICAL, INC., a Delaware corporation (“Borrower”) whose address is 25881 Industrial Boulevard, Hayward, CA 94545. 

RECITALS 
 A. Bank and Borrower have entered into that certain Loan and Security Agreement dated as of March 9, 2009, as amended from time to time, including by that certain First Amendment to Loan and
Security Agreement dated as of March 27, 2009, that certain Second Amendment to Loan and Security Agreement dated as of June 30, 2009, that certain Third Amendment to Loan and Security Agreement dated as of March 30, 2010, that
certain Fourth Amendment to Loan and Security Agreement dated as of October 15, 2010, that certain Fifth Amendment to Loan and Security Agreement dated as of April 20, 2011 and that certain Sixth Amendment to Loan and Security Agreement
dated as of September 12, 2011 (as the same may from time to time be further amended, modified, supplemented or restated, the “Loan Agreement”). 
 B. Bank has extended credit to Borrower for the purposes permitted in the Loan Agreement. 
 C. Borrower has requested that Bank amend the Loan Agreement to extend additional credit to be used by Borrower and/or certain of its Subsidiaries to enter into the Medicis Stock Purchase and
consummate the transaction contained therein, as more fully set forth herein. 
 D. Bank has agreed to so amend certain
provisions of the Loan Agreement, but only to the extent, in accordance with the terms, subject to the conditions and in reliance upon the representations and warranties set forth below. 

AGREEMENT 
 NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and
intending to be legally bound, the parties hereto agree as follows: 
 1. Definitions. Capitalized terms used but
not defined in this Amendment shall have the meanings given to them in the Loan Agreement. 
 2. Amendments to Loan
Agreement. 
 2.1 Section 2.1.1 (Revolving Advances). Section 2.1.1(c) is hereby amended in its entirety
and replaced with the following: 
 “(c) Early Termination. At Borrower’s option, Borrower shall
have the option to terminate the Revolving Line prior to the Revolving Maturity Date, provided Borrower (a) provides written notice to Bank of its election to exercise to terminate the Revolving Line at least fifteen (15) days prior
to such termination, and (b) pays, on the date of such termination (i) all accrued and unpaid interest with respect to the outstanding Advances through the date of such Termination; (ii) all outstanding principal with respect to the
Advances; (iii) an early termination fee equal to Eighty Thousand Dollars ($80,000) (the “Revolving Line Termination Fee”); and (iv) all other sums, if any, that shall have become due and payable hereunder with respect to this
Agreement.” 

 2.2 Section 2.1.3 (Term Line). Section 2.1.3 is hereby amended in its
entirety and replaced with the following: 
 “2.1.3 Term Line. 

(a) Availability. Subject to the terms and conditions of this Agreement, during the Draw Period, Bank shall make advances (each,
a “Term Advance” and, collectively, “Term Advances”) not exceeding the Term Line. After repayment, no Term Advance may be reborrowed. Borrower may use the Term Advances to finance the Medicis Stock Purchase.

 (b) Repayment. Each Term Advance shall be interest only through the end of the Draw Period at which time all Term
Advances shall immediately amortize and be payable in thirty nine (39) equal payments of principal and interest beginning July 1, 2012 and continuing on the first day of each month thereafter through the Term Maturity Date. Notwithstanding
the foregoing, all unpaid principal and interest on the Term Advance shall be due on the Term Maturity Date. 
 (c)
Prepayment. Borrower shall have the option to prepay all, but not less than all, of the Term Advances, provided Borrower (a) provides written notice to Bank of its election to exercise to prepay the Term Advances at least fifteen
(15) days prior to such prepayment, and (b) pays, on the date of the prepayment (i) all accrued and unpaid interest with respect to the Term Advances through the date the prepayment is made; (ii) all unpaid principal with respect
to the Term Advances; (iii) the Final Payment Fee for the Term Advances in accordance with the terms of Section 2.4(a), (iv) a prepayment fee equal to two percent (2.00%) of the aggregate principal amount of the Term Advances
made to Borrower (the “Term Line Prepayment Fee”) and (v) all other sums, if any, that shall have become due and payable hereunder with respect to this Agreement.” 

2.3 Section 2.3 (Payment of Interest on the Credit Extensions). Section 2.3(a)(iii) is hereby amended in its
entirety and replaced with the following: 
 “(iii) Term Advances. Subject to Section 2.3(b), the principal
amount outstanding with respect to each Term Advance shall accrue interest at a fixed per annum rate equal to three and three quarters percent (3.75%).” 
 2.4 Section 2.4 (Fees). Section 2.4(a) is amended in its entirety and replaced with the following: 
 “(a) Final Payment Fees. On the earlier of (i) the Tranche I Term Loan Maturity Date or the Tranche II Term Loan Maturity Date (as applicable for each tranche) or (ii) the date such
Term Loan is prepaid in full, a Final Payment Fee equal to three and one half percent (3.50%) of the aggregate principal amount of Tranche I or Tranche II of the Term Loan (as applicable) made by Bank to Borrower hereunder and on the earlier of
(i) the Term Maturity Date or (ii) the date the Term Advances are prepaid in full, a Final Payment Fee equal to six percent (6.00%) of the aggregate principal amount of the Term Advances made by Bank to Borrower hereunder;”

 2.5 Section 3.4 (Procedures for Borrowing). Section 3.4(b) is amended in its entirety and replaced with the
following: 
 “(b) Term Loan, Term Advances. Subject to the prior satisfaction of all other applicable conditions to
the making of either tranche of the Term Loan or a Term Advance, to obtain either tranche of the Term Loan or a Term Advance, Borrower shall notify Bank (which notice shall be irrevocable) by electronic mail, facsimile, or telephone by 12:00 p.m.
Pacific time on the Funding Date of the applicable tranche of the Term Loan or a Term Advance. Together with any such electronic or facsimile notification, Borrower shall deliver to Bank (I) by electronic mail or facsimile a completed
Payment/Advance Form executed by a Responsible Officer or his or her designee and (II) a duly executed original Warrant in the form attached hereto as Exhibit F. Bank may rely on any telephone notice given by

  
 2 

 
a person whom Bank believes is a Responsible Officer or designee. Bank shall credit the applicable tranche of the Term Loan or a Term Advance to the Designated Deposit Account.” 

2.6 Section 6.2 (Financial Statements, Reports, Certificates.) Section 6.2(b) is hereby amended in its entirety and
replaced with the following: 
 (b) Within thirty (30) days after the last day of each month, deliver to Bank
(i) company prepared consolidated and consolidating balance sheet and income statement covering Borrower’s and each of its Subsidiary’s operations for such month certified by a Responsible Officer and in a form acceptable to Bank
(ii) aged listings of accounts receivable and accounts payable (by invoice date), (iii) a duly completed Borrowing Base Certificate signed by a Responsible Officer and (iv) a report of Deferred Revenue.” 

2.7 Section 6.7 (Financial Covenants.) Section 6.7 is hereby amended in its entirety and replaced with the following:

 “6.7 Financial Covenants. Borrower shall maintain at all times, to be tested as of the last day of each quarter,
unless otherwise noted, on a consolidated basis with respect to Borrower and its Subsidiaries: 
 (a) Fixed
Charge Coverage Ratio. A Fixed Charge Coverage Ratio not less than 2.0 to 1.0. 
 (b) Leverage Ratio.
A Leverage Ratio not more than (i) 3.25 to 1.00 for each calendar quarter through the quarter ending March 31, 2012 and (ii) 3.00 to 1.00 for each calendar quarter thereafter. 

(c) Liquidity. Liquidity of not less than (i) Twelve Million Five Hundred Thousand Dollars at all times
through March 31, 2012 and (ii) Ten Million Dollars ($10,000,000) at all times beginning on April 1, 2012.” 

2.8 Section 13 (Definitions). Section 13.1 of the Loan Agreement hereby is amended by adding or amending and restating
the following terms and their respective definitions: 
 “Adjusted EBITDA” shall mean
(a) Net Income, plus (b) Interest Expense, plus (c) to the extent deducted in the calculation of Net Income, depreciation expense and amortization expense, plus (d) income tax expense of Borrower and its Subsidiaries on a
consolidated basis, plus (e) non-cash compensation expenses or other non-cash expenses or charges incurred during such period arising from the sale of stock, the granting of stock options, stock appreciation rights and other similar
arrangements of Borrower and its Subsidiaries, plus, (f) for the quarters ending September 30, 2011 and December 31, 2011 only, one-time transaction costs and severance and transition costs associated with the acquisition of Medicis
Technology Corporation in an amount not to exceed Three Million Dollars ($3,000,000) in the aggregate for both quarters. 
 “Basic Rate” is the per annum rate of interest (based on a year of 360 days) equal to the sum of (a) U.S. Treasury note yield to maturity for a term equal to a three (3) year
Treasury Note Maturity as reported in the Federal Reserve Statistical Release H.15-Selected Interest Rates under the heading “U.S. Government Securities/Treasury Constant Maturities” on the Funding Date of Tranche I of the Term Loan with
respect to any Term Loan, plus (b) the applicable Loan Margin. (In the event Release H.15 is no longer published, Bank shall select a comparable publication to determine the U.S. Treasury note yield to maturity.) 

“Borrowing Base” means eighty percent (80%) of Eligible Accounts, as determined by Bank from
Borrower’s most recent Borrowing Base Certificate; provided, however, that Bank may decrease the foregoing percentage in its good faith business 

  
 3 

 
judgment based on events, conditions, contingencies, or risks which, as determined by Bank, may adversely affect Collateral. 

“Borrowing Base Certificate” is that certain certificate in the form attached hereto as Exhibit F.

 “Draw Period” is the period of time from (i) the date that FDA clearance is received for
the commercial launch of the second generation Liposonix product through June 30, 2012. 
 “Eligible
Accounts” means Accounts which arise in the ordinary course of Borrower’s business that meet all Borrower’s representations and warranties in Section 5.3. Bank reserves the right upon prior written notice to Borrower at any
time after the Effective Date to adjust any of the criteria set forth below and to establish new criteria in its good faith business judgment. Unless Bank otherwise agrees in writing, Eligible Accounts shall not include: 

(a) Accounts for which the Account Debtor is Borrower’s Affiliate, officer, employee, or agent; 

(b) Accounts that the Account Debtor has not paid within ninety (90) days of due date regardless of invoice payment
period terms; 
 (c) Accounts with credit balances over ninety (90) days from due date; 

(d) Accounts owing from an Account Debtor, in which fifty percent (50%) or more of the Accounts have not been paid
within ninety (90) days of due date; 
 (e) Accounts owing from an Account Debtor which does not have its
principal place of business in the United States to the extent such accounts exceed Five Million Dollars ($5,000,000); 
 (f) Accounts billed and/or payable outside of the United States (sometimes called foreign invoiced accounts); 
 (g) Accounts owing from an Account Debtor to the extent that Borrower is indebted or obligated in any manner to the Account Debtor (as creditor, lessor, supplier or otherwise - sometimes called
“contra” accounts, accounts payable, customer deposits or credit accounts); 
 (h) Accounts owing from
an Account Debtor which is a United States government entity or any department, agency, or instrumentality thereof unless Borrower has assigned its payment rights to Bank and the assignment has been acknowledged under the Federal Assignment of
Claims Act of 1940, as amended; 
 (i) Accounts for demonstration or promotional equipment, or in which goods are
consigned, or sold on a “sale guaranteed”, “sale or return”, “sale on approval”, or other terms if Account Debtor’s payment may be conditional; 

(j) Accounts owing from an Account Debtor where goods or services have not yet been rendered to the Account Debtor
(sometimes called memo billings or pre-billings); 
 (k) Accounts subject to contractual arrangements between
Borrower and an Account Debtor where payments shall be scheduled or due according to completion or 

  
 4 

 
fulfillment requirements where the Account Debtor has a right of offset for damages suffered as a result of Borrower’s failure to perform in accordance with the contract (sometimes called
contracts accounts receivable, progress billings, milestone billings, or fulfillment contracts); 
 (l) Accounts
owing from an Account Debtor the amount of which may be subject to withholding based on the Account Debtor’s satisfaction of Borrower’s complete performance as specified in the Borrower’s end-user agreement with customer (but only to
the extent of the amount withheld; sometimes called retainage billings); 
 (m) Accounts subject to trust
provisions, subrogation rights of a bonding company, or a statutory trust; 
 (n) Accounts owing from an Account
Debtor that has been invoiced for goods that have not been shipped to the Account Debtor unless Bank, Borrower, and the Account Debtor have entered into an agreement acceptable to Bank in its sole discretion wherein the Account Debtor acknowledges
that (i) it has title to and has ownership of the goods wherever located, (ii) a bona fide sale of the goods has occurred, and (iii) it owes payment for such goods in accordance with invoices from Borrower (sometimes called “bill
and hold” accounts); 
 (o) Accounts for which the Account Debtor has not been invoiced; 

(p) Accounts that represent non-trade receivables or that are derived by means other than in the ordinary course of
Borrower’s business; 
 (q) Accounts for which Borrower has permitted Account Debtor’s payment to
extend beyond 90 days; 
 (r) Accounts arising from chargebacks, debit memos or other payment deductions taken by
an Account Debtor; 
 (s) Accounts arising from product returns and/or exchanges (sometimes called
“warranty” or “RMA” accounts); 
 (t) Accounts in which the Account Debtor disputes liability
or makes any claim (but only up to the disputed or claimed amount), or if the Account Debtor is subject to an Insolvency Proceeding, or becomes insolvent, or goes out of business; 

(u) Accounts owing from an Account Debtor with respect to which Borrower has received Deferred Revenue (but only to the
extent of such Deferred Revenue); 
 (v) Accounts owing from an Account Debtor, whose total obligations to
Borrower exceed twenty-five percent (25%) of all Accounts, for the amounts that exceed that percentage, unless Bank approves in writing; and 
 (w) Accounts for which Bank in its good faith business judgment after inquiry and consultation with Borrower determines collection to be doubtful, including, without limitation, accounts represented by
“refreshed” or “recycled” invoices. 
 “Fixed Charge Coverage Ratio” means a
ratio of (i) consolidated Adjusted EBTIDA less unfunded capitalized expenditures less cash taxes paid to (ii) the sum of Borrower’s trailing twelve (12) month principal and interests payments on Total Consolidated Indebtedness.

  
 5 

 “Leverage Ratio” means a ratio of (i) all funded
Indebtedness owing from Borrower to Bank to (ii) trailing twelve (12) month EBITDA. 
 “Loan
Margin” is five hundred one (501) basis points with respect to the Term Loan. 

“Liquidity” is the sum of (i) Borrower’s cash at Bank plus (ii) the Availability Amount.

 “Revolving Line Maturity Date” is October __, 2013. 

“Term Line” is an Term Advance or Term Advances in an aggregate amount of up to Twenty Million Dollars
($20,000,000). 
 “Term Maturity Date” is September 1, 2015. 

“Total Consolidated Indebtedness” means outstanding Indebtedness for borrowed money, including all
outstanding Indebtedness for borrowed money under the Loan Documents and all capital lease obligations. 
 2.9
Exhibit D is hereby replaced with Exhibit D attached hereto. 
 2.10 New Exhibit F is hereby added in
the form attached hereto. 
 2.11 New Exhibit G is hereby added in the form attached hereto. 

3. Limitation of Amendments. 
 3.1 The amendments set forth in Section 2, above, are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a
consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right or remedy which Bank may now have or may have in the future under or in connection with any Loan
Document. 
 3.2 This Amendment shall be construed in connection with and as part of the Loan Documents and all terms,
conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect. 

4. Representations And Warranties. To induce Bank to enter into this Amendment, Borrower hereby represents and warrants to
Bank as follows: 
 4.1 Immediately after giving effect to this Amendment (a) the representations and warranties
contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such
date), and (b) no Event of Default has occurred and is continuing; 
 4.2 Borrower has the power and authority to
execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment; 

4.3 The organizational documents of Borrower delivered to Bank on the Effective Date remain true, accurate and complete and have
not been amended, supplemented or restated and are and continue to be in full force and effect; 

  
 6 

 4.4 The execution and delivery by Borrower of this Amendment and the performance by
Borrower of its obligations under the Loan Agreement, as amended by this Amendment, have been duly authorized; 
 4.5 The
execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (a) any law or regulation binding on or affecting
Borrower, (b) any contractual restriction with a Person binding on Borrower, (c) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (d) the
organizational documents of Borrower; 
 4.6 The execution and delivery by Borrower of this Amendment and the performance
by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental
or public body or authority, or subdivision thereof, binding on either Borrower, except as already has been obtained or made; and 
 4.7 This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such
enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights. 

5. Counterparts. This Amendment may be executed in any number of counterparts and all of such counterparts taken together shall be
deemed to constitute one and the same instrument. 
 6. Effectiveness. This Amendment shall be deemed effective
upon (i) the due execution and delivery to Bank of this Amendment by each party hereto, (ii) the due execution and delivery to Bank of duly executed original signatures to the completed Borrowing Resolutions for Borrower and (iii) the
due execution and delivery to Bank by Aesthera Corporation of (a) an Unconditional Guaranty; (a) a Security Agreement and (iii) an Intellectual Property Security Agreement; each in favor of Bank and in form and substance reasonably
acceptable to Bank. 

  
 7 

 IN WITNESS WHEREOF, the parties hereto
have caused this Amendment to be duly executed and delivered as of the date first written above. 
  

									
	BANK	 		 	BORROWER
			
	SILICON VALLEY BANK	 		 	SOLTA MEDICAL, INC.
					
	By:	 	 /s/ James Taylor
	 		 	By:	 	 /s/ John F. Glenn

	Name:	 	 James Taylor
	 		 	Name:	 	 John F. Glenn

	Title:	 	 Relationship Manager
	 		 	Title:	 	 CFO

 BORROWER TO PROVIDE FORM OF SECRETARY’S CERTIFICATE FOR BANK REVIEW AND

 APPROVAL 

 EXHIBIT D - COMPLIANCE CERTIFICATE 

 

					
	TO:	  	SILICON VALLEY BANK	  	Date:                    
	FROM:	  	SOLTA MEDICAL, INC.	  	

 The undersigned authorized officer of SOLTA MEDICAL, INC. (“Borrower”) certifies that under the
terms and conditions of the Loan and Security Agreement between Borrower and Bank (the “Agreement”), (1) Borrower is in complete compliance for the period ending
                    with all required covenants except as noted below, (2) there are no Events of Default, (3) all representations and
warranties in the Agreement are true and correct in all material respects on this date except as noted below; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified
or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date, (4) Borrower,
and each of its Subsidiaries, has timely filed all required tax returns and reports, and Borrower has timely paid all foreign, federal, state and local taxes, assessments, deposits and contributions owed by Borrower except as otherwise permitted
pursuant to the terms of Section 5.9 of the Agreement, and (5) no Liens have been levied or claims made against Borrower or any of its Subsidiaries relating to unpaid employee payroll or benefits of which Borrower has not previously
provided written notification to Bank. Attached are the required documents supporting the certification. The undersigned certifies that these are prepared in accordance with GAAP consistently applied from one period to the next except (i) as
explained in an accompanying letter or footnotes and (ii) with respect to unaudited financials for the absence of footnotes and subject to year-end adjustments. The undersigned acknowledges that no borrowings may be requested at any time or
date of determination that Borrower is not in compliance with any of the terms of the Agreement, and that compliance is determined not just at the date this certificate is delivered. Capitalized terms used but not otherwise defined herein shall have
the meanings given them in the Agreement. 
 Please indicate compliance status by circling Yes/No under “Complies” column.

  

					
	 Reporting Covenant
	  	 Required
	  	 Complies

	 Monthly financial statements with Compliance Certificate
	  	Monthly within 30 days	  	Yes   No
	 Annual Financial Projections
	  	Within 7 days of approval by board	  	Yes   No
	 10-Q, 10-K and 8-K
	  	Within 5 days after filing with SEC	  	Yes   No
	 Borrowing Base Certificate, A/R & A/P Agings, Deferred Revenue Report
	  	Monthly within 30 days	  	Yes No
	  
 The following
Intellectual Property was registered (or a registration application submitted) after the Effective Date (if no registrations, state “None”)

  

							
	 Financial Covenant
	  	 Required
	  	 Actual
	  	Complies
	 Minimum FCCR
	  	2.00 to 1.00	  	            :1.00	  	Yes   No
	 Minimum Leverage Ratio
	  	 3.25 to 1.00 through 3/31/12

and 3.00 to 1.00 thereafter
	  	$            	  	Yes   No
	 Minimum Liquidity
	  	$12,500,000 through 3/31/12 and $10,000,000 thereafter	  		  	

 The following financial covenant analyses and information set forth in Schedule 1 attached hereto are
true and accurate as of the date of this Certificate. 

 The following are the exceptions with respect to the certification above: (If no exceptions
exist, state “No exceptions to note.”) 
  
  

 
  
  

 
  

 

							
		
	SOLTA MEDICAL, INC.	 	BANK USE ONLY
				
	By:	 	  
	 	Received by:	 	  

	Name:	 	  
	 		 	AUTHORIZED SIGNER
	Title:	 	  
	 	Date:	 	  

				
		 		 	Verified:	 	  

		 		 		 	AUTHORIZED SIGNER
		 		 	Date:	 	  

		 		 		 	
		 		 	Compliance Status:	 	Yes     No
		 		 		 	

 Schedule 1 to Compliance Certificate 

Financial Covenants of Borrower 
 In the event of a conflict between this Schedule and the Loan Agreement, the terms of the Loan Agreement shall govern. 
 Dated:                      

 

	I.	Fixed Charge Coverage Ratio (Section 6.7(a)) 

 Required: at least 2.00 to 1.00 (measured quarterly on a trailing twelve month basis) 
  

	Actual:	

  

			
	 A.     Net Income
	  	$            
	 B.     To the extent included in the determination of Net Income
	  	
	 1.      The provision for income taxes
	  	$            
	 2.      Depreciation expense
	  	$            
	 3.      Amortization expense
	  	$            
	 4.      Net Interest Expense
	  	$            
	 5.      non-cash compensation expenses or other non-cash expenses or charges incurred during such
period arising from the sale of stock, the granting of stock options, stock appreciation rights and other similar arrangements of Borrower and its Subsidiaries (plus, for the quarters ending September 30, 2011 and December 31, 2011 only, one- time
transaction costs and severance and transition costs associated with the acquisition of Medicis Technology Corporation in an amount not to exceed Three Million Dollars ($3,000,000) in the aggregate for both quarters).
	  	
	 6.      The sum of lines 1 through 5
	  	$            
	 C.     Adjusted EBIDTA (line A plus line B.6)
	  	$            
	 D.     Unfunded Capitalized Expenditures
	  	$            
	 E.     Cash Taxes
	  	$            
	 F.      Total Consolidated Indebtedness
	  	$            
	 G.     Fixed Charge Coverage Ratio (the sum of line C minus line D minus line E all divided by line
F)
	  	        :1.00

 Is line G equal to or greater than the amount required above? 

 

			
	         No, not in compliance
	 	         Yes, in compliance

	II.	Leverage Ratio (Section 6.7(b)) 

  

			
	 Required:
	  	not more than (i) 3.25 to 1.00 for each calendar quarter through the quarter ending March 31, 2012 and (ii) 3.00 to 1.00 for each calendar quarter thereafter (Measured
quarterly on a trailing twelve month basis)

 Actual: 
  

							
	 A.
	  	Funded SVB Debt	  			
			
	 B.
	  	Net Income	  	$	            	  
			
	 C.
	  	To the extent included in the determination of Net Income	  			
			
		  	1. The provision for income taxes	  	$	            	  
			
		  	2. Depreciation expense	  	$	            	  
			
		  	3. Amortization expense	  	$	            	  
			
		  	4. Net Interest Expense	  	$	            	  
			
		  	5. non-cash compensation expenses or other non-cash expenses or charges incurred during such period arising from the sale of stock, the granting of stock options, stock
appreciation rights and other similar arrangements of Borrower and its Subsidiaries (plus, for the quarters ending September 30, 2011 and December 31, 2011 only, one- time transaction costs and severance and transition costs associated with the
acquisition of Medicis Technology Corporation in an amount not to exceed Three Million Dollars ($3,000,000) in the aggregate for both quarters).	  			
			
		  	6. The sum of lines 1 through 5	  	$	            	  
			
	 C.
	  	Adjusted EBITDA (line B plus line C.6)	  	$	            	  
			
	 D.
	  	Leverage Ratio (line A divided by line C)	  	 	            :1.00	  

 Is line D less than or equal to the amount required above? 

 

			
	             No, not in compliance
	 	            Yes, in compliance

	III.	Liquidity (Section 6.7(c)) 

 Required:
(i) Twelve Million Five Hundred Thousand Dollars ($12,500,000) at all times through March 31, 2012 and (ii) Ten Million Dollars ($10,000,000) at all times thereafter. 

 

	Actual:	

  

					
	 A.     
	  	 Aggregatevalue of the unrestricted balance sheet cash of Borrower
	  	$            
			
	 B.     
	  	 AvailabilityAmount
	  	$            
			
	 C.     
	  	 Liquidity(line A plus line B)
	  	$            

 Is line C equal to or greater than (i) Twelve Million Five Hundred Thousand Dollars ($12,500,000) at all times
through March 31, 2012 and (ii) Ten Million Dollars ($10,000,000) at all times thereafter? 
  

			
	            No, not in compliance	  	            Yes, in compliance

 EXHIBIT F 

BORROWING BASE CERTIFICATE 
 Borrower: SOLTA MEDICAL, INC. 
 Lender: Silicon Valley Bank 

Commitment Amount: $8,000,000 
  

			
	ACCOUNTS RECEIVABLE	  	
	 1.      Accounts Receivable (invoiced) Book Value as of
            
	  	$            
	 2.      Additions (please explain on reverse)
	  	$            
	 3.      TOTAL ACCOUNTS RECEIVABLE
	  	$            
		
	ACCOUNTS RECEIVABLE DEDUCTIONS (without duplication)	  	
	 4.      Amounts over 90 days due
	  	$            
	 5.      Balance of 50% over 90 day accounts
	  	$            
	 6.      Foreign Accounts
	  	$            
	 7.      Foreign Invoiced Accounts
	  	$            
	 8.      Contra/Customer Deposit Accounts
	  	$            
	 9.      Intercompany/Employee Accounts
	  	$            
	 10.    Credit balances over 90 days
	  	$            
	 11.    Concentration Limits
	  	$            
	 12.    U.S. Governmental Accounts
	  	$            
	
13.    Promotion or Demo Accounts; Guaranteed Sale or Consignment Sale 
Accounts
	  	$            
	 14.    Accounts with Progress/Milestone/Pre-billings; Contract Accounts
	  	$            
	 15.    Accounts for Retainage Billing
	  	$            
	 16.    Trust Accounts
	  	$            
	 17.    Bill and Hold Accounts
	  	$            
	 18.    Unbilled Accounts
	  	$            
	 19.    Non-Trade Accounts
	  	$            
	 20.    Accounts with Extended Term Invoices
	  	$            
	 21.    Accounts subject to Chargebacks
	  	$            
	 22.    Disputed Accounts
	  	$            
	 23.    Other (please explain on reverse)
	  	$            
	 24.    TOTAL ACCOUNTS RECEIVABLE DEDUCTIONS
	  	$            
	 25.    Eligible Accounts (#3 minus #24)
	  	$            
	 26.    ELIGIBLE AMOUNT OF ACCOUNTS (80% of #25)
	  	$            
		
	BALANCES	  	
	 27.    Maximum Loan Amount
	  	$8,000,000
	 28.    Total Funds Available [Lesser of #26 or $27)]
	  	$            
	 29.    Present balance owing on Line of Credit
	  	$            
	 30.    RESERVE POSITION (#28 minus #30)
	  	$            

 [Continued on following page.] 

 The undersigned represents and warrants that this is true, complete and correct, and that
the information in this Borrowing Base Certificate complies with the representations and warranties in the Loan and Security Agreement between the undersigned and Silicon Valley Bank. 

 

									
	COMMENTS:	 		 	BANK USE ONLY
		 		 		 	Received by:	 	  

	By:	 	  
	 		 		 	AUTHORIZED SIGNER
		 	Authorized Signer	 		 		 	 
		 		 		 	Date:	 	  

	Date:	 	  
	 		 	Verified:	 	  

		 		 		 		 	AUTHORIZED SIGNER
		 		 		 	Date:	 	  

		 		 		 	Compliance Status:	 	    Yes     No

 EXHIBIT G 
 Form of Warrant 
 [Please see attached] 

 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT
AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION. 

WARRANT TO PURCHASE STOCK 
  

			
	 Company:
	  	SOLTA MEDICAL, INC., a Delaware corporation
	 Number of Shares:
	  	[1.5% of the principal amount of the applicable Term Advance made by SVB to the Company]
	 Class of Stock:
	  	Common Stock
	 Warrant Price:
	  	$            per share [FMV on date of issuance]
	 Issue Date:
	  	            , 2011
	 Expiration Date:
	  	The 10th anniversary after the Issue Date
	 Credit Facility:
	  	This Warrant is issued in connection with the Loan and Security Agreement between Company and Silicon Valley Bank dated as of March 9, 2009.

 THIS WARRANT CERTIFIES THAT, for good and valuable consideration, SILICON VALLEY BANK (together with any
registered holder from time to time of this Warrant or any holder of the shares issuable or issued upon exercise of this Warrant, “Holder”) is entitled to purchase the number of fully paid and nonassessable shares of the class of
securities (the “Shares”) of the Company at the Warrant Price, all as set forth above and as adjusted pursuant to Article 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant.

 ARTICLE 1. EXERCISE. 
 1.1 Method of Exercise. Holder may exercise this Warrant by delivering a duly completed and executed Notice of Exercise in substantially the form attached as Appendix 1 to the principal office of
the Company. Unless Holder is exercising the conversion right set forth in Article 1.2, Holder shall also deliver to the Company a check, wire transfer (to an account designated by the Company), or other form of payment acceptable to the Company for
the aggregate Warrant Price for the Shares being purchased. 
 1.2 Conversion Right. In lieu of exercising this Warrant
as specified in Article 1.1, Holder may from time to time convert this Warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares or other securities for which the Warrant is
then being converted minus the aggregate Warrant Price of such Shares by (b) the fair market value of one Share. The fair market value of the Shares shall be determined pursuant to Article 1.3. 

1.3 Fair Market Value. The fair market value of each Share shall be the average closing price of a Share reported for the five
business days immediately prior to the date of determination thereof. 

 1.4 Delivery of Certificate and New Warrant. Promptly after Holder exercises or
converts this Warrant, and, if applicable, the Company receives payment of the aggregate Warrant Price, the Company shall deliver to Holder certificates for the Shares acquired and, if this Warrant has not been fully exercised or converted and has
not expired, a new Warrant representing the Shares not so acquired. 
 1.5 Replacement of Warrants. On receipt of
evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and amount to the
Company or, in the case of mutilation on surrender and cancellation of this Warrant, the Company shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor. 

1.6 Treatment of Warrant Upon Acquisition of Company. 
 1.6.1 “Acquisition”. For the purpose of this Warrant, “Acquisition” means any sale, license, or other disposition of all or substantially all of the assets of the Company, or
any reorganization, consolidation, or merger of the Company where Holders of the Company’s securities before the transaction beneficially own less than 50% of the outstanding voting securities of the surviving entity after the transaction.

 1.6.2 Treatment of Warrant at Acquisition. 
 A) Upon the written request of the Company, Holder agrees that, in the event of an Acquisition that is not an asset sale and in which the sole consideration is cash or Marketable Securities (or a
combination thereof), either (a) Holder shall exercise or convert this Warrant in full with respect to all remaining Shares subject to the warrant and such exercise or conversion will be deemed effective immediately prior to the consummation of
such Acquisition or (b) if Holder elects not to exercise or convert the Warrant, this Warrant will expire upon the consummation of such Acquisition. The Company shall provide Holder with written notice of its request relating to the foregoing
(together with such reasonable information as Holder may request in connection with such contemplated Acquisition giving rise to such notice), which is to be delivered to Holder not less than ten (10) days prior to the closing of the proposed
Acquisition. 
 B) Upon the written request of the Company, Holder agrees that, in the event of an Acquisition that is an “arms
length” sale of all or substantially all of the Company’s assets (and only its assets) to a third party that is not an Affiliate (as defined below) of the Company (a “True Asset Sale”), either (a) Holder shall exercise its
conversion or purchase right under this Warrant and such exercise will be deemed effective immediately prior to the consummation of such Acquisition or (b) if Holder elects not to exercise the Warrant, this Warrant will continue until the
Expiration Date if the Company continues as a going concern following the closing of any such True Asset Sale. The Company shall provide Holder with written notice of its request relating to the foregoing (together with such reasonable information
as Holder may request in connection with such contemplated Acquisition giving rise to such notice), which is to be delivered to Holder not less than ten (10) days prior to the closing of the proposed Acquisition. 

C) Upon the closing of any Acquisition other than those particularly described in subsections (A) and (B) above, the successor entity shall
assume the obligations of this Warrant, and this Warrant shall be exercisable for the same securities, cash, and property as would be payable for the Shares issuable upon exercise of the unexercised portion of this

  
 2 

 
Warrant as if such Shares were outstanding on the record date for the Acquisition and subsequent closing. The Warrant Price and/or number of Shares shall be adjusted accordingly. 

As used herein (a) “Affiliate” shall mean any person or entity that owns or controls directly or indirectly ten (10) percent
or more of the stock of Company, any person or entity that controls or is controlled by or is under common control with such persons or entities, and each of such person’s or entity’s officers, directors, joint venturers or partners, as
applicable (b) “Marketable Securities” means securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is then current in its filing of all required reports and other information under the Act and the Exchange Act; (ii) the class and series of shares or other
security of the issuer that would be received by Holder in connection with the Acquisition were Holder to exercise this Warrant on or prior to the closing thereof is then traded in a Trading Market, and (iii) Holder would be able to publicly
re-sell, within six (6) months following the closing of such Acquisition, all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise this Warrant in full on or prior to
the closing of such Acquisition and (c) “Trading Market” means a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market. 
 ARTICLE 2. ADJUSTMENTS TO THE SHARES. 
 2.1 Stock Dividends, Splits,
Etc. If the Company declares or pays a dividend on the Shares payable in common stock of the Company, or other securities, then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total
number and kind of shares of common stock of the Company to which Holder would have been entitled had Holder owned the Shares of record as of the date the dividend occurred. If the Company subdivides the Shares by reclassification or otherwise into
a greater number of shares or takes any other action which increases the amount of stock into which the Shares are convertible, the number of shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be
proportionately decreased. If the outstanding shares are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be
proportionately decreased. 
 2.2 Reclassification, Exchange, Combinations or Substitution. Upon any reclassification,
exchange, substitution, or other event that results in a change of the number and/or class of the securities issuable upon exercise or conversion of this Warrant (other than an Acquisition which is subject to the provisions of Section 1.6),
Holder shall be entitled to receive, upon exercise or conversion of this Warrant, the number and kind of securities and property that Holder would have received for the Shares if this Warrant had been exercised immediately before such
reclassification, exchange, substitution, or other event. The Company or its successor shall promptly issue to Holder an amendment to this Warrant setting forth the number and kind of such new securities or other property issuable upon exercise or
conversion of this Warrant as a result of such reclassification, exchange, substitution or other event that results in a change of the number and/or class of securities issuable upon exercise or conversion of this Warrant. The amendment to this
Warrant shall provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Article 2 including, without limitation, adjustments to the Warrant Price and to the number of securities or
property issuable upon exercise of the new Warrant. The provisions of this Article 

  
 3 

 
2.2 shall similarly apply to successive reclassifications, exchanges, substitutions, or other events. 
 2.3 Intentionally Omitted. 
 2.4 No Impairment. Without the consent
of the Holder, the Company shall not, by amendment of its Certificate of Incorporation or through a reorganization, transfer of assets, consolidation, merger, dissolution, issue, or sale of securities or any other voluntary action, avoid or seek to
avoid the observance or performance of any of the terms to be observed or performed under this Warrant by the Company, but shall at all times in good faith assist in carrying out of all the provisions of this Article 2 and in taking all such action
as may be necessary or appropriate to protect Holder’s rights under this Article against impairment. 
 2.5 Fractional
Shares. No fractional Shares shall be issuable upon exercise or conversion of this Warrant and the number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise or
conversion of the Warrant, the Company shall eliminate such fractional share interest by paying Holder the amount computed by multiplying the fractional interest by the fair market value of a full Share. 

2.6 Certificate as to Adjustments. Upon each adjustment of the Warrant Price, the Company shall promptly notify Holder in writing,
and, at the Company’s expense, promptly compute such adjustment, and furnish Holder with a certificate of its Chief Financial Officer, Corporate Secretary or a senior financial officer setting forth such adjustment and the facts upon which such
adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant Price in effect upon the date thereof and the series of adjustments leading to such Warrant Price. 

ARTICLE 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY. 
 3.1 Representations and Warranties. The Company represents and warrants and covenants to the Holder as follows: all Shares which may be issued upon the exercise of the purchase right represented by
this Warrant, and all securities, if any, issuable upon conversion of the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for restrictions on transfer
provided for herein or under applicable federal and state securities laws. 
 3.2 Notice of Certain Events. If the
Company proposes at any time (a) to declare any dividend or distribution upon any of its stock, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) effect any reclassification or
recapitalization of any of its stock; (c) to merge or consolidate with or into any other corporation, or sell, lease, license, or convey all or substantially all of its assets, or to liquidate, dissolve or wind up, then, in connection with each
such event, the Company shall give Holder: (1) at least 10 days prior written notice of the date on which a record will be taken for such dividend or distribution (and specifying the date on which the holders of common stock will be entitled
thereto) or for determining rights to vote, if any, in respect of the matters referred to in (a) above; and (2) in the case of the matters referred to in (b) and (c) above at least 10 days prior written notice of the date when
the same will take place (and specifying the date on which the holders of common stock will be entitled to exchange their common stock for securities or other property deliverable upon the occurrence of such event). Company will also provide such
information in its possession as is requested by Holder and as is reasonably necessary to enable the Holder to comply with the Holder’s accounting or reporting requirements. 

  
 4 

 3.3 No Shareholder Rights. Except as provided in this Warrant, the Holder will not
have any rights as a shareholder of the Company until the exercise of this Warrant. 
 ARTICLE 4. REPRESENTATIONS, WARRANTIES OF THE
HOLDER. The Holder represents and warrants to the Company as follows: 
 4.1 Purchase for Own Account. This Warrant
and the securities to be acquired upon exercise or conversion of this Warrant by the Holder will be acquired for investment for the Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the
meaning of the Securities Act of 1933 (the “Act”) and the Holder has no present intention, and upon exercise or conversion will have no intention, of selling or engaging in any public distribution of the same except pursuant to a
registration or exemption. Holder also represents that the Holder has not been formed for the specific purpose of acquiring this Warrant or the Shares. 
 4.2 Disclosure of Information. The Holder has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to
the acquisition of this Warrant and its underlying securities. The Holder further has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying
securities and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to the Holder or to which the Holder has
access. 
 4.3 Investment Experience. The Holder understands that the purchase of this Warrant and its underlying
securities involves substantial risk. The Holder has experience as an investor in securities of companies in the development stage and acknowledges that the Holder can bear the economic risk of such Holder’s investment in this Warrant and its
underlying securities and has such knowledge and experience in financial or business matters that the Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting
personal or business relationship with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables the Holder to be aware of the character, business acumen and financial circumstances of such
persons. 
 4.4 Accredited Investor Status. The Holder is an “accredited investor” within the meaning of
Regulation D promulgated under the Act. 
 4.5 The Act. The Holder understands that this Warrant and the Shares issuable
upon exercise or conversion hereof have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed
herein. The Holder understands that this Warrant and the Shares issued upon any exercise or conversion hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless
exemption from such registration and qualification are otherwise available. 
 ARTICLE 5. MISCELLANEOUS. 

5.1 Term. This Warrant is exercisable in whole or in part at any time and from time to time on or before the Expiration Date.

  
 5 

 5.2 Legends. This Warrant and the Shares (and the securities issuable, directly or
indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend in substantially the following form: 
 THIS
WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE
OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES,
SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION. 
 5.3 Compliance with Securities Laws on
Transfer. This Warrant and the Shares issuable upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part without compliance
with applicable federal and state securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably
requested by the Company). The Company shall not require Silicon Valley Bank (“Bank”) to provide an opinion of counsel if the transfer is to Bank’s parent company, SVB Financial Group (formerly Silicon Valley Bancshares), or any other
affiliate of Bank. Additionally, the Company shall also not require an opinion of counsel if there is no material question as to the availability of current information as referenced in Rule 144(c), Holder represents that it has complied with Rule
144(d) and (e) in reasonable detail, the selling broker represents that it has complied with Rule 144(f), and the Company is provided with a copy of Holder’s notice of proposed sale. 

5.4 Transfer Procedure. After receipt by Holder of the executed Warrant, Bank will transfer all of this Warrant to Holder’s
parent company, SVB Financial Group, by execution of an Assignment substantially in the form of Appendix 2. Subject to the provisions of Article 5.3 and upon providing Company with written notice, SVB Financial Group and any subsequent Holder may
transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the Shares issuable directly or indirectly, upon conversion of the Shares, if any) to any transferee, provided, however, in connection with any such
transfer, SVB Financial Group or any subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the name, address and taxpayer identification number of the transferee and Holder will surrender this Warrant to
the Company for reissuance to the transferee(s) (and Holder if applicable). The Company may refuse to transfer this Warrant or the Shares to any person who directly competes with the Company, unless, in either case, the stock of the Company is
publicly traded. 
 5.5 Notices. All notices and other communications from the Company to the Holder, or vice versa,
shall be deemed delivered and effective when given personally or mailed by first-class registered or certified mail, postage prepaid, at such address as may have been furnished to the Company or the Holder, as the case may (or on the first business
day after transmission by facsimile) be, in writing by the Company or such Holder from time to time. Effective upon receipt of the fully executed Warrant and the initial transfer described in Article 5.4 above, all notices to the Holder shall be
addressed as follows until the Company receives notice of a change of address in connection with a transfer or otherwise: 

  
 6 

 SVB Financial Group 

Attn: Treasury Department 
 3003 Tasman Drive, HA 200 
 Santa Clara, CA 95054 

Facsimile: 408-496-2405 

Notice to the Company shall be addressed as follows until the Holder receives notice of a change in address: 

SOLTA MEDICAL, INC. 
 25881 Industrial Boulevard, Hayward, CA 94545 
 Attn:
Jack Glenn, Chief Financial Officer 
 Fax: 510-786-6990 

5.6 Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing
signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 
 5.7
Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such
dispute, including reasonable attorneys’ fees. 
 5.8 Automatic Conversion upon Expiration. In the event that, upon
the Expiration Date, the fair market value of one Share as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be
converted pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised or converted, and the Company shall promptly deliver a certificate representing the Shares (or such other
securities) issued upon such conversion to the Holder. 
 5.9 Counterparts. This Warrant may be executed in counterparts,
all of which together shall constitute one and the same agreement. 
 5.10 Governing Law. This Warrant shall be governed
by and construed in accordance with the laws of the State of California, without giving effect to its principles regarding conflicts of law. 
 [Balance of Page Intentionally Left Blank] 

  
 7 

									
	“COMPANY”	 		 	Date:	 	  

				
	SOLTA MEDICAL, INC.	 		 		 	
					
	By:	 	  
	 		 	By:	 	  

	Name:	 	  
	 		 	Name:	 	  

		 	(Print)	 		 		 	(Print)
	Title:	 	 Chairman of the Board, President or Vice President
	 		 	Title:	 	Chief Financial Officer, Secretary, Assistant Treasurer or Assistant Secretary

  

			
	“HOLDER”
	
	SILICON VALLEY BANK
		
	By:	 	  

	Name:	 	  

		 	(Print)
	Title:	 	  

 APPENDIX 1 
 NOTICE OF EXERCISE 
 1. Holder elects to purchase
            shares of the Common Stock of SOLTA MEDICAL, INC. pursuant to the terms of the attached Warrant, and tenders payment of the purchase price of the shares in full. 

[or] 
 1.
Holder elects to convert the attached Warrant into Shares/cash [strike one] in the manner specified in the Warrant. This conversion is exercised for             of the Shares covered by the
Warrant. 
 [Strike paragraph that does not apply.] 
 2. Please issue a certificate or certificates representing the shares in the name specified below: 
  

	
	  

	            Holders Name
	
	  

	
	  

	            (Address)

 3. By its execution below and for the benefit of the Company, Holder hereby restates each of the
representations and warranties in Article 4 of the Warrant as the date hereof. 
  

			
	HOLDER:
	
	  

		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

		
	(Date):	 	  

 APPENDIX 2 
 ASSIGNMENT 
 For value received, Silicon Valley Bank hereby sells,
assigns and transfers unto 
  

			
	Name:	 	SVB Financial Group
	Address:	 	3003 Tasman Drive (HA-200)
		 	Santa Clara, CA 95054
		
	Tax ID:	 	91-1962278

 that certain Warrant to Purchase Stock issued by SOLTA MEDICAL, INC. (the “Company”), on
            , 2011 (the “Warrant”) together with all rights, title and interest therein. 

 

			
	SILICON VALLEY BANK
		
	By:	 	  

	Name:	 	  

	Title:	 	  

Date:                        
                         
 By its execution below, and for the benefit of the Company, SVB Financial Group makes each of the representations and warranties set forth in Article 4 of the Warrant and agrees to all other provisions of
the Warrant as of the date hereof. 
  

			
	SVB FINANCIAL GROUP
		
	By:	 	  

	Name:	 	  

	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}]]